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In all things of nature,  
there is something of the marvelous 
- Aristotle   -   
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SUMMARY 
Sex development is without a doubt one of the most intriguing developmental 
processes in early embryonic life. Given the complexity of the underlying molecular 
pathways it is not surprising that sex developmental defects are among the most 
common birth defects. Severe forms of DSD have a prevalence of ~1/2 000 – 4 500 births 
but milder forms of genital ambiguity, like hypospadias or micropenis, are seen in as 
much as 1/200 births. Despite significant progress in the identification of new genes 
and pathways, a molecular diagnosis is only obtained in ~50% of cases. A molecular 
diagnosis enables refining of a clinical diagnosis and results in improved management. 
In addition, unraveling of the molecular pathways behind these rare phenotypes can 
provide insights in the pathogenesis of more frequent conditions like male infertility 
and primary ovarian insufficiency (POI).  
The main aim of this doctoral project was to unravel pieces of the molecular pathways 
behind sex development and to identify new genes responsible for DSDs and related 
conditions like POI.  
The first part of this thesis aimed to assess the appropriateness of a standardized 
genetic work-up in a cohort of 32 neonates and infants with 46,XY undervirilization 
phenotypes. Our results showed that array-CGH is still a valuable technique in 
syndromic cases, with a detection rate of 33%, while it is less useful in non-syndromic 
cases. Sanger sequencing of AR, WT1 and SRY did not reveal any mutations in this 
cohort, but we did identify three novel NR5A1 mutations. One of these mutations 
showed preserved male fertility, which is rarely seen in men with NR5A1 mutations. 
Given the low diagnostic yield of this sequential Sanger sequencing approach and the 
high costs, we anticipated that targeted resequencing of gene panels and whole exome 
sequencing would become the first choice testing methods in the diagnostic work-up 
of DSD. Furthermore, we concluded that this extensive screening approach had a 
comparable diagnostic yield in both severe cases (low external masculinization score 
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(EMS); <7; detection rate 17.6%) and less severe cases (high EMS; ≥ 7; detection rate 
26.5%), indicating that the decision for a genetic work-up cannot only be based on 
phenotypic presentation.  
The second part of this dissertation focusses on the identification of new disease genes 
for DSD and related phenotypes. First of all, we propose ESR2 as a novel disease gene 
for 46,XY DSD. We identified three novel ESR2 mutations in unrelated patients: one 
homozygous in-frame deletion in a syndromic 46,XY DSD case, and two heterozygous 
missense variants in girls with isolated 46,XY DSD. In vitro functional characterization 
of these variants showed increased transcriptional activation for the in-frame deletion, 
suggesting a gain-of-function effect. For the heterozygous missense variants, no 
significant differences were observed. Structural analysis of the mutant proteins 
showed altered protein conformations, which likely perturb protein functioning. 
Furthermore, immunohistochemistry on an 8-week old male embryo revealed a 
ubiquitous expression of ER-β, which is reflected in the syndromic phenotype of the 
first syndromic case. The exact working mechanism of these mutations is currently 
unknown, although we propose a mechanism via early MAPK signaling. Further 
experimental work is necessary to address these assumptions.   
In a third study, we have shown the involvement of a single recurrent NR5A1 
mutation, c.274C>T, p.(Arg92Trp), in the pathogenesis of 46,XX testicular and 
ovotesticular DSD. Genetic and structural data were both in favor of pathogenicity. 
The results of luciferase transcriptional activation assays were not in line with our 
initial gain-of-function hypothesis. We proposed an alternative working mechanism 
via the so far under-recognized pro-ovarian functions of NR5A1. Almost 
simultaneously with our paper, two other groups reported on the identification of 
exactly the same mutation. Experimental work in these papers confirmed the pro-
ovarian hypothesis.  
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The fourth paper of this thesis reports on the identification of FOG2 as a novel disease 
gene for POI. Previously this gene had been implicated in the pathogenesis of cardiac 
malformation syndromes in combination or not with 46,XY gonadal dysgenesis. The 
starting point of this study was the identification of a maternally inherited FOG2 
encompassing deletion in a boy with 46,XY DSD. Interestingly, hormonal 
investigations revealed a lowered AMH value in his mother, suggesting a potential 
risk for POI development. We decided to screen FOG2 in a French-Belgian POI cohort, 
resulting in the identification of four additional, likely pathogenic FOG2 mutations. 
Luciferase assays to assess the functional implications of these variants showed  
significantly reduced transcriptional activation for three out of four of these variants.  
Finally, we have reviewed the hitherto known non-coding, cis-regulatory defects 
underlying DSD. Currently, DSD genetic research has mainly been focused on the 
identification of coding defects. But as for other developmental disorders, 
development is dependent on a correct spatiotemporal regulation of different 
developmental factors. With the quickly reducing costs of whole genome sequencing, 
we anticipate that this technique will quickly be introduced in a clinical setting, 
allowing the assessment of both coding and non-coding defects with only one test.  
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SAMENVATTING 
De menselijke geslachtsontwikkeling is zonder twijfel één van de meest fascinerende 
processen tijdens de embryonale ontwikkeling. Gezien de complexiteit van de 
onderliggende moleculaire signalisatiepaden, is het niet verwonderlijk dat 
afwijkingen van de geslachtsontwikkeling tot de meest voorkomende aangeboren 
aandoeningen behoren. Ernstige vormen van DSD worden gezien bij ~1/2000-4500 
geboorten, maar mildere vormen van een atypisch genitaal uiterlijk, zoals hypospadie 
en micropenis, komen voor bij maar liefst 1/200 geboorten. Ondanks de belangrijke 
vooruitgang van de identificatie van nieuwe DSD ziektegenen en signalisatiepaden, 
kan men vandaag slechts in ~50% van de gevallen een moleculaire diagnose 
verkrijgen. Dit kan echter van belang zijn voor de verfijning van een klinisch gestelde 
diagnose en kan leiden tot een aangepaste behandeling. Verder kan het begrijpen van 
de moleculaire achtergrond van deze zeldzame aandoeningen bijdragen tot het 
verkrijgen van meer inzicht in de pathogenese van frequentere aandoeningen zoals 
mannelijke infertiliteit en primaire ovariële insufficiëntie (POI).  
Het voornaamste doel van dit doctoraatsproject was de ontrafeling van de moleculaire 
signalisatiepaden die betrokken zijn bij geslachtsontwikkeling en de identificatie van 
nieuwe ziektegenen voor DSD en gerelateerde aandoeningen. 
Het eerste deel van deze thesis was erop gericht om de geschiktheid van een 
gestandaardiseerde genetische uitwerking na te gaan in een cohorte van 32 jonge 
kinderen met 46,XY ondervirilisatie fenotypes. Deze studie toonde aan dat array-CGH 
een waardevolle strategie is, met een detectie ratio van 33%, wanneer er sprake is van 
een syndromaal fenotype. Wanneer er enkel sprake is van ondervirilisatie bleek array-
CGH minder goed te scoren. Sanger sequenering van AR, WT1 en SRY was negatief in 
deze cohorte, maar er werden drie nieuwe NR5A1 mutaties gevonden. Eén van deze 
varianten werd eveneens teruggevonden bij een man zonder fertiliteitssproblemen, 
wat slechts zelden wordt gezien bij NR5A1 mutaties. Gezien de lage detectie ratio van 
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deze sequentiële aanpak en de hoge kost die ermee gepaard gaat, stelden we voorop 
dat een dergelijke aanpak op korte termijn zou vervangen worden door parallelle 
hersequenering van genpanels en door exoomsequenering voor de genetische 
uitwerking van DSD casussen. Onze resultaten toonden eveneens aan dat de beslissing 
om een uitgebreide genetische uitwerking op te starten niet enkel gebaseerd mag zijn 
op het fenotype. Er werden gelijkaardige detectieratio’s gezien voor de groep met 
ernstigere ondervirilisatie (lage EMS; <7; detectie ratio 17.6%) als voor de groep met 
een milder fenotype (hogere EMS; ≥ 7; detectie ratio 26.5%). 
Het tweede deel van dit doctoraatsonderzoek, was gericht op de identificatie van 
nieuwe ziektegenen voor DSD en gerelateerde fenotypes. Ten eerste, identificeerden 
we ESR2 als nieuw kandidaat ziektegen voor 46,XY DSD. In totaal werden drie 
nieuwe, potentieel pathogene ESR2 varianten geïdentificeerd: een homozygote in-
frame deletie bij een syndromale 46,XY DSD casus en twee heterozygote missense 
varianten bij niet verwante meisjes met geïsoleerd 46,XY DSD. In vitro functionele 
validatie voor deze varianten, toonde een verhoogde transcriptionele activatie aan 
voor de in-frame deletie, suggestief voor een gain-of-function effect. Voor de 
heterozygote missense varianten kon geen significant verschil waargenomen worden. 
Structurele analyse van de mutante eiwitten toonde wel veranderde eiwitconformaties 
aan, met een waarschijnlijk effect op eiwitfunctie. Verder toonden we via 
immuunhistochemie op materiaal van een 8-weken oud mannelijk embryo aan dat ER-
β verspreid tot expressie komt, wat gereflecteerd wordt in het syndromaal fenotype 
van de syndromale DSD casus. Tot nog toe is het exacte werkingsmechanisme van 
deze varianten onbekend, onze hypothese is dat dit kan gebeuren via vroege MAPK 
signalisatie. Verder experimenteel werk zal leiden tot meer inzichten hierin.  
In een derde studie toonden we aan dat een specifieke, recurrente NR5A1 mutatie, 
c.274C>T, p.(Arg92Trp), betrokken is bij de pathogenese van 46,XX testiculair en 
ovotesticulair DSD. Zowel genetische als structurele argumenten waren suggestief 
voor een pathogeen effect. De resultaten van luciferase transcriptionele activatie 
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assays konden onze initiële gain-of-function hypothese niet bevestigen. Een alternatieve 
hypothese waarbij de tot nog toe onderschatte pro-ovariële functies van NR5A1 een 
rol spelen, lijkt relevanter te zijn. Dit werd bevestigd door twee nagenoeg gelijktijdige 
publicaties over dezelfde NR5A1 mutatie.  
Een vierde paper beschrijft de identificatie van FOG2 als een nieuwe ziektegen voor 
POI. Voordien werd dit gen reeds betrokken bij de pathogenese van congenitale 
hartafwijkingen, al dan niet in combinatie met 46,XY gonadale dysgenesie. Het 
uitgangspunt van deze studie was de identificatie van een materneel overgeërfde, 
FOG2 overspannende deletie bij een jongen met 46,XY DSD. Hormonale uitwerking 
bij de moeder bracht een verlaagde AMH concentratie aan het licht, suggestief voor 
een risico op POI. De daaropvolgende screening van een Frans-Belgische POI cohorte 
resulteerde in de identificatie van vier bijkomende, waarschijnlijk pathogene FOG2 
varianten. Luciferase experimenten toonden een gedaalde transcriptionele activatie 
aan voor drie van deze varianten.  
Ten slotte hebben we een overzicht gemaakt van tot nu toe gekende niet-coderende, 
cis-regulatorische defecten die aan de basis liggen van DSD. Momenteel is genetisch 
DSD onderzoek voornamelijk toegespitst op de identificatie van coderende defecten. 
Aangezien geslachtsontwikkeling sterk afhankelijk is van een correcte 
spatiotemporele expressie van verschillende factoren, kan verwacht worden dat een 
aanzienlijk aantal casussen zal kunnen verklaard worden door cis-regulatorische 
defecten. Door de dalende kostprijs voor genoomsequenering wordt verwacht dat 
deze technologie op korte termijn zal geïntroduceerd worden in een klinische setting. 
Hierdoor zal men in staat zijn om met één test zowel coderende als niet-coderende 
veranderingen op te pikken.  
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1 SEX DEVELOPMENT 
To understand the pathogenesis of disorders of sex development (DSD) it is essential 
to have a profound knowledge of the physiological processes driving human sex 
development, beyond doubt one of the most intriguing processes of embryonic life. In 
general, sex development can be divided in two important steps: sex determination 
and sex differentiation. Sex determination comprises the initial developmental 
decision of the bipotential gonad to follow either the testicular or ovarian path. This 
step is tightly regulated by the temporospatial expression of different genes, mainly 
encoding transcription factors. Subsequent sex differentiation involves the 
development of phenotypic sex, both  the internal and external genitalia, which is 
mediated by hormones that are secreted by the developing gonads, the testes in 
particular1,2. Gonads possess two distinct functions; first of all, they produce hormones 
that are responsible for different effects throughout the entire body and second, they 
produce gametes that are indispensable for reproduction3. 
1.1 The undifferentiated stage 
Sex development is initiated in the fourth week of embryonic life and starts with the 
formation of the undifferentiated urogenital ridges, a ventromedial thickening of the 
coelomic epithelium of the mesodermal mesonephros3,4 (Figure 1). This urogenital 
ridge is the precursor of a urinary ridge, that is the anlage of the urinary system, and 
an adreno-genital ridge (week 5), that gives rise to the adrenal glands and the gonads4. 
The proliferating cells of the gonadal ridge will penetrate the underlying mesenchyme, 
resulting in the formation of primitive sex cords3. These genital ridges are 
subsequently colonized by primordial germ cells that are derived from the 
ectoderm5,6. At the same time two unipotential duct systems develop from the 
(para)mesonephros: the mesonephric ducts (Wolffian duct) and the paramesonephric 
ducts (Müllerian duct). These ducts are the precursors of the internal genitalia and 
both of them debouch in the cloaca, the terminal end of the hindgut, which is closed 
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by a cloacal membrane at that time. The cloaca is later divided in a recto-anal sinus 
and a urogenital sinus, covered by a rectal and a genital membrane respectively. 
Underneath this membrane, two mesodermal swellings develop: the urethral folds 
and the labioscrotal swellings. These structures, together with the genital tubercle 
that arises as a separate swelling, will give rise to the external genitalia1,4,7. 
 
Figure 1: Development of the undifferentiated gonads (adapted from Gilbert et al.8). (A) The 
gonadal ridge at 4 weeks. The coelomic epithelium starts proliferating and germ cells start 
migrating from the yolk sac to the gonadal ridges. (B) The gonadal ridge at 6 weeks. The 
coelomic epithelium keeps proliferating with the formation of primitive sex cords that invade 
the underlying mesenchyme.  
1.2 Sex determination  
Sex determination commences around week 7 and leads to the development of testes 
in 46,XY embryos and ovaries in 46,XX embryos.  
1.2.1 Male sex determination 
Testis formation can be divided in three distinct steps: (1) continuous proliferation of 
the pre-Sertoli cells, (2) compartmentalization into secondary sex cords that are now 
called testis cords and (3) elongation of these cords to form seminiferous tubules3. At 
the end these tubules get narrower and form the rete testis that connects the developing 
testes with the efferent ducts. The seminiferous tubules are separated from the surface 
epithelium by a layer of extracellular matrix, called the tunica albuginea, and from each 
other by interstitial tissue in which Leydig cells will develop4,8 (Figure 2). Leydig cell 
development begins around the eighth week of development and their origin remains 
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a matter of debate as it is currently unclear whether they arise from the coelomic 
epithelium or from specialized cells in the gonadal-mesonephric border9,10. In general, 
three cell types are present in the developing and adult testis: (1) germ cells, with an 
extra-embryonic origin, (2) somatic Sertoli cells and (3) the sex steroid producing 
Leydig cells.  
1.2.2  Female sex determination 
 Unlike during male sex determination, the primitive sex cords will regress during 
female development. The coelomic epithelium will allow the formation of a second 
generation of sex cords, the so-called cortical cords, which will organize themselves 
around the oocytes with the formation of the first primordial follicles (Figure 2). The 
cortical cells surrounding the oocytes are now called granulosa cells, while the 
mesenchymal cells are called theca cells. These cells form the female counterpart of 
the Sertoli and Leydig cells respectively3,8.  
 
Figure 2: Sex determination leads to the formation of testes and ovaries (adapted from 
Gilbert el al.8) 
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1.3  Sex differentiation  
Sex differentiation takes place during weeks 8-14 of development and involves the 
development of both internal and external genitalia. According to early research by 
Jost et al., female development is the default pathway and can even occur 
independently of the existence of ovaries, while male differentiation depends on the 
adequate production and action of testicular hormones11. 
1.3.1 Male sex differentiation  
Once testes are formed, Sertoli cells will start to produce anti-Müllerian hormone 
(AMH) resulting in the regression of the paramesonephric ducts in male embryos 
during weeks 8-9 of development. Apoptosis and epithelial-mesenchymal 
transformation progresses in a cranio-caudal direction12. Adequate timing of AMH 
expression is crucial as the Müllerian ducts become insensitive to AMH by the tenth 
week13. At the same time, cholesterol will be transformed to testosterone in the Leydig 
cells through coordinated action of different steroidogenic enzymes14. Testosterone 
action is important for development of the internal genitalia and results in 
mesonephric duct differentiation into the epididymides, vasa deferentia and the 
seminal vesicles15 (Figure 3). Subsequently, testosterone is converted to 
dihydrotestosterone (DHT), which has a higher affinity for the androgen receptor and 
is responsible for the virilization of the urogenital sinus and external genitalia (week 
10-14)1. The bladder, the proximal part of the urethra and the prostate are urogenital 
sinus’ derivatives. The prostate develops from the dorsal wall of the urethra and has 
both a meso- and endodermal origin: the stroma and smooth muscle cells are 
mesodermal derivatives and mesenchymal signals induce proliferating signals on the 
overlying epithelium, resulting in the formation of the glandular epithelium and the 
prostatic ducts. Around week 9, virilization of the external genitalia starts with the 
lengthening of the anogenital distance, later followed by fusion of the labioscrotal folds 
with formation of the scrotum. Fusion of the urethral folds leads to the formation of 
the distal part of the urethra. The genital tubercle will form the penis4,16 (Figure 4).  
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Figure 3: Differentiation of the internal genitalia. On the top, the undifferentiated duct 
system with the Wolffian duct in dark blue and the Müllerian duct in light blue. In male 
embryos the developing testis will start to secrete AMH, responsible for Müllerian duct 
regression, and testosterone, which cause differentiation of the Wolffian duct. In absence of 
these hormones in female embryos, the Wolffian duct will regress, while the Müllerian duct 
gives rise to the fallopian tubes, the uterus and the upper part of the vagina.  
1.3.2 Female sex differentiation 
In the female embryo, the paramesonephric ducts are not influenced by AMH and will 
therefore not regress. The female gonads will start to produce estrogens, which are 
responsible for differentiation of the paramesonephric duct to the Fallopian tubes 
(oviduct), the uterus and the proximal third of the vagina (Figure 3). In the absence of 
testosterone, the mesonephric ducts on the other hand will regress. The urogenital 
sinus will differentiate into the bladder, the urethra and the distal part of the vagina, 
the urethral folds will form the labia minora and the labioscrotal folds will give rise to 
the labia majora. Finally, the genital tubercle will form the clitoris (Figure 4). 
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Figure 4: Differentiation of the external genitalia (adapted from www.embryology.ch). In 
light blue, the labioscrotal folds which differentiate to the scrotum in male embryos and to the 
labia majora in female embryos. In darker blue, the urethral folds which form the anlage of the 
penis and the labia minora in males and females respectively.  
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2 DISORDERS OF SEX DEVELOPMENT 
According to the Jost paradigm, sex development consists of four successive steps; first 
of all, the karyotype is determined at fertilization, followed by the formation of 
undifferentiated gonads and subsequent sex determination; the last step involves 
differentiation of both internal and external genitalia (sex differentiation). 
Disorders of sex development can occur due to errors in each of these four steps17.  
The term DSD was first introduced in the 2006 consensus statement18,19. Before that 
time, these conditions were referred to as intersex, pseudohermaphroditism or sex 
reversal. These terms were perceived as stigmatizing by individuals having a DSD and 
did not give any specifications about the actual condition. Currently, the normative 
character of the word “disorder” is contested, and is therefore gradually replaced by 
“differences (of sex development)”, especially in the clinical setting. The current 
nomenclature is based on three main classification levels20. A first division is based on 
the karyotype: sex chromosomal DSD, 46,XY DSD and 46,XX DSD. The sex 
chromosomal DSD class includes the conditions Klinefelter and Turner syndrome (KS 
and TS), characterized by 47,XXY and 45,X karyotypes respectively. Secondly, for the 
46,XY and 46,XX DSD conditions, a distinction is made between disorders of gonadal 
development and disorders of steroid hormone synthesis or action, and a rest group. 
Thirdly, a genetic diagnosis can be added if available20.  Table 1 shows an overview of 
the DSD nomenclature. The different types of DSD are discussed below, a thorough 
description of the molecular pathways that are involved in the pathogenesis of these 
conditions is given in section 3 of this chapter.  
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Table 1: Overview of the DSD classification system, based on Hiort et al.21 
 Sex chromosomal DSD 46,XY DSD 46,XX DSD  
  Disorders of testicular 
development 
Disorders of ovarian 
development  
 
 47,XXY (Klinefelter 
syndrome) 
Complete or partial gonadal 
dysgenesis (monogenic forms) 
Testicular DSD  
 45,X (Turner syndrome) Ovotesticular DSD Ovotesticular DSD  
 45,X/46,XY (mixed gonadal 
dysgenesis) 
Syndromic forms Syndromic forms  
 46,XX/46,XY (chimerism)    
  Disorders of androgen 
synthesis/action 
Androgen excess  
  Syndromic e.g. Smith-Lemli-Opitz 
syndrome 
Congenital adrenal 
hyperplasia (mostly steroid 
21-hydroxylase deficiency) 
 
 Congenital adrenal hyperplasia 
Early androgen biosynthesis 
defects 
Aromatase deficiency  
 Isolated androgen biosynthesis 
defects 
Luteoma  
  Associated with endocrine 
disruption 
Iatrogenic  
  Complete and partial androgen 
insensitivity syndrome 
  
  Hypospadias of unknown genetic 
origin 
  
  Other Other  
  Syndromic associations of male 
genital development 
Mayer–Rokitansky–Küster–
Hauser syndrome 
 
 
 
Persistent Müllerian duct 
syndrome 
Complex syndromic 
disorders 
 
23 
 
 
 Vanishing testis syndrome   
  Isolated hypospadias   
 
 
Congenital hypogonadotropic  
hypogonadism 
  
  Cryptorchidism   
 
2.1 Sex chromosome DSD 
All conditions in this group are characterized by numerical changes in the sex 
chromosomes. The most prevalent of them are KS and TS, other conditions such as 
45,X/46,XY and 46,XX/46,XY are less common.  
Klinefelter syndrome 
KS is the most common form of DSD and the most common genetic cause of 
hypogonadism in males. Prevalence is estimated at 1 in 600 births; however it is 
believed that over 60% of cases remain undiagnosed due to unpronounced clinical 
features or low self-reporting because of the social stigma surrounding the 
condition22,23. KS is mostly characterized by a 47,XXY karyotype although 10-20% of 
patients display a higher supernumeracy of sex chromosomes and various mosaic 
forms have been described22,24. In general these variants with increased aneuploidy 
show more severe clinical features22,25. Many attempts have been undertaken to present 
a clear phenotype for KS. Klinefelter himself described patients as tall, broad at the hip 
and narrow at the shoulder, with absent or sparse body hair, gynecomastia, 
azoospermia, small testes, and elevated follicle stimulating hormone (FSH)26, however 
multiple parameters like behavioral difficulties and decreased bone mineral density 
were added to the list27. In general, there is a wide phenotypic variability of the 
condition. 
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Turner syndrome 
TS has a prevalence of 1 in 2 000 newborn girls and is the result of partial or complete 
X chromosome monosomy28,29. As in KS, the phenotype associated with TS varies and 
in general more severe phenotypes are observed in cases with X monosomy compared 
to other chromosomal rearrangements30. Short stature, webbed neck, cubitus valgus, 
widely-spaced nipples, infertility, and streak ovaries are among the most common 
characteristics of TS31.  Structural cardiac defects and cardiovascular abnormalities are 
found in 20-45% of TS cases, however studies with more advanced technologies 
suggest an even higher number. Besides these cardiac defects, which have an 
important impact on patients’ life expectancy, neurological and metabolic 
disturbances, hearing impairment, thyroid dysfunction, diabetes, auto-immune 
diseases and psychosocial difficulties are frequently observed in TS. Clinical 
management of TS patients should cover all these different aspects29,31. 
Mosaicism and chimerism 
Less frequent types of sex chromosomal DSD occur when the karyotype is 45,X/46,XY 
(mosaicism) or 46,XX/46,XY (chimerism), or variants of these. Both mosaicism and 
chimerism refer to the presence of two genetically distinct cell lineages in the same 
individual. However, chimerism is defined by the fusion of two different zygotes to a 
single embryo while mosaicism is the result of a mitotic error in one zygote32. 
45,X/46,XY mosaicism has a prevalence of 1.5-1.7 in 10 000 and is characterized by a 
broad spectrum of phenotypes ranging from phenotypic women with or without 
Turner-like features to men with variable virilization of external genitalia. Besides 
concerns about gender assignment, genital surgery and gonadal tumor risk, medical 
care should concentrate on problems related to Turner syndrome, such as short stature 
and cardiac malformation, due to the presence of a 45,X cell population33,34. The 
phenotype in 46,XX/46,XY chimerism varies from phenotypically normal males and 
females to cases with ambiguous genitalia32.  
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2.2   46,XY Disorders of sex development 
2.2.1 Disorder of testicular development 
Complete and partial 46,XY gonadal dysgenesis 
Complete and partial 46,XY gonadal dysgenesis (GD) are the consequence of abnormal 
gonadal determination in the presence of an XY karyotype. Complete GD has a 
prevalence of 1 in 20 000 births and was first described by Swyer et al.35,36, partial GD 
occurs more frequently. Complete GD is characterized by typical female internal and 
external genitalia, absence of secondary sex characteristics and bilateral non-functional 
gonads that may appear as streaks or have areas of undifferentiated gonadal tissue37. 
Most patients present at adolescence after referral for absent pubertal development, 
but the diagnosis is increasingly made prenatally with the finding of a prenatal XY 
karyotype in discordance with the external phenotype. Girls with complete gonadal 
dysgenesis have a uterus due to absence of intrauterine AMH production. The partial 
form is characterized at the gonadal level by incomplete testicular differentiation in 
one or both gonads, most often in combination with areas of undifferentiated gonadal 
or streak tissue. The dysgenetic testes are somewhat hormonally active, resulting in 
ambiguous external genitalia with or without Müllerian structures36,38,39. Hormonal 
investigations in patients with complete and partial GD reveal elevated FSH and 
luteinizing hormone (LH) levels, while sex steroids, AMH and inhibin-B 
concentrations are below the male reference range36,38,39. While interpreting these 
hormonal tests, age-specific reference ranges must be taken into account.  
 The first gene that was associated with complete GD is Sex-determining region of Y 
(SRY) and mutations in this gene account for 10-20% of cases36,40. Several other disease 
genes for complete and partial GD have been described: ARX, ATRX, CBX2, DHH, 
DMRT1, GATA4, MAMLD1, MAP3K1, NR0B1, NR5A1, SOX9, WNT4, WT1 and 
WWOX. Some of these genes are associated with syndromic phenotypes, the most 
important ones are described below. 
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SRY-box 9 (SOX9) mutations and deletions are associated with campomelic dysplasia, 
characterized by a skeletal malformation syndrome and 46,XY DSD, the latter in 75% 
of male cases41–43. Decreased activity of Nuclear receptor subfamily 5 group A member 
1 (NR5A1; steroidogenic factor-1, SF-1) can cause a plethora of different phenotypes 
ranging from undervirilization to complete 46,XY GD with primary adrenal 
insufficiency44,45. In addition it has been shown that variants in NR5A1 can cause 
primary ovarian insufficiency (POI) in females and spermatogenic failure in males44. 
Wilms Tumor 1 (WT1) mutations can underlie three different syndromes depending 
on the type and location of the mutation: WAGR syndrome, Denys-Drash and Frasier 
syndrome. WAGR syndrome can be caused by WT1 encompassing deletions and is 
characterized by Wilms tumor, aniridia, genitourinary abnormalities and intellectual 
disability. Denys-Drash syndrome is characterized by 46,XY complete or partial GD, 
early onset renal failure and the development of a Wilms tumor during the first decade 
of life. This syndrome is caused by heterozygous missense mutations in the zinc 
fingers of WT146,47. Frasier syndrome is characterized by partial or complete 46,XY GD, 
proteinuria and end-stage renal failure in the second decade and a particularly high 
risk of gonadoblastoma development. This syndrome is caused by specific 
heterozygous splice site mutations in exon 9, leading to decreased amounts of the 
KTS+ transcript and a perturbed KTS-/KTS+ transcript balance48,49.  
46,XY ovotesticular DSD 
Ovotesticular (OT) DSD is a rare condition that is characterized by the coexistence of 
both testicular and ovarian tissue in one individual. Testicular and ovarian tissue can 
be found each on one side or in the same gonad. OT DSD is mostly found in patients 
with 46,XX DSD (60%), the remainder have sex chromosomal DSD (more specifically 
46,XX/46,XY DSD.  Although a small number of cases with OT DSD and a 46,XY 
karyotype have been reported, it is currently unclear if this entity exists, given the 
possible confusion between ovarian tissue and undifferentiated gonadal tissue (UGT), 
leading to misdiagnosis in a number of cases37,50.  
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2.2.2 Disorders of androgen synthesis 
Disorders of androgen synthesis can occur in every step of the testosterone 
biosynthesis process starting from the transport of cholesterol to the mitochondria in 
order to start steroidogenesis to the conversion of testosterone to dihydrotestosterone.  
Impaired Leydig cell differentiation: Leydig cell hypoplasia 
Most cases of Leydig cell hypoplasia (LCH) present as phenotypical females, who have 
absence of secondary sexual characteristics and undescended, slightly hypotrophic 
testes. Partial LCH has a less strictly defined phenotype, with micropenis and 
hypospadias being the most common features51. These patients show no or a 
subnormal response to prepubertal human chorionic gonadotropin (HCG) stimulation 
and increased LH levels in puberty52. 
LCH is a genetically heterogeneous condition with an autosomal recessive inheritance 
mode53. Several inactivating mutations in the Luteinizing Hormone/ 
Choriogonadotropin Receptor (LHGCR) gene, encoding the LH receptor, have been 
identified in patients with complete or partial LCH51. Recently a new disease 
mechanism was added to the LCH pathogenesis. Vezzoli et al. described a patient with 
partial LCH and a compound heterozygous LHGCR mutations. The first variant was a 
known missense variation, but the second variant was novel and affected the putative 
signaling peptide of the receptor. Functional and structural validation shows that this 
signaling peptide is indispensable for correct receptor biosynthesis54. So far, no other 
genes have been linked to human LCH.  
Testosterone biosynthesis defects 
DSDs can also be the result of enzymatic defects in each of the steps necessary to 
convert cholesterol to functional steroid hormones. An overview of the steroid 
biosynthesis pathway is provided in Figure 5. All of these conditions are characterized 
by autosomal recessive inheritance51. We will make a distinction between (1) 
cholesterol synthesis defects, (2) defects affecting adrenal and testicular 
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steroidogenesis and leading to congenital adrenal hyperplasia (CAH), and (3) defects 
in testicular steroidogenesis. 
- DSD associated to cholesterol synthesis defects: Smith-Lemli-Opitz syndrome 
Cholesterol is the precursor of all steroid hormones, and cholesterol deficiency or 
decrease of cholesterol precursors are involved in different conditions, among them 
46,XY DSD. The final step in cholesterol biosynthesis is the reduction of 7-
dehydrocholesterol (7-DHC) by 7-DHC reductase, encoded by the DHCR7 gene. 
Defects of this gene cause Smith-Lemli-Opitz syndrome (SLOS) 55. SLOS was first 
described in three male patients with small stature, failure to thrive, severe feeding 
disorder, hypospadias, a characteristic facial appearance and microcephaly56.  
However, examination of additional cases showed a wider phenotypic variability55. 
The condition can be diagnosed on biochemical grounds, based on elevated levels of 
7-DHC and reduced cholesterol levels57.  
In 1998, three groups independently reported the first DHCR7 mutations58–61. Today, 
over 150 different mutations have been identified55. More recently, a number of exon 
deletions were identified as the causal defect in SLOS cases62,63. Although several 
attempts have been undertaken to find genotype-phenotype correlations, none of them 
are reliable enough to allow individual counseling and it is highly likely that the SLOS 
phenotype is influenced by modifier genes55.  
- Congenital adrenal hyperplasia 
Defects at the top of the steroid hormone biosynthesis cascade not only affect sex 
hormone production, but also lead to impaired gluco- and/or mineralocorticoids. CAH 
can be caused by mutations in four different genes: Cytochrome P450 Family 11 
Subfamily A Member 1 (CYP11A), Steroidogenic Acute Regulatory Protein (StAR), 
Hydroxysteroid 3-β Dehydrogenase 2 (HSD3B2) and Cytochrome P450 Family 17 Subfamily 
A Member 1 (CYP17A1). These different enzymatic defects are reflected in slightly  
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Figure 5: Overview of the steroid hormone biosynthesis pathways (based on 
Mendonca et al. 201051)
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Table 2: Overview of the different types of congenital adrenal hyperplasia, based 
on Mendonca et al. and references therein51. 
  StAR CYP11A CYP17A1 HSD3B2  
 Enzyme 
function 
Cholesterol 
transport within the 
mitochondria 
 
Cholesterol 
 
Pregnenolone 
17-OH pregnenolone 
 
DHEA 
DHEA 
 
Androstenedione 
 
 Phenotype -   Phenotypic 
females 
-   External genitalia 
slightly virilized 
-   Cryptorchidism 
-   Underdeveloped 
internal genitalia 
-   Enlarged adrenal 
cortex, engorged 
with 
cholesterol(esters) 
-   Salt-wasting 
-   Hyponatraemia 
-   Hyperkalaemia 
-   Hypovolaemia 
-   Acidosis 
-   Death in infancy 
 
-   Similar to StAR 
deficiency 
-   No adrenal 
hyperplasia 
-   Female-like, 
slightly virilized 
external genitalia 
-   Hypoplastic 
internal genitalia 
-   Gynaecomastia 
-   Cryptorchidism 
-   High blood 
pressure 
-   Hypokalaemia 
-   Ambiguous 
external genetalia 
-   Micropenis 
-   Hypospadias 
-   Bifid scrotum 
-   Gynaecomastia 
-   Possible salt-loss 
 
 Biochemistry   -   High ACTH and 
renin 
-   Low/undetectable 
gluco- and 
mineralocorticoids 
-   Low androgens 
- High 
corticosterone, 
deoxycorticosterone 
and progesterone 
-   Low aldosterone, 
17-OH progesterone, 
cortisol, androgens 
and estrogens 
- High (17-OH) 
pregnenolone, 
DHEA(S),  
-   High ratio 
17OHPreg/17OHP 
-   Low cortisol 
-   Low androgens 
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 Therapy  -   Gluco-and 
mineralocorticoids 
-   Gluco-and 
mineralocorticoids 
-   Androgens/ 
Estrogens 
-   Glucocorticoids 
(for hypertension) 
-   Androgens 
-   Glucocorticoids 
-   Androgens 
-   Mineralocorticoid 
in case of salt-losing 
 
 
 DHEA(S)= dehydroandrostenedione (-sulphate), ACTH= adrenocorticotropic hormone, LH= luteinizing 
hormone, FSH= follicle stimulating hormone 
 
 
different phenotypes and distinctive biochemical patterns. Treatment strategies 
include gluco- and/or mineralocorticoid supplementation and androgen replacement 
therapy in affected males. An overview of the phenotypical and biochemical findings 
in these patients is shown in Table 251. 
- Testicular steroidogenesis defects 
DSDs can also be caused by defects in enzymes that are further down in the 
steroidogenesis pathway, these conditions are not associated with adrenal 
insufficiency. Causal genes here are Hydroxysteroid 17-β Dehydrogenase 3 (HSD17B3) 
and Steroid 5 α-Reductase 2 (SRD5A2)51. The HSD17B3 gene encodes the enzyme that is 
necessary for the conversion of androstenedione to testosterone. Its deficiency is 
characterized by abnormal androstenedione/testosterone ratios, both in basal 
conditions as after HCG stimulation. Phenotypically, patients with HSD17B3 variants 
present with female-like or ambiguous genitalia and abdominal or inguinal testes. 
HSD17B3 deficiency is the most common disorder of androgen biosynthesis. SRD5A2 
encodes the 5α-reductase enzyme that is responsible for the metabolization of 
testosterone to its more potent derivative DHT. Patients with SRD5A2 variants 
typically present with ambiguous genitalia, micropenis and prostate hypoplasia. 
Internal genitalia and testes develop normally. Although spermatogenesis is reduced, 
in part due to the cryptorchic position of the testis, several cases have offspring, mainly 
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through assisted reproductive techniques. Biochemical diagnosis relies on elevated 
testosterone/DHT ratios51. 
2.2.3 Disorders of androgen action 
Male gonadal differentiation is not solely depending on correct testosterone and DHT 
biosynthesis, it is also crucial to have functioning receptors to bind these androgens 
and thereby facilitate their effects on the developing genitalia. Inactivating mutations 
in the androgen receptor (AR) gene are known to cause various forms of androgen 
insensitivity syndromes (AIS)64,65. Very recently, a new mechanism was added to AIS 
pathogenesis; mutations in the AR 5’ untranslated region resulting in the formation of 
an upstream open reading frame. These mutations lead to a decreased amount of AR 
protein without decreasing messenger RNA (mRNA) levels66. Interestingly, for a 
subset of AIS cases, ~15% of complete AIS (CAIS) cases and ~65% of partial AIS (PAIS) 
cases, no inactivating AR mutations can be found. Hornig et al. have set-up a study in 
which the AR transcription activity of this group was tested in genital skin fibroblasts. 
This test could distinguish normal male controls from genetically confirmed AIS cases 
and was also positive for a subset of AR-mutation negative cases that were suggestive 
for AIS. Further investigation of these cases might result in the discovery of novel AIS 
genes67. The prevalence of AIS is estimated between 1 in 20 000 and 1 in 99 000 births68.  
CAIS is characterized by complete female external genitalia with absence of Müllerian 
structures. PAIS has a broad phenotypic spectrum but in most cases a short penis and 
hypospadias are observed. Puberty in AIS patients is characterized by spontaneous 
breast development often in combination with reduced sexual hair growth69. Lab 
results for these patients show normal levels of all testosterone precursor molecules; 
AMH and inhibin-B are also normal (hence the absence of paramesonephric 
structures). Gonadotropins and testosterone are elevated, since feedback mechanisms 
are perturbed69.   
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2.2.4 Other 46,XY DSD conditions 
The rest group contains three important entities, being testicular regression syndrome 
(TRS), isolated hypospadias and cryptorchidism. They are included in the DSD 
classification because they represent other forms of divergent sex development. 
However, their etiology is more diverse than the “classic” forms of DSD.   
TRS or vanished testes is a condition in which testicular differentiation is initially 
normal but is followed by degeneration during fetal or early postnatal life70. TRS is 
estimated to be present in 5% of all cryptorchidism cases71. TRS has been associated 
with microdeletions of the Y chromosome and has been seen more frequently in boys 
with persistent Müllerian duct syndrome72. One case has been associated with an 
NR5A1 mutation but this observation has never been reported afterwards73. However, 
it should be recognized that far from all cases of TRS are caused by genetic defects or 
an underlying endocrinopathy. Other, more common causes of TRS include vascular 
accidents and prenatal torsion events72. 
The same is true for isolated hypospadias and cryptorchidism. While some cases 
related to monogenic defects in DSD associated genes have been reported, 
multifactorial genetic changes are more commonly observed74,75. A general 
observation is that severe hypospadias cases are more likely to be associated with a 
monogenic defect compared to distal hypospadias74. Furthermore, different 
associations have been described with environmental factors like exogenous exposure 
to estrogens or progestins, assisted reproductive technologies, maternal smoking and 
drug use and exposure to endocrine disrupters, heavy metals or phthalates. Although, 
for some of these factors the association is inconsistent74,75.   
34 
 
2.3   46,XX Disorders of sex development 
2.3.1 Disorders of ovarian development 
46,XX ovarian dysgenesis 
The most common forms of ovarian dysgenesis are TS and other conditions with X-
chromosome abnormalities (described above). However, rare cases of ovarian 
dysgenesis in patients with a 46,XX karyotype have been described. Affected girls 
present with typical female genitalia, but do not experience puberty. Müllerian 
structures have fully developed and streak gonads are present; biochemical analyses 
reveal hypergonadotrophic hypogonadism. Ovarian dysgenesis is a genetically 
heterogeneous condition with, in most cases, autosomal recessive inheritance; 
however the molecular cause remains enigmatic in the majority of cases76. Several 
syndromes like Perrault syndrome and blepharophimosis – ptosis – epicanthus 
inversus syndrome (BPES), which are respectively attributed to autosomal recessive 
mutations in Hydroxysteroid 17-β Dehydrogenase 4 (HSD17B4) and autosomal dominant 
mutations in Forkhead box L2 (FOXL2) respectively, are also characterized by gonadal 
dysgenesis77–79. 
46,XX testicular and ovotesticular DSD  
46, XX testicular DSD has a prevalence of 1 in 20 000 births and the majority of patients 
are infertile males with typical male genitalia (85%); 15% of patients have a variable 
degree of genital ambiguity, sometimes with gynaecomastia. In men who have typical 
male genitalia, the diagnosis is usually made due to slow progression of puberty or 
work-up for infertility. Affected men have hypergonadotropic hypogonadism76. 
Gonadal biopsies reveal testicular tissue with small Sertoli-cell only (depending on the 
timing), SOX9 positive seminiferous tubules, even in SRY-negative cases37,80,81. In 
general 46,XX testicular DSD can be caused by activating mutations in pro-testis 
genes and inactivation of ovary-specific genes82. In 90% of men who have a typical 
male phenotype, an SRY translocation can be identified, however this finding is far 
less frequent in patients with an ambiguous phenotype. Other causes of 46,XX 
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testicular DSD are SOX9 duplications, genomic rearrangements of the SOX3 locus 
resulting in ectopic expression, copy number variants (CNVs) of SOX10 and 
inactivating R-spondin 1 (RSPO1) mutations43,83–86. Management of these affected men 
involves life-long follow-up and androgen replacement therapy in the presence of low 
testosterone values. In case of SRY translocation, the presence of the gonadoblastoma 
region of Y (GBY) region (including testis-specific protein, Y-encoded, TSPY) should be 
investigated, as it is believed to increase the risk of germ cell tumor development87–89.   
46,XX OT DSD also has a prevalence of 1 in 20 000 births and accounts for 
approximately 3-10% of all DSD cases76. In these individuals the ovotestis do not have 
germ cells in the testicular part, however follicles are present in the ovarian regions of 
the gonad and they can undergo ovulatory changes during puberty90. This condition 
generally results in a varying degree of external genital ambiguity and the presence of 
both male and female internal genitalia. Diagnosis should be confirmed histologically. 
Hormonal profiles may show normal sex steroid production and age-appropriate 
gonadotropins. Given that both testicular and ovarian parts will start steroidogenesis 
during puberty, both male and female secondary sex characteristics will emerge76,90. 
Ten percent of 46,XX OT DSD cases show a translocation of SRY and RSPO1 
mutations have been described in a number of cases with 46,XX testicular DSD, 
palmoplantar hyperkeratosis and a predisposition for squamous cell carcinoma76,85,86. 
Management of these patients includes specialized psychological care and follow-up 
to assess gender identity before the start of steroid hormone production at puberty. 
Once a clear gender identity has developed conservative surgery can be attempted 
with preservation of the gonadal tissue in agreement with gender identity. As for other 
types of DSD, it is advisable to delay surgery until the patient him- or herself can 
participate in this decision. As follicles are present in the ovarian parts of ovotestis and 
normal menstrual cycles have been observed, there is a chance of fertility. However, 
as most of these patients develop amenorrhea, they should be counseled for possible 
infertility and eventually oocyte cryopreservation76,90. 
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2.3.2 Androgen excess 
Apart from defective ovarian development, 46,XX DSD can also be related to defects 
in steroid hormone production. Female fetuses that are exposed to excess androgen 
levels will have virilized external genitalia. The origin of these androgens can be fetal, 
feto-placental or maternal82.  
CAH is the most prevalent cause of 46,XX DSD and is actually a disorder of impaired 
cortisol synthesis (see above). Decreased cortisol levels result in insufficient feedback 
inhibition and increased secretion of adrenocorticotrope hormone inducing adrenal 
hyperplasia and increased androgen production. The clinical presentation of CAH is 
the result of (1) the cortisol deficiency, (2) the accumulation of cortisol precursors 
and their biological activity and (3) the diversion of these precursors to steroid 
hormones that are normally present in lower amounts91. CAH is associated with 
defects in different steroid producing enzymes: CYP21A2, CYP17A1, CYP11B1, 
HSD3B2 and POR. The different types of CAH were reviewed in detail by Auchus 
and Chang91. 
Another extremely rare cause of 46,XX DSD due to androgen excess is placental 
aromatase deficiency, which has to date been described in fewer than 40 cases. During 
pregnancy CYP19A1, the gene encoding aromatase, is expressed in the placenta. 
Aromatase has a critical function in protecting the developing (female) fetus against 
high concentrations of androgens that are produced by the fetal adrenals and maternal 
androgens. Aromatase deficiency can be expected in case of maternal virilization 
during pregnancy in women with low estriol levels. Affected females are born with 
ambiguous genitalia similar to other forms of 46,XX DSD due to androgen excess91.  
In rare cases, fetal virilization is related to a maternal source of androgens. Chronic 
conditions with androgen excess like polycystic ovaries or maternal CAH, generally 
do not lead to fetal virilization, underlining the capability of aromatase to protect the 
fetus from these androgens. However, several other sources that may lead to 
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virilization have been described. Several types of both malignant (granulosa cell 
tumors,…) and benign tumors (adrenal adenoma, luteoma,…) produce high levels of 
androgens. Furthermore androgen excess can be related to certain medication like 
progestins and potassium-sparing diuretics91.  
2.4   Disorders of ovarian maintenance: primary ovarian insufficiency 
POI, previously termed premature ovarian failure is defined by a triad of symptoms 
before the age of 40: amenorrhea for at least 4-6 months, sex hormone deficiency and 
elevated levels of FSH on at least two measurements and with an interval of at least 
one month apart92,93. The prevalence of POI is estimated to be one in 10 000 women by 
age 20 and reaches approximately one in 100 women by age 4094. POI can be classified 
based on the pathophysiological mechanism eventually leading to the disorder. The 
maximum number of follicles a girl will ever have is obtained at 20 weeks of gestation 
(6-7 million), followed by physiological follicle atresia reducing their number to 
approximately 700 000 at birth and 400 000 follicles at the start of puberty. Early 
menopause can therefore be related to ovarian follicle depletion and it can occur in 
women who started life with a decreased number of follicles or in women who 
experience accelerated follicle atresia postnatally. Second, early menopause can be 
related to ovarian follicle dysfunction, where a correct number of follicles is reached 
but where they cannot react appropriately on gonadotropic stimuli92,93. The causes of 
POI are very diverse ranging from iatrogenic (surgery, chemo- and radiotherapy) to 
autoimmune disorders or genetic causes. Some of these genetic causes, like NR5A1 
mutations, have been identified by studying DSD families. Genetic causes of POI have 
been recently reviewed by Cordts et al. and Tucker et al.95,96. Taken together, the 
currently known POI genes can be divided in ten categories: (1) genes involved in 
gonadogenesis, (2) genes required for cell division/cohesion, (3) homologous 
recombination genes, (4) genes involved in follicular development, maturation and 
activation, (5) genes functioning in DNA damage repair processes, (6) genes related to 
cell death and autophagy, (7) protein translation associated genes, (8) genes 
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supporting hormone production and functioning, (9) genes providing metabolic 
support and (10) genes to protect against auto-immunity. An overview is given in 
Figure 6 and a selection of them is discussed below.  
A first group of genetic defects associated with POI is formed by the different 
numerical X chromosome aberrations ranging from partial and complete X deletions 
to trisomy X. The phenotypical characteristics of TS (45,X) have been described above 
(section 2.1). POI in Turner women is related to accelerated follicle atresia. In general, 
oocyte depletion occurs already in the first decade of life, allowing only around 10% 
of TS women to reach menarche. Girls who have a 45,X/46,XX karyotype have a higher 
chance of menstruating for at least a few years92,95. Several hypotheses concerning the 
underlying mechanism for ovarian dysgenesis in TS women have been proposed; 
incorrect pairing of the X chromosome during meiosis could form an obstacle at a 
meiotic checkpoint leading to apoptosis or alternatively, haploinsufficiency of some X 
chromosome genes directly causes oocyte depletion92. Bone morphogenic protein 15 
(BMP15) is such a candidate gene as heterozygous point mutations have been 
described in women with POI97,98. 
A second X-chromosome-related POI cause are premutations of the Fragile X mental 
retardation 1  (FMR1) gene. FMR1 is characterized by an expandable CGG repeat in 
its 5’UTR. Depending on the number of repeats, three different types of alleles can 
occur: normal and intermediate alleles (from 6 to 54 CGG repeats), premutated alleles 
(from 55 to 200 CGG repeats) and full mutations (>200 CGG repeats)99. Full mutations 
lead to fragile X syndrome, an X-linked recessive disorder causing intellectual 
disability mainly in boys99. Premutations result in POI in approximately 20% of female 
carriers100 and it is estimated that they account for 13% of familial POI cases and 1-7.5% 
of sporadic POI cases101. The exact pathogenic mechanism is not yet elucidated99. Allen 
et al. proposed that premutated mRNA has a toxic effect during reproductive life 
resulting in increased follicular atresia. This toxic effect could be attributed to 
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Figure 6: Overview of genes involved in the pathogenesis of POI (Adapted from Tucker et 
al. 201696). 
 ‘kidnapping’ of mRNA-binding proteins by the mutated FMR1-mRNA, causing a 
depletion of these proteins for other cellular processes99.  
Several genes involved in gonadogenesis are also involved in POI, for instance the 
FOXL2 and NR5A1 genes. FOXL2 is one of the early female defining genes and is not 
only known to have a function in ovarian development but also in ovarian 
maintenance102. The gene is expressed in developing eyelids and ovaries and 
autosomal dominant mutations are associated with the BPES syndrome. This 
condition is characterized by complex eyelid malformations associated (type I) or not 
with POI (type II)103. Several attempts have been undertaken to identify FOXL2 
mutations in patients with isolated, idiopathic POI; however identification rates are 
low104–106. The mechanism leading to POI can differ in women with FOXL2 mutations; 
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some of them show a block in follicle maturation, while others show an altered ratio 
of primordial to primary follicles107. NR5A1 is a second gonadogenesis-related gene 
involved in the pathogenesis of POI. First associated with 46,XY DSD (and adrenal 
insufficiency)108, NR5A1 inactivating mutations were later also found in women with 
POI109. NR5A1 disruption can disturb ovarian functioning on several levels including 
reduced germ cell number, impaired stromal integrity, abnormal folliculogenesis and 
defective steroidogenesis44. 
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3 GENETIC PATHWAYS INVOLVED IN SEX DEVELOPMENT AND DSD 
The following section will summarize some basic genetic concepts, necessary for 
understanding the genetic signaling pathways underlying DSD pathogenesis, 
followed by an overview of the different genes and pathways that are involved in 
gonadal development.  
3.1  Basic genetics 
3.1.1  The central dogma  
(Human) genetics is a rather young research field, as it was only in 1953 that the 
chemical structure of our genetic material, deoxyribonucleic acid (DNA), was 
elucidated by James Watson and Francis Crick110. The human genome is build up out 
of 3 billion repeats of only four building stones or nucleotides: dATP, dGTP, dCTP and 
dTTP (desoxy-(A,G,C or T)-triphosphate with A = adenine, G= guanine, C= cytosine 
and T= thymine).  These nucleotides are paired up according to the Chargaff’s rule; 
each basepair contains a purine (A and G) and a pyrimidine (C and T)111. In 2003, the 
exact sequence of all the nucleotides of our genome was determined by the Human 
Genome Project and it was estimated that our genes, functional DNA units that encode 
proteins, account for only 2% of our DNA112,113. The remaining portion of our DNA was 
refered to as “junk” DNA, as it did not have an apparent function at that time. To exert 
its function a gene first has to be transcribed to so-called messenger ribonucleic acid 
(mRNA) and translated to the corresponding protein, these processes form the central 
dogma of molecular biology114.  
However, this central dogma cannot explain the complex diversity of cell types (and 
functions) that are present in our body. If all our cells contain exactly the same genetic 
material, then how is it possible that a testicular Leydig cell is so different from a 
vascular endothelial cell. The answer to that question lays within the remaining 98% 
of non-coding DNA. In 2003, the Encyclopedia Of DNA Elements (ENCODE) project 
was initiated, aiming to catalogue all functionally important regulatory sequences115. 
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In general, the expression level of a gene is determined by (1) interaction of the 
transcription complex with the gene’s minimal promoter, (2) interactions with cis-
regulatory regions (enhancers, repressors, insulators) and (3) the surrounding 
chromatin structure116.   
3.1.2  Genetic defects: coding vs. non-coding 
Changes in our genetic code can result in altered protein functioning of expression 
patterns and can therefore cause diseases. Monogenic or Mendelian disorders are 
caused by a molecular defect in only a single gene and their inheritance follows clearly 
distinguished patterns (autosomal dominant/recessive, X-linked dominant/recessive 
and Y-linked). However situtions like de novo mutations, incomplete penetrance and 
genetic heterogeneity greatly complicate the genetic diagnostic process114.  
 Coding defects 
Initially genetic research only focused on the effects of variation in the coding regions 
of our genome. First of all, a distinction is made between sequence variations, in which 
only one or a couple of nucleotides have been changed; and structural variations, like 
copy number variations, in which a larger portion of our genome is disturbed. Each of 
these classes contains several types of variation and they are classified based on the 
change on DNA level and their consequence on the RNA or protein level. An overview 
of the most important types of coding variation (those relevant for this thesis) is given 
in Figure 7.  
Needless to say, that not every genetic variation is pathogenic, as these small changes 
mostly account for interpersonal phenotypic variations. Interpretation of the identified 
variants remains challenging despite the publication of classification guidelines by the 
American College of Medical Genetics117. Classification criteria include segregation 
analysis, absence in the general population, the nature of the variant and functional 
evidence. Based on these criteria a variant can be classified as not disease causing, 
likely not disease causing, possibly disease causing, likely disease causing, disease 
causing or as a variant of unknown significance117.  
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Figure 7: Coding genetic variations. Left: different types of sequence variations and their 
effect on the encoded protein. Missense substitution lead to the alteration of one amino acid, a 
nonsense substitution changes a regular codon to a stopcodon, leading to premature ending 
of the protein and in most cases degradation. In-frame deletion/duplications (multiple of three 
nucleotides) result in the deletion/insertion of one or several amino acids, without an effect on 
the reading frame. Frameshif deletions/duplications on the other hand to hamper the reading 
frame and result in a completely different amino acid sequence and an altered stop codon  
Right: different types of structural variation. Structural variations involve bigger portions of 
the genome. The most important ones are duplications, in which additional copies of a 
genomic region are present; and deletions, in which a genomic region is missing. Inversions 
of a genomic region can also perturb the correct genomic sequence.  
Furthermore, mutations can also be classified based on their functional effects, namely 
loss-of-function and gain-of-function variation. Loss-of-function mutations result in 
a diminished protein function and are caused by hypomorphic alleles or null alleles 
(in this case all function is lost). Loss-of-function mutations are usualy associated with 
autosomal recessive disorders as for most genes 50% of the normal gene product is 
sufficient for normal functioning114. A DSD-related example of loss-of-function 
variation can be found in the steroid hormone biosynthesis disorders. Both alleles of 
an enzyme need to be abrogated to have a phenotypic consequence. Gain-of-function 
mutations result in either increased function of a protein (hypermorphic allele) or in a 
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newly acquired function (neomorphic allele). This type of mutations is generally 
associated with an autosomal dominant inheritance pattern114.  
Non-coding defects 
Besides an intact coding sequence, appropriate gene expression, and subsequent 
protein expression, requires correct interactions with the surrounding, non-coding 
regions as well. These regulatory regions enable expression of the right gene, at the 
right time. Over the years more and more mechanisms have been elucidated by which 
these regulatory regions exert their functions and how they can cause phenotypes 
when perturbed. These mechanisms include disruption of cis-regulatory elements, the 
interplay with non-coding RNAs and epigenetic modifications. Cis-regulatory DNA 
elements are the non-coding DNA fragments, located in the proximity of coding genes, 
that regulate the expression of these neighbouring genes118–123. Most of the regulatory 
defects in DSD pathogenesis involve defects of these cis-regulatory elements resulting 
in aberrant gene expression pattern. Specific examples ars reviewed in paper 5 of this 
thesis and include regulatory structural variation, deep intronic variation resulting in 
alternative splicing and the introduction of upstream open reading frames124. The 
importance of non-coding RNAs, genes that are transcribed to RNA but not translated 
to proteins, and epigenomic regulation in gonadal development and function has 
recently been reviewed by Wilhelm and Bernard125.  
3.2  The undifferentiated stage 
Sex development starts with the correct formation of the bipotential gonadal 
primordium from the intermediate mesoderm. Studies in mice have shown that many 
genes are implicated in this process; however human mutations leading to gonadal 
agenesis are very rare. Two groups of genes have been related to these earliest stages 
of gonadal development: homeobox genes (Lim homeobox 9, Lhx9; Empty spiracles 2, 
Emx2; Chromobox 2, Cbx2/M33) and genes encoding transcription factors (Wt1, Sf-1). 
Maintenance of the urogenital ridge is achieved by promoting cell proliferation and 
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preventing apoptosis1,2,126. The known and presumed interactions between these early 
genes are shown in Figure 8.  
 
Figure 8: Overview of the early regulators of sex development. These genes are implicated 
in the development of the bipotential urogenital ridge. The Wt1-KTS isoform is known to 
activate Sf-1 expression together with Lhx9. Both Wt1 and Sf-1 have an effect on Dax1 
expression. It is currently unclear where M33 and Emx2 fit in this model and what their 
interaction partners are (based on Wilhelm et al. 2007126). 
Lhx9 belongs to the Lim homeobox gene family and is required for proliferation of the 
genital ridge cells. Lhx9-/- mice are all phenotypically female and are characterized by 
absence of gonads in both sexes127. These mice also show reduced levels of Sf-1 
expression, implicating that Lhx9 is an upstream regulator of this gene. Wilhelm et al. 
showed that Lhx9 can bind directly on the Sf-1 promoter, both in vitro and in vivo, and 
that this has an additive effect on Wt1 induced Sf-1 expression128. Emx2 is the mouse 
orthologue of the Drosophila empty spiracles gene and is expressed in the epithelial parts 
of the developing urogenital system. Emx2 deficient mice show a complete lack of 
gonads and genital tract. Up to now, nothing is known about its regulation and 
interactions with target genes129. In humans rare EMX2 mutations have been associated 
with schizencephaly and somatic mutations have been found in endometrial cancer, 
no gonadal defects have been described130. Cbx2 is the mouse orthologue of the 
Drosophila gene Polycomb. Deficient male mice show male-to-female sex reversal and 
ovaries are absent or hypoplastic in female mice. The gene has been implicated in 
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adrenal Sf-1 regulation, but it is unclear whether it has a similar function in the 
developing gonads131,132. So far, one case with a CBX2 mutation and gonadal 
dysgenesis has been described. Initially, this girl was reported to have normal ovaries, 
but reassessment of the gonadal tissue revealed streak gonads, in accordance with the 
presence of hypergonadotropic hypogonadism observed in this girl (unpublished 
observations). 133.  
Transcription factors Wt1 and Sf-1 have multiple roles during sex development, 
starting in the earliest stages. Wt1 is expressed in the undifferentiated gonad and acts 
as a repressor of apoptosis. Wt1-/- mice are characterized by gonadal and adrenal 
apoptosis, which can be linked to two different pathways134,135. First of all Wt1 is co-
expressed with Sf-1 in the gonadal primordium and it was shown that Sf-1 is a direct 
target gene of Wt1; therefore gonadal apoptosis might be related to the absence of Sf-
1 signaling in Wt1 deficient mice128. A second pathway is Sf-1 independent and acts 
through Bcl2 signaling, an anti-apoptotic gene and known Wt1 target gene136. Sf-1 
deficiency itself also leads to abnormal gonadal development; both female and male 
mice fail to develop gonads beyond the early differentiated stage. All Sf-1 deficient 
mice show a female phenotype without adrenals and gonads137,138.  
3.3  Male sex developmental pathways 
3.3.1 SRY: the master switch and how to turn it on 
Up to this point of development there is no difference between the expression patterns 
of the gonadal primordium in 46,XX or 46,XY embryos, nor is there a phenotypical 
difference. A first molecular event in the testis determination pathway is the 
upregulation of SRY expression. The single-exon SRY gene encodes a transcription 
factor with a highly conserved DNA-binding domain, the so-called high mobility 
group (HMG) box that binds and bends DNA139. In mice, Sry is expressed from 10.5 
days post coitum (dpc) until 12.5 dpc starting from the center of the genital ridges and 
proceeding to the poles; in humans SRY expression is initiated at embryonic day 41 
and is maintained at lower levels beyond embryogenesis140–142. Despite intensive 
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research, little is known about SRY’s function and target genes. Some reports suggest 
a role for SRY in transcriptional activation, others in transcriptional repression143,144. An 
activating role is supported by transgenic mice in which the trans-activating domain 
is depleted; these mice fail to undergo normal male development143.  
Human SRY mutations 
Since the identification of SRY, numerous mutations and structural variants have been 
described in a plethora of phenotypes145–149. Altogether, translocations of the SRY gene 
to the X chromosome or the autosomes can explain roughly 90% of 46,XX testicular 
DSD and inactivating point mutations, most of which are located in the conserved 
HMG-box, account for approximately 15% of 46,XY GD cases2. Besides these coding 
variants, several SRY regulatory defects have been described150–152, emphasizing the 
necessity of its spatiotemporal regulation for normal gonadal development. This fits 
the current belief that SRY expression should reach a certain threshold in a specific 
time window to direct the precursor supporting cells towards a Sertoli cell fate. 
Additional proof for this hypothesis is given by the B6-Ypos mouse, that possesses a 
‘weak’ Sry allele, leading to delayed Sry expression and subsequent development of 
ovotestes. Similar mouse experiments also confirmed the existence of a threshold of 
Sry expression levels for the induction of testis development153,154.  
The path towards SRY 
Despite its functional importance, the pathways regulating SRY expression are far 
from elucidated. Early insights were gathered via knock-out mouse models and 
validated by the identification of human mutations in 46,XY GD phenotypes. The most 
important factors and their working mechanisms are described and depicted below 
(Figure 9). 
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Figure 9: Overview of the most important regulators of SRY expression. (A) SRY expression 
is regulated by WT1, more specifically the +KTS isoform, the GATA4/FOG2 transcription 
complex and the MAPK pathway. (B) The WT1+KTS isoform is involved in SRY activation by 
binding and stabilizing the SRY mRNA155,156. (C) GATA4 together with its co-factor FOG2 
upregulates SRY expression. Besides this role in testicular determination, the complex is also 
believed to be involved in the upregulation of AMH later on. (Based on Zaytouni et al, 
2011157.(D) Overview of the mechanism of MAP3K1 action during normal male development. 
MAP3K1 gain-of-function mutations will lead to increased binding of RHOA and Rock, two 
female specific factors that can inhibit SOX9 and to increased phosphorylation of p38 and 
ERK1/2. Hyperphosphorylation will stabilize β-catenin and initiate female developmental 
pathways. Furthermore these gain-of-funtion mutations will sequestrate AXIN and MAP3K4, 
thereby abolishing SRY activation. (Based on Ostrer, 2014158). 
The previously mentioned WT1 gene is not only important for development of the 
undifferentiated gonad (specifically the –KTS isoform); a second isoform WT1+KTS is 
involved in SRY upregulation. Both isoforms are the result of alternative splicing at 
the end of exon 9 and only differ by the absence (-KTS) or presence (+KTS) of three 
amino acids; Lysine, Threonine and Serine (KTS). The functional difference between 
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these two isoforms was described by Hammes et al.; transcript specific knock-out mice 
displayed different phenotypes. Heterozygous mice with reduced Wt1+KTS 
expression develop a phenotype resembling Frasier syndrome. Homozygous 
Wt1+KTS deficient mice die shortly after birth because of renal insufficiency and they 
show complete male to female sex reversal due to lowered levels of Sry159. 
Homozygous Wt1-KTS deficient mice are characterized by hypo- and dysplastic 
kidneys and streak gonads159. These phenotypical differences are also encountered in 
human WT1 mutations: mutations perturbing the functioning of all WT1 transcripts 
result in Denys-Drash syndrome, mutations leading to reduced levels of WT1+KTS 
and perturbing the –KTS/+KTS balance cause Frasier syndrome (described in section 
2.2.1). Additional research revealed that the WT1+KTS isoform is not a direct activator 
of SRY transcription, but that it preferentially binds to SRY mRNA, functioning as a 
posttranscriptional stabilizer155,156 (Figure 9B). 
A second transcription factor acting on SRY activation is GATA-binding protein 4 
(GATA4) and its co-factor Friend of GATA4-2 (FOG2 or ZFPM2) (Figure 9C). Both 
genes/proteins are highly expressed in the developing gonads and cardiac tissue157. 
Their involvement in the regulation of the initial steps of gonadal differentiation was 
first assessed by evaluation of knock-out models160. Gata4-/-  mice die at 7-9.5 dpc due 
to severe cardiac abnormalities, making it impossible to study the effect on gonadal 
differentiation161. This restriction was overcome by generation of a Gata4ki/ki knock-in 
mouse model, that specifically abrogates the interaction between Gata4 and its co-
factor Fog2, these mice survive up to 13.5 dpc162. Fog2-/- mice survive until 14.5 dpc, 
allowing assessment of early gonadal development163. Both Fog2-/- and Gata4ki/ki mice 
show similar defects in gonadal development: testicular cords fail to form by 13.5 dpc, 
Sry expression is reduced, Sry target gene expression is absent as is expression of genes 
essential for the onset of testosterone biosynthesis157,160. Besides this early role in sex 
determination, the GATA4/FOG2 complex is also believed to play a role in regulation 
of SOX9 and AMH expression157. In humans, GATA4 and FOG2 
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mutations/translocations were first identified in patients with heart septation defects 
and tetralogy of Fallot respectively164–166. Later on, identification of point mutations in 
patients with 46,XY DSD confirmed their importance in human sex development167,168.  
More recently, the Mitogen-activated protein kinase (MAPK) pathway has been 
implicated in these early stages of testicular development. Using a forward genetic 
screen in mice, Bogani et al. identified a homozygous boygirl (byg) mutation, a 
missense variant in the mouse Map3k4 gene leading to male-to-female sex reversal. On 
the cellular level, this mutation leads to decreased somatic cell proliferation in the 
coelomic epithelium and to decreased mesonephric cell migration. On the molecular 
level, a dramatic reduction in the expression of Sox9 and Sry was noticed on both 
mRNA and protein level169. One year later, Pearlman et al. described MAP3K1 
mutations in two families and 11 sporadic cases with 46,XY DSD.  Follow-up studies 
aimed to unravel the molecular mechanism behind these mutations which are 
different in mice and humans (reviewed in Ostrer et al. 2014 158). In mice, Map3k4 
together with its binding partner Gadd45γ induce Sry expression via p38 
phosphorylation and subsequent Gata4 activation. Homozygous loss-of-function 
mutations perturb this pathway and cause male-to-female sex reversal170,171. So far, no 
homozygous MAP3K4 mutations have been identified in humans, most likely because 
they are embryonically lethal. The identified human MAP3K1 variants on the other 
hand have a gain-of-function effect. During normal male development, MAP3K1 
interacts with AXIN1 and MAP3K4 which in its turn interacts with GADD45γ to 
augment SRY expression. At the same time MAP3K1 phosphorylates p38 and ERK1/2 
that have a suppressing effect on female development via β-catenin inhibition. In case 
of MAP3K1 gain-of-function mutations, the female developmental situation is 
mimicked. These mutations lead to an increased phosphorylation of downstream 
targets like p38 and ERK1/2 and increased binding of female specific co-factors like 
RHOA and Rock. Hyperphosporylation of p38 and ERK1/2 leads to inhibition of SOX9 
and stabilization of β-catenin and upregulation of its downstream targets like FOXL2. 
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A possible sequestration of male specific proteins AXIN and MAP3K4 abolishes 
MAP3K4-induced SRY expression158. Figure 9D summarizes the MAP3K1 related 
events during normal male development.  
3.3.2 Downstream events in testicular development 
Once SRY is activated, a male specific gene expression cascade is initiated resulting in 
Sertoli and Leydig cell differentiation. The following paragraphs will focus on the most 
important genes in male development: NR5A1 and the SOX genes. Figure 10 
schematically shows the different interactions of these genes during development. An 
overview of other involved genes is given in Table 3 at the end of this section, genes 
implicated in the undifferentiated stage are also mentioned.  
 
Figure 10: Overview of the most important genes for male sex development and their 
interactions (based on Ono et al. 2014172) 
NR5A1: a gene with many faces 
NR5A1 or steroidogenic factor-1 (SF-1) was first mentioned as one of the genes 
responsible for the development of the undifferentiated gonad, but later it turned out 
to be crucial in several subsequent steps of gonadal development and functioning such 
as Sertoli cell differentiation and steroidogenesis. Furthermore, NR5A1 plays a role 
in the regulation of the hypothalamic-pituitary axis. 
The NR5A1 protein belongs to the nuclear receptor family and has a broad expression 
range, consistent with a role in different processes. In mice, Sf-1 expression is observed 
in the adrenogonadal primordium as early as 9 dpc108. In humans, expression starts in 
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the bipotential gonad at embryonic day 32-33, and it is consistently maintained in the 
somatic cells of the early testis, where it first serves a critical role in Sertoli cell 
differentiation108,173. A study by Sekido and Lovell-Badge has demonstrated that Nr5a1, 
together with Sry, can bind on multiple elements of a Sox9 gonad-specific enhancer in 
mice. Their work is also in favor of a feedforward, self-reinforcing signaling loop in 
which Sox9 together with Nr5a1 bind the same enhancer elements to maintain Sox9 
expression174.  In humans, adequate SOX9 expression is critical for Sertoli cell 
differentiation (discussed below). Once Sertoli cells are functional, a second role for 
NR5A1 emerges. Starting at approximately 7 weeks of gestation, NR5A1 activates the 
expression of AMH resulting in the regression of Müllerian ducts in male fetuses175. 
NR5A1 can also be seen as the initial trigger for virilization of the external genitalia, as 
it is a key activator of the CYP and the HSD enzymes that are crucial for steroid 
hormone production176. Besides expression in the developing gonads and adrenals, 
NR5A1 expression also occurs in the ventromedial hypothalamus and the pituitary 
where it contributes to the reproductive axis by transcriptional activation of the genes 
encoding gonadotropin-releasing hormone (GnRH), FSH and LH177,178. Most recently, 
a role for NR5A1 in the development of the spleen has been postulated179,180. Despite 
extensive knowledge on NR5A1 target genes, far less is known about regulation of 
NR5A1 itself108. 
In the mid-80’s three different Nr5a1 knock-out (KO) mice were independently 
generated. Despite using different approaches, all three groups reported a similar 
phenotype. Homozygous NR5A1 KO mice exhibit complete gonadal and adrenal 
agenesis resulting in severe adrenal failure and a female phenotype with persistent 
Müllerian ducts in male mice. Moreover, these animals have an abnormal spleen and 
ventromedial hypothalamus, and reduced gonadotropin secretion138,181,182. 
Heterozygous KO mice show a less severe phenotype including hypoplastic adrenals 
and gonads during development. Remarkably, the adrenal hypoplasticity is partially 
compensated at later developmental stages and in adult life by increased proliferation 
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and these adrenals show an increased steroidogenic capacity. In the hypoplastic 
gonads no compensatory mechanisms have been observed. This disparity  might by 
related to upregulation of a related transcription factor Ngfib in the adrenals which 
could compensate for Nr5a1 haploinsufficiency and which is not expressed in gonadal 
tissue183. This mechanism might also explain why human heterozygous mutations 
have a more distinct gonadal phenotype and apparently normal adrenal functioning. 
Zhao et al. created a conditional KO mice, exclusively targeting NR5A1 expression in 
the central nervous system. These pituitary-specific KO mice are sterile and fail to 
develop normal male secondary characteristics. Ovaries and testes are significantly 
hypoplastic and FSH and LH levels are diminished. These studies established an 
essential role for NR5A1 in pituitary functioning178.  
This broad functional spectrum of NR5A1 is mirrored in the plethora of phenotypes 
seen in patients with NR5A1 mutations. The first human NR5A1 mutation was a 
homozygous mutation identified in a patient with 46,XY DSD and primary adrenal 
failure45 and was quickly followed by the identification of heterozygous mutations in 
numerous patients with isolated 46,XY DSD. Screening of larger patient populations 
allows a prevalence estimation of NR5A1 mutations in 46,XY DSD cohorts; several 
studies report identification rates of ~15%184,185. For unknown reasons, the negative 
impact of NR5A1 mutations on steroidogenesis seems to resolve at least partially in 
puberty, leading to marked virilization of female and undermasculinised male 
patients186. Moreover, NR5A1 mutations have also been associated with distinct 
reproductive phenotypes such as hypospadias, bilateral anorchia and male infertility 
(reviewed by Ferraz-de-Souza)44. In women, NR5A1 mutations are associated with 
POI, and very recently a specific mutation, c.274C>T p.(Arg92Trp), has been 
implicated in 46,XX (ovo)testicular DSD by our group and two other teams (Chapter 
4)109,187–189 
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SOX genes 
To date, the only genuine candidate target gene for SRY is SOX9, also a transcription 
factor belonging to the SOX family characterized by the presence of a HMG-box. The 
first indication of its role in male sex development is its expression pattern; in the 
undifferentiated gonad Sox9 is expressed at low levels in both sexes, but it is 
extensively upregulated immediately after Sry expression in Sertoli cells. In addition, 
Sox9 expression is observed in developing chondrocytes190. As mentioned above Sox9 
is activated by a synergistical interaction of Sry and Nr5a1 on the Sox9 promoter174. The 
importance of Sox9 in testis development was confirmed by the phenotype of a Sox9 
knock-out mouse; gonads of this XY KO mice are characterized by ovarian 
differentiation191. Furthermore, SOX9 overexpression in XX mice revealed that Sox9 is 
not only indispensable but also sufficient for testis development192. 
Once SOX9 is expressed, it initiates multiple feedforward loops to maintain its own 
expression. A first loop starts with Sox9-induced upregulation of Fibroblast growth 
factor 9 (Fgf9). The Fgf9 protein activates the FGF receptor 2 (FGFR2), which has a 
positive effect on Sox9 expression193. Loss-of-function mouse models of both Fgf9 and 
Fgfr2 are characterized by male-to-female sex reversal194,195. A second loop acts via the 
prostaglandin D synthase (Ptgds) gene, resulting in increased prostaglandin D2 
secretion which acts in paracrine and autocrine ways and promotes the nuclear 
translocation of Sox9196,197. Remarkably, both feedforward loops can also induce Sox9 
expression in neighbouring cells without endogenous Sry, showing that not Sry 
expression but indeed Sox9 expression is a prerequisite for Sertoli cell differentiation84. 
Besides activation of these maintenance target genes, different SOX9 target genes have 
been discovered, as described below126. SOX9 expression also seems to be responsible 
for maintenance of NR5A1 expression in Sertoli cells198. Together with NR5A1, SOX9 
has a critical role in upregulation of AMH. Based on experiments by Arango et al, it is 
SOX9 that effectuates the actual transcriptional activation, while NR5A1 has a 
modulatory function199. Likewise, the SOX9-NR5A1 tandem is required for 
55 
 
upregulation of Vanin-1, a gene implicated in protection of primordial germ cells 
against oxidative stress200. 
 In humans, loss-of-function mutations and regulatory defects are a known cause of 
campomelic dysplasia, a semi-lethal skeletal malformation syndrome with 46,XY DSD 
in 75% of male cases42. Duplications, both coding and regulatory, cause 46,XX DSD or 
Cooks syndrome (brachydactyly and anonychia), depending on the duplication size 
and position43,201. Disruption of specific long-range cis-regulatory elements are a 
known cause for Pierre-Robin-sequence, a condition characterized by craniofacial 
malformations202,203. This phenotypic spectrum emphasizes the need of an intact SOX9 
regulatory region, known to be over 1 Mb long. The regulatory mechanisms leading 
to these different phenotypes were reviewed recently by our group (see this thesis, 
Chapter 5)124. 
SOX9 appears not to be the only SOX gene involved in sex development. Gain-of-
function variants of SOX3 are known to cause 46,XX DSD and ectopic expression of 
Sox3 in a transgenic mouse resulted in a comparable phenotype84,204. In mice, ectopic 
expression of Sox10 was also reported to induce Sry-independent female-to-male sex 
reversal. Sox10 KO mice on the other hand did not have a phenotype, suggesting that 
Sox10 is not necessary for testis development but that it can function as a testis- 
determining gene205. A few SOX10 encompassing duplications have been described in 
patients with 46,XX DSD, however, it remains debatable whether the sex seversal is 
attributed to SOX10 as these rearrangements also contained other genes2. Based on its 
expression pattern and its ability to induce in vitro Amh expression, a sex 
developmental function was also suggested for Sox8. Despite the absence of a severe 
gonadal phenotype in Sox8-/- mice, a double Sox8/Sox9 KO model confirmed a role for 
Sox8 as a reinforcer of Sox9. Both genes are functionally redundant206.  
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Table 3: Overview of the genes involved in the development of the undifferentiated gonad and genes involved in testicular 
development (based on reviews by Ono et al. and Eggers et al.2,172) 
 Gene Locus Function Inheritance Mouse Phenotype Human Phenotype  
      DSD related Other  
 Genes involved in the development of the bipotential gonad  
 Emx2 10q26.11 TF ? Emx2 −/− lacking kidneys, ureters, 
gonads and genital tracts 
* *  
 Lhx9 1q31.3 TF ? Lhx9 −/− fail to develop bipotential 
gonad 
* *  
 M33/Cbx2 17q25 TF AR Cbx2 −/− 
XY male-to-female sex reversal 
XX impaired ovary development 
46,XY DSD 
 
Normal   
 Nr5a1 9q33 NR/TF AD/AD Nr5a1 −/− : fail to develop 
bipotential gonad and adrenal 
Nr5a1+/–: impaired adrenal stress 
response, small gonads 
46,XY gonadal dysgenesis, 
hypospadias, micropenis 
46,XX (ovo)testicular DSD, XX POI 
Primary adrenal failure  
 Wt1 11p13 TF AD Wt1 −/− mice fail to develop bi-
potential gonad 
46,XY DSD Wilms tumor, renal 
abnormalities, gonadal tumours  
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 Genes involved in testis development  
 Arx Xp22.13 TF X ARX– : Arrest of Leydig cell 
differentiation, abnormal neuronal 
migration 
Dysgenetic testis, no Müllerian 
structures, ambiguous external 
genitalia 
Lissencephaly, epilepsy, 
temperature instability 
 
 Atrx Xq13.3 Chromatin 
remodeling 
protein 
X ATRX–: embryonically lethal 
Sertoli-cell-specific ATRX–: small 
testes and discontinuous tubules 
(fetal period), delayed onset of 
spermatogenesis (postnatal)  
Dysgenetic testis, no Müllerian 
structures, female/ambiguous/male 
external genitalia 
α-Thalassaemia, mental 
retardation, dysmorphic face 
 
 Dhh 12q13.1 Signaling 
molecule 
AD/AR Dhh −/− disruption of testis cord 
formation due to abnormal 
peritubular tissue 
46,XY partial or complete gonadal 
dysgenesis 
Minifascicular neuropathy  
 Dmrt1 9p24.3 TF Monosomic 
deletion 
Dmrt1 −/− impaired testis 
development and loss of Sertoli and 
germ cells 
46,XY gonadal dysgenesis Facial abnormality, intellectual 
disability, microcephaly 
 
 Fgf9  13q12.11 Signaling 
molecule 
? Fgf9 −/− XY male-to-female sex 
reversal and impaired development 
of Sertoli cells 
*   
 Fog2 8q22.3 Co-factor AD Fog2 −/− Reduced Sry levels, XY 
male-to-female sex reversal 
46,XY DSD Congenital heart malformations  
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 Gata4 8p23.1– 
p22 
TF AD Gata4 −/− embryo lethality (E7–E9.5) 
 
Gata4ki severe anomalies of testes 
46,XY DSD Congenital heart malformations  
 Mamld1 Xq28 Co-
activator 
X Normal  Hypospadias  Normal   
 Map3k1 5q11.2 Kinase AD ° 46,XY partial or complete gonadal 
dysgenesis 
Normal  
 Map3k4  Kinase   XY male-to-female sex reversal *   
 Nr0b1/Dax1 Xp21.3 NR/TF X XY impaired testis cord formation 
and spermatogenesis (genetic 
background dependent 
LOF: congenital adrenal hypoplasia 
Duplications: 46,XY gonadal 
dysgenesis with hypogonadotropic 
hypogonadism 
Cleft palate, intellectual 
disability 
 
 Sox3 Xq27.1 TF X ° Duplications (including SOX3) and 
regulatory deletion: 46,XX testicular 
DSD 
  
 Sox8 16p13.3 TF ? Sox8 −/− reduced fertility *   
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Sox8 −/−, Sox9 −/− XY variable 
degree of male-to-female sex 
reversal 
 Sox9 17q24–
q25 
TF AD Sox9 −/− XY male-to-female sex 
reversal 
46,XY gonadal dysgenesis  Campomelic dysplasia  
 Sox10 22q13.1 TF ? ° Duplication encompassing SOX10 
(includes also other genes): 46,XX 
(ovo)testicular DSD 
  
 Sry Yp11.3 TF Y Sry- : XY male-to-female sex 
reversal 
Sry translocation: XX female-to-
male sex reversal 
LOF: 46,XY DSD GOF/Translocation: 
46,XX testicular DSD 
  
 AD= autosomal dominant, AR= autosomal recessive, GOF = gain of function, LOF = loss of function, NR=nuclear receptor, TF= transcription factor,  X= X-
linked, *= no mutations described so far, °= no gonadal phenotype observed 
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3.4   Female sex developmental pathways 
For a long time, ovarian development has been seen as the default developmental 
pathway in the absence of SRY, for which no active genetic steps are required. 
However, several lines of evidence contradict these views and are more in favor of the 
existence of ovary-specific genes and pathways. First, like any other organ, ovaries 
are build up out of different interacting cell types and as for other tissues it would be 
more likely that these complex differentiation processes require specific gene 
expression patterns. Second, human 46,XY DSD phenotypes, in the absence of Sry (e.g. 
SRY deletions), result in complete gonadal dysgenesis rather than ovarian 
development and/or function, suggesting that active processes are necessary for 
ovarian development. Thirdly, observations of sex reversed mice showed that Sry 
needs to act during a specific time window to prevent ovarian differentiation, 
implying that competitive ovarian factors are present and need to be inhibited in a 
timely fashion126. Two different mechanisms underlying ovarian development were 
proposed: the existence of an SRY counterpart, an ovary-determining gene, and the 
Z-factor hypothesis207. The first mechanism hypothesized that, given the importance 
of SRY in testis determination, the existence of a parallel ovary-determining gene is 
very likely208. Given the ovary-specific expression and its location on the X 
chromosome, Dosage-Sensitive Sex Reversal (DAX1) was initially considered a good 
candidate. Transgenic and KO mouse studies counter this assumption; Dax1 depletion 
has no or little effect on ovarian development and causes severe testicular 
dysgenesis207. The Z-factor model, on the other hand, could form an explanation for 
those cases in which 46,XX individuals in the absence of SRY, develop testes. The Z-
factor is supposed to be a gene expressed in the XX gonad to repress testis 
development, thereby allowing ovarian differentiation. In XY gonads, the Z-factor is 
repressed by SRY expression. Inactivation of the Z-factor in XX individuals, would 
abrogate inhibition of the male pathways, thereby causing female-to-male sex 
reversal144. Due to their ability to antagonize testis development, genes like Foxl2 and 
Wingless-Type MMTV Integration Site Family, Member 4 (Wnt4) have been suggested as 
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candidate Z-factor genes, however KO mice do not show female-to-male sex reversal, 
which is considered to be a critical feature of the Z-factor. The absence of one clear 
candidate gene suggests that a more complex pathway probably exists in which 
several genes play a role, but none of them are sufficient on their own207.  Below, the 
two most studied pathways in ovarian differentiation will be elaborated: the 
Wnt/RSPO1/β-catenin pathway and FOXL2. An overview of their interactions is given 
in Figure 11.  
 
Figure 11: Overview of the most important genes for female sex development and their 
interactions (based on Ono et al. 2014172). 
3.4.1 The WNT/RSPO1/β-catenin pathway 
The “canonical” WNT signaling pathway is widely used during developmental 
processes, including ovarian development. WNT protein ligands can bind with the 
membrane-associated Frizzled/LRP5/6 receptor complexes leading to receptor 
dimerization. Subsequently, β-catenin is detached from a β-catenin destruction 
complex, allowing nuclear translocation and interaction with target gene promoters. 
In the absence of Wnt ligand, β-catenin is retained in the destruction complex, and can 
therefore not act as a transcriptional activator209.  
In mice, Wnt4 expression starts in the undifferentiated gonads of both female and male 
mice. At 11.5 dpc its expression is upregulated in differentiating ovaries and the 
mesenchyme surrounding the Müllerian ducts and downregulated in males210. Wnt4 
KO mice display partial female-to-male sex reversal, suggesting that Wnt4 has a 
positive role in ovarian development. Wnt4-/- XX gonads show both masculine and 
feminine characteristics; they display testis-like vascularization and androgen 
production, but on the other hand oocytes are still present although drastically 
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reduced in number and gonads lack testis cords210,211. Transgenic XY mice 
overexpressing Wnt4 do not show male-to-female sex reversal; suggesting that 
although Wnt4 plays an important role in at least some aspects of ovarian 
development, it is not sufficient to trigger these processes212. Inactivating WNT4 
mutations in humans mimic to a certain extent the observed mouse phenotype, 
indicating a conserved role for WNT4 in mice and humans213–215.  
Work by Chassot et al. has shown that other factors like RSPO1 also play a role in β-
catenin upregulation. They developed a Rspo1 KO mouse characterized by 
masculinized females. These Rspo1-/- mice fail to activate Wnt4 and display testicular 
vascularization and steroidogenesis as a consequence. Furthermore gonadal Sox9 
expression is observed around birth,  resulting in sex cord formation216. Expression 
analysis experiments in Wnt4-/- and Rspo1-/- mice proved that Rspo1 is necessary for 
robust Wnt4 activation in the developing gonad and that it functions as an upstream 
regulator of β-catenin stabilization. The first human RSPO1 mutations were found in 
families with an autosomal recessive syndrome that includes 46,XX testicular DSD and 
skin abnormalities85  
Conditional β-catenin KO mice confirm its importance in ovarian development, as they 
display ovarian defects comparable to those observed in Wnt4 and Rspo1 KO mice217. 
Overexpression of β-catenin in the somatic cells of developing XY gonads, results in 
disruption of testis development and male-to-female sex reversal. These data 
underscore the importance of β-catenin as a key ovarian-promoting gene and an anti-
testis gene. No human β-catenin mutations have been identified so far218.  
3.4.2 FOXL2 
A fourth important gene in ovarian development is FOXL2, first implicated in sex 
development with the identification of a deletion in the proximity of Foxl2 in the polled 
intersex (PIS) goat. These goats are characterized by polledness in both sexes and 
female-to-male sex reversal in XX goats219. FOXL2 mutations in humans are associated 
with BPES syndrome, as previously mentioned, characterized by eyelid malformations 
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and POI in a number of cases. To date, no FOXL2 mutations have been found in 46,XX 
testicular or OT DSD cases. The BPES phenotype is mimicked in Foxl2-/- mice and no 
sex reversal has been reported78,220,221. Curiously, Foxl2-/-, Wnt4-/- double knock-out mice 
do display testis differentiation, underlining the relevance of a synergistic action of the 
two genes for ovarian development and inhibition of testicular development222. 
Moreover, conditional Foxl2 KO in adult XX mice results in transdifferentiation of 
ovarian tissue to testicular tissue with upregulation of male specific genes like Sox9. 
More information on transdifferentiation and interaction between male and female 
pathways is presented below102.   
3.5    Interactions between the male and female pathways and gonadal  
transdifferentiation  
In contrast to environmentally regulated sex determination, that has been studied in 
species like fish, amphibians, reptiles and birds, genetically determined sex 
development has been believed to be irreversible once the decision has been taken. In 
recent years however, it has become increasingly clear that active gene expression 
throughout life is required for gonadal maintenance. These findings have led to the 
elucidation of several inhibitory interactions between male and female specific genes 
(Figure 12) 6,207,223.  
Ottolenghi et al. were the first to attribute an ovarian maintenance role to FOXL2224. 
Gene expression analysis in Foxl2-/- adult mice revealed upregulation of male specific 
genes like Sox9. Furthermore, these mice had ovaries containing a cord-like structure, 
resembling testicular cords. These results are in favor of ongoing requirement of Foxl2 
to maintain ovarian cell fate224.  Creation of a conditional Foxl2 KO mouse model 
confirmed this hypothesis. Adult mice showed upregulation of Sox9 and other genes 
and transdifferentiation of granulosa and theca cells to Sertoli and Leydig cells 
respectively. They showed that Foxl2, together with estrogen receptors, inhibits Sox9 
expression by interaction with Testic-specific Enhancer of SOX9 Core region (TESCO) 
in the ovary102. Similarly, testicular cell fate is also unstable; loss of Dmrt1 in mouse 
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Sertoli cells reprograms them to a granulosa fate through activation of Foxl2225. These 
examples suggest that antagonism between male and female specific genes is required 
at least for gonadal maintenance in mice. Comparable antagonistic pathways have 
been described during the fetal period; Sox9 and Fgf9 expression in male mice 
represses expression of Wnt4/β-catenin and vice versa, however the molecular 
mechanism regulating this repression remains enigmatic193.  
 
 
Figure 12: Summary of the interactions and antagonisms between male and female genes 
during gonadal development and after birth. Black arrows: established pathways leading to 
male and female development. Orange lines and boxes: female specific genes and their 
repressing roles on male specific genes. Blue lines and boxes: male specific genes and their 
repressing actions on female specific genes. (Adapted from Wilhelm et al. 20136).  
The existence of these mutual antagonistic interactions, led to the hypothesis that 
abrogation of both pathways should result in neither testicular nor ovarian 
development. This hypothesis was tested by generation of two double KO mice: a Fgf9-
/-, Wnt4-/- mouse and a Sox9-/-, Rspo1-/- mouse226,227. Remarkably, neither of the XY mice 
showed sex reversal. Male Sox9-/-, Rspo1-/- mice are characterized by delayed testicular 
development resulting in hypoplastic testes with well-defined seminiferous cords, the 
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early stages of spermatogenesis are supported as well however these germ cells fail to 
initiate meiosis226. For male Fgf9-/-, Wnt4-/- mice similar observations were made227. In 
both double KO models, the XX phenotype resembled the one observed in Wnt4 and 
Rspo1 single KO mice226,227. The results in both XX and XY double KO mice suggest that 
Rspo1 and Wnt4 are truly necessary for ovarian development and that Sox9 functions 
can be taken over by redundant Sox genes. Furthermore the Fgf9, Wnt4 double KO 
model shows that Fgf9 signaling has a role in suppressing female differentiation rather 
than in supporting male development6. 
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4 DIAGNOSIS AND MANAGEMENT OF DSD PATIENTS 
Today it is generally accepted that care for DSD patients requires the professional 
expertise of a multidisciplinary team (MDT) in which each member has specific know-
how about the different aspects of these conditions21. These multidisciplinary teams 
are ideally coordinated by a “patient navigator” who forms a bridge between the team 
and the patient. Other members include an endocrinologist, urologist, gynaecologist, 
psychologist, biochemist, and clinical and molecular geneticist (Figure 13)228.  
Furthermore DSD care should be centered in so-called centers of expertise that are 
capable of providing care for the entire spectrum of conditions and all age groups to 
ensure effective transition from childhood to adolescence and adulthood21. The 
sections below provide a concise overview of the current views regarding different 
aspects of diagnosis and management for DSD patients. 
 
Figure 13: Overview of the multidisciplinary DSD team. (Adapted from Brain et al. and 
Hiort et al.21,228)  
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4.1  Diagnosis 
Diagnosis of DSD conditions is based on the interplay of three important types of 
information: physical examination, biochemical analysis and genetic tests (section 
5).  
Structured clinical assessment of the appearance of the genitals is usually based on 
Prader and/or external masculinization scores (EMS) (Figure 14). The study described 
in chapter 3 questions if a diagnostic strategy can be stratified according to the degree 
of virilization as assessed by the EMS. The EMS provides a tool for standardized and 
objective description of external genitalia, based on the meatus urethrae, phallic size, 
fusion of the labioscrotal folds and location of the gonads229,230. Previous studies have 
linked the EMS at diagnosis with important clinical outcome parameters such as sex 
assignment and tumor risk37,231. Next to a thorough general physical examination, it is 
important to screen for the presence of dysmorphic features, that may direct the 
diagnostic process towards a specific condition (e.g. ear abnormalities in the Mowat-
Wilson syndrome, see chapter 3, and structural organ anomalies such as cardiac 
defects, suggestive of GATA4 or FOG2 mutations). 
 
Figure 14: The external masculinization score ( adapted from Ahmed et al. 2016232) 
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Laboratory investigations guide further diagnostic (genetic) tests as they permit an 
evaluation of gonadal and adrenal function21. Decreased levels of Sertoli cell products 
AMH and Inhibin-B direct towards conditions associated with gonadal dysgenesis, 
whereas these markers are within the age-specific reference range in disorders of 
androgen synthesis or action233,234. When suspecting a defect of androgen synthesis, 
liquid chromatography–tandem mass spectrometry is superior to antibody-based 
methods to assess at what level steroid synthesis is perturbed, due to reduced cross-
reactivity of steroids235,236. In case of normal steroid precursor levels in an individual 
with female or ambiguous genitalia, androgen insensitivity is expected. However, in 
some cases, expected to result from AIS, especially in case of partial AIS, no AR 
mutations can be found. In those cases the apolipoprotein D (APOD) test, which 
assesses AR-mediated APOD transcription, can be beneficial. These cases might be 
explained by defects in currently unknown AR cofactors. The main disadvantage of 
this test is the requirement of genital skin fibroblasts, which requires invasive 
sampling methods67,237.  
As important during the diagnostic phase as the quest for the underlying genetic 
etiology and its and endocrine consequences is to document the internal and external 
anatomy. A first step is imaging of internal genital structures by ultrasound or 
eventually magnetic resonance imaging. Both techniques have limitations and in 
complex cases,  more invasive procedures like laparoscopic evaluation of the gonads 
and gonadal biopsies are necessary 238. Though these procedures are more invasive, 
they can give an irrefutable answer about the internal genital situation e.g. presence of 
a uterus and the degree of gonadal differentiation (dysgenetic testis, ovotestis, 
UGT,…), important for predicting hormonal function and tumor risk238,239.  
4.2  Management 
The management of DSD patients and their families poses many challenges, and the 
initial step in this process is sex assignment. In the past sex assignment was mainly 
based on the appearance of the external genitalia and was accompagnied by early 
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surgical adjustment of the child’s genitalia to fit into a standard male or female 
phenotypic box. At that point it was believed that gender identity was primarily  
influenced by the gender of rearing and that early surgical interventions, in 
combination with a non-disclosing policy, would be in the best interst of the patient. 
However, testimonials from adults who had had these early interventions and reports 
on gender change following these interventions have challenged this concept of 
gender neutrality at birth. Current believes allocate a role for early hormonal 
imprinting to gender development240,241. Today the gender assignment decision is 
mainly based on the expected gender outcome and several aspects like the karyotype 
and genetic diagnosis, the appearance of internal and external genitalia, gonadal 
hormone production and sensitivity and fertility aspect are taken into account. Given 
the low prevalence of each separate DSD condition, it is currently not possible to make 
straight-forward recommendations concerning gender development for all of them, 
although some general trends have been reported21. For instance, all individuals with 
CAIS are raised as girls and have no gender issues.   This situation is in contract with 
PAIS, were gender assignment and acceptance is particularly difficult242,243. Regardless 
of the situation, the gender assignment decision is always taken by the MDT, together 
with the parents. 
A second point of concern in DSD management is the risk for the development of 
gonadal germ cell tumors, which is significantly increased in DSD patients who have 
Y chromosomal material, especially the GBY (gonadoblastoma region on Y). Germ cell 
cancer (GCC) development is initiated with the retention of pluripotent primordial 
germ cells, probably related to malfunctioning of Sertoli cells that are needed for the 
intrinsic germ cell maturation program. These pluripotent germ cells may expand in 
later life, resulting in the development of GCC244. Two types of precursor lesions have 
been observed depending on the cellular context; in case of dysgenetic gonads the GCC 
precursor is called a gonadoblastoma, in a testicular contex the precursor stage is 
referred to as germ cell neoplasia in situ (GCNIS), formerly known as carcinoma in 
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situ245,246. The main goal in DSD-related GCC research is to obtain a straight-forward 
clinical decision model based on reliable parameters and risk factors. These risk factors 
are: the presence of Y chromosomal material in the (gonadal) karyotype (specifically 
the GBY region), the presence of immature germ cells, a low degree of gonadal 
differentiation (“testicularization” in the context of an XY karyotype), and aberrant 
expression of KITLG (stem cell factor). The initial location of the gonad is a modifying 
factor, with abdominally or inguinally positioned testes increasing the risk. The 
ultimate decision to perform gonadectomy is based on germ cell cancer risk 
assessment, (expected) gonadal function, modalities for non-conservative follow-up 
and patient/parent preferences. Alternatives for gonadectomy are self-examination 
and regular imaging of gonads in situ. Serum tumor markers are currently of limited 
use in a prophylactic setting244. 
A third major aspect of DSD management lies in the preservation of potential fertility. 
For most of the individuals with a DSD condition, sub- or infertility is inherent to their 
condition and their reproductive potential can be affected by several medical and 
surgical therapies. In general, DSD patients can benefit from commonly available 
reproductive techniques like ovarian or testicular tissue cryopreservation, ovarian 
stimulation and oocyte/embryo cryopreservation and testicular sperm extraction. 
However, today infertility treatment in DSD patients is limited as their gonadal 
abnormalities limit the success rate of these technologies. Most reports of succesfull 
reproduction involve men with KS, PAIS or 5-alfa reductase deficiency247. 
Furthermore, women with CAH appear to have pregnancy rates comparable with the 
general population. When fertility preservation is impossible or unsuccessfull, options 
like egg of sperm donation, surrogacy or adoption can fulfill the desire to have 
children248. Although these reproductive options contribute greatly to the management 
plan for DSD patients, some ethical concerns should be considered as well. For 
instance, some families postpone tumorrisk-related gonadectomy for possible fertility 
purposes. As counseling for the risk of malignancies and fertility are both uncertain, it 
71 
 
is currently unclear which arguments are decisive and where the trade-off should be. 
Furthermore, as most DSD conditions are the result of a genetic mutation, which could 
be passed on to the offspring, genetic counseling and pre-implantation genetic 
diagnosis are crucial for DSD individuals247. 
One of the most debatable aspects of DSD management is surgery. Today, surgical 
interventions on genitalia and gonads in neonates and infants who have a DSD are 
addressed with extreme caution and postponing genital surgery until the child can 
give consent has become a valuable alternative in recent years249,250. Long term data on 
satisfaction with surgery indeed show that informed consent and realistic expectations 
are of utmost importance21. However, given the heterogeneity of DSD conditions and 
the different arguments for both sides of the dilemma, thusfar no consensus on the 
indications, timing, procedure or outcome evaluation has been reached251. The general 
aims of surgery in DSD are extensive and include both functional (restoration of 
genital function anatomy, facilitation of future reproduction, reduction of urological 
hazards like urogenital infection of incontinence, avoidance of late virilization, 
reduction of gonadal tumor risk) and social (avoidance of social stigmatization and the 
address the parents desire to raise their child in the best possible way) 
considerations252. In general, DSD specialists do agree that each decision concerning 
surgery should be taken in agreement of a multidisciplinary expert DSD team and that 
it can only been undertaken at centers of expertise, given the complexity and 
irreversibility of these procedures. Furthermore, decisions concerning gonadectomy 
should be conservative unless a significant risk for gonadal tumor development 
necessitates an early intervention251,252. Even in case of augmented tumor risk, a 
decision can not only be based on estimated group risks but should also consider 
pathological examination of a gonadal biopsy, the age of the patient, the anatomical 
position and possible residual function of the gonad and possible side effects of the 
surgery253. As a final remark in this debate, it should also be noted that despite several 
reports on dissatisfaction with early childhood surgical interventions, only very 
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limited data is available on the impact on non-treated DSD during childhood252. This 
ongoing debate and the lack of clear scientific evidence on the preferential approach 
clearly emphasizes the importance of case-specific decision making addressing the 
needs and quality of life of all stake-holders.  
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5 TOWARDS A FASTER GENETIC DIAGNOSIS FOR DSD PATIENTS 
Due to the development of new sequencing techniques, substantial progress has been 
made in the molecular diagnosis of DSD conditions, both at the level of mutation 
detection and of gene identification. Previously, with Sanger sequencing being the 
only available method, a sequential (gene-by-gene) approach was used, making the 
diagnostic process both laborious and expensive. With the advent of novel, high-
throughput sequencing techniques, such as next generation sequencing (NGS), it has 
become possible to screen gene panels in parallel in a flexible manner. Today, 
techniques like whole exome and whole genome sequencing (WES/WGS) are greatly 
facilitating the discovery of new disease genes and step-by-step they are being 
introduced in a clinical setting as a broad screening test for genetically heterogeneous 
disorders, and thus also in the DSD diagnostic workflow254,255. In the following sections 
a brief overview is given of the different strategies that are used in our department 
(Center for Medical Genetics Ghent, CMGG) to unravel the underlying genetic cause 
in individuals who have a DSD. 
5.1  Pre-screening approach  
5.1.1  Targeted resequencing of known DSD genes 
Sanger sequencing  
In the seventies of the previous century, Fred Sanger developed a groundbreaking 
method for DNA sequencing256. Due to Sanger sequencing it became possible to 
screen the sequence of one or a small set of genes for variants. This polymerase chain 
reaction (PCR)-based technique relies on cyclic repeats of template denaturation, 
primer annealing and elongation. By using a combination of standard 
deoxynucleotides (dNTPs) and modified fluorescently-labeled dideoxynucleotides 
(ddNTPs), fragments are generated that differ in length by one nucleotide. These 
fragments are subsequently separated by capillary electrophoresis and their 
fluorescent signal is detected by laser excitation257 (Figure 15). The per-base accuracy 
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of Sanger sequencing reaches 99.999%258, making it still a valuable technique for 
validation of identified variants.  However due to the high-cost and its labor intensity, 
new techniques are quickly replacing Sanger sequencing for mutation screening in 
genetically heterogeneous conditions like DSD.  
 
Figure 15: Sanger sequencing is based on a modified PCR reaction where fluorescently-
labeled ddNTPs are added to the reaction mix. PCR fragments are generated that differ in 
length by one nucleotide. Separation of these fragments by capillary electrophoresis followed 
by laser excitation of the fluorescent label allows base calling. 
Targeted resequencing using next-generation sequencing technologies 
Given the disadvantages of Sanger sequencing, the quest for better sequencing 
technologies has generated several so-called NGS technologies; the most successful of 
them being the sequencing-by-synthesis (SBS) method, for instance developed by 
Illumina259. This method is build up by three sequential steps: (1) library preparation, 
(2) bridge PCR amplification and (3) SBS (Figure 16). A comprehensive video on how 
this technology works is available at http://www.illumina.com/technology/next-
generation-sequencing/sequencing-technology.html. This sequencing process is 
followed by read mapping against the human reference genome and variant calling 
using different software tools258,259. The biggest advantage of this technology is its 
ability to generate millions of DNA reads in parallel, thereby increasing cost-
efficiency and decreasing labor intensity260.  
In the CMGG this NGS technology is used for several applications, amongst them 
targeted resequencing of gene panels. De Leeneer et al. developed an elegant system 
based on standardized singleplex PCR reactions for target enrichment261. This method 
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is highly suitable for sequencing small gene panels and allows flexibility as new genes 
can easily be added. An in-house DSD gene panel was developed containing relevant 
DSD genes like SRY, NR5A1, SOX9, WT1, DMRT1, GATA4 and AR.  
 
 
Figure 16: The sequencing-by-synthesis NGS method. (Adapted from Illumina.com). The 
sequencing by synthesis method involves three major steps. First of all, DNA is fragmentized 
during the library preparation, followed by adaptor ligation. Subsequently, these DNA 
fragments are loaded on a flowcell, where the adaptors hybridize with complementary probes 
on the surface. Bridge amplification results in clustering of identical DNA fragments. As a final 
step, modified nucleotides are added and incorporated with the formation of double stranded 
molecules. Laser excitation of the chromofores enables base calling. 
5.1.2  Copy number detection: MLPA 
Several reports on the identification and importance of CNVs in DSD, underscore the 
importance of CNV screening in the diagnostic package for DSD262,263. Multiplex 
Ligation-dependent Probe Amplification (MLPA), is a very accurate technique for 
targeted CNV detection. MLPA distinguishes itself from other techniques by 
amplifying MLPA probes instead of target DNA and by the fact that only a single pair 
of PCR primers is used264. The principle behind MLPA is shown in Figure 17. 
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Advantages of MLPA are its cost-effectiveness, technical simplicity and high 
resolution, however this technique is not suited for genome-wide CNV detection264. 
In our diagnostic setting two different commercially available MLPA kits are used. The 
first is the Intersex MLPA kit with probes for DAX1, NR5A1, SOX9, SRY and WNT4 
(P185-Intersex, MRC Holland), the second kit contains probes for WT1 (P118-WT1, 
MRC Holland). This combination allows us to detect CNVs in a subset of important 
DSD genes. 
  
Figure 17: The MPLA-principle. MLPA reactions are based on a standard PCR reaction. For 
each target specific probes are designed, consisting of three parts. (1) the hybridization 
sequence, complementary with the target sequence, (2) a stuffer sequence that differs in length 
between the different targets and allows a separation of the different fragments and (3) the 
universal primers X and Y, that enable multiplex fragment amplification. After DNA 
denaturation, probes are hybridized on targed DNA, followed by a ligation step. In case of 
deletions of duplications, this ligation is perturbed. Probe ligation is followed by a PCR 
amplification using primers X and Y. Subsequent capillary electrophoresis allows fragment 
separation and detection of the different fragments. 
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5.2  Identification of new DSD genes: whole exome sequencing 
A second NGS application is WES, by which the coding regions of the human DNA 
are enriched and sequenced. This technique has proven to be a valuable tool to identify 
new disease genes underlying Mendelian disorders. However, the use of WES in a 
clinical setting should be applied with caution as complex filtering procedures are 
needed and false-positive and false-negative rates are considerably higher as 
compared to targeted approaches. From an ethical point-of-view it is important to 
notice that WES might also uncover secondary findings beyond the scope of the 
diagnostic question, emphasizing the necessity of detailed informed consent265.  
During this thesis, two different WES approaches were used to identify novel disease 
genes in our DSD patient cohort. In cases with a consanguineous background, where 
we expect a homozygous causal mutation, data filtering was facilitated by use of 
identity-by-descent (IBD) regions. To understand this technology, knowing the 
difference between identity-by-state (IBS) and identity-by-descent is crucial, shown 
in Figure 18A and B respectively. In both situation A and B, two brothers share the 
same allele A1, however in situation A the allele originates from a different ancestor 
in both brothers while in situation B both brothers have inherited the A1 allele from 
their father. Alleles originating from the same ancestor are called IBD-alleles, alleles 
originating from a different ancestor are called IBS-alleles. Children originating from 
a consanguineous marriage have a higher chance of being homozygous for the same 
allele, because both parents share a larger proportion of their genome as compared to 
non-related parents. This is shown in Figure 18C: both parents share allele A1, which 
they both inherited from their common ancestor. The chance that their offspring are 
homozygous for A1 is 25%. Off course, this concept does not apply only to the A1 allele 
but also to the surrounding alleles, resulting in homozygous regions by descent. In 
general the size of such regions is directly proportional to the degree of 
consanguinity266. Homozygosity-mapping enables the identification of those regions 
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and when combined with WES, it can reduce the number of variants that need to be 
filtered out267. 
In our center homozygosity-mapping is performed by using the genome-wide SNP-
chip analysis with the Illumina HumanCytoSNP-12 DNA Analysis Beadchip, allowing 
genotyping of  over 200 000 single nucleotide polymorphisms (SNPs). The obtained 
data are subsequently analyzed with the PLINK software package which is 
incorporated in ViVar, an online platform for data storage and analysis268,269. The 
homozygous regions are then applied for filtering of WES data. 
 
Figure 18: Identity-by-state (IBS) and identity-by-descent (IBD) 
When no consanguinity is suspected, a trio-sequencing strategy is applied. DSD 
phenotypes are usually associated with infertility, implying that most cases will be due 
to a de novo mutation. However, when looking for a causal variant for DSD phenotypes 
it is to be kept in mind that a variant can be present in one of the parents without 
causing a phenotype. For example, if a disease-causing GATA4 variant is suspected in 
an individual who has 46,XY DSD, one would not expect the same variant to be present 
in the patient’s healthy father. However, the same variant can be allowed in the 
patients mother given that “feminizing” mutations would not harm her. An 
important pitfall is that for a lot of DSD genes, incomplete penetrance in same sex 
individuals has been described270–272.  
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Given the complexity of the many underlying molecular pathways it is not surprising 
that disorders/differences of sex development (DSD) are among the most common 
birth defects. Severe forms of DSD have a prevalence of ~1/2 000 – 4 500 births but 
milder genital variations, like hypospadias or micropenis, are seen in as much as 1/200 
births. Despite significant progress in the identification of new genes and pathways, a 
(likely) molecular diagnosis is only obtained in ~50% of 46,XY cases. Obtaining a 
molecular diagnosis enables refining of a clinical diagnosis and can in some cases 
facilitate clinical decision making with respect to sex assignment, gonadal tumor risk 
and lifelong care. For affected individuals and families, understanding the etiology of 
their condition can contribute to a better acceptance and it opens perspectives for 
genetic counseling and eventually reproductive options. In addition, unraveling of the 
molecular pathways behind these rare phenotypes can greatly enhance translational 
research (e.g. with respect to associated anomalies, germ cell cancer risk or outcome) 
and provide insights in human-typical gonadal development and the pathogenesis of 
more frequent conditions like male infertility and primary ovarian insufficiency (POI). 
The aim of this doctoral project was to unravel pieces of the molecular pathways 
behind the sex developmental processes and to identify new genes implicated in DSD 
and/or related conditions such as POI.  
Objective 1: Assessing the appropriateness and diagnostic yield of a standardized 
work-up in a large consecutive cohort of 46,XY neonates and infants with atypical 
gonadal development 
From a clinical point of view and given that DSD (in the sense of Differences of Sex 
Development) represent a spectrum of genital and gonadal atypicalities, it is not 
always clear which individuals with a variant sex development need to be referred for 
extensive molecular genetic diagnostic work-up and if persons with less severe 
phenotypes like isolated hypospadias or micropenis may benefit from such a referral. 
Milder genital variations have been attributed to environmental factors, low birth 
weight and multiple gene polymorphisms rather than to single gene mutations. 
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However, there have been reports associating these milder phenotypes to mutations 
in genes known to cause genital ambiguity in other cases. In study 1, we aimed to 
assess the appropriateness of a standardized work-up in a large series of 46,XY cases 
with atypical gonadal development. Our screening approach involved structured 
clinical examination, biochemical assessment and genetic work-up consisting of 
consecutive Sanger sequencing of selected DSD genes and copy number analysis using 
array-comparative genomic hybridization (array-CGH) and MLPA. Results were 
interpreted in the light of clinical and hormonal findings. 
Objective 2: Identification of novel disease genes underlying 46,XY and 46,XX 
disorders of sex development 
The  main aim of this PhD project was to identify novel disease genes and mechanisms 
for both 46,XX and 46,XY DSD by use of whole exome sequencing (WES). In case of 
known consanguinity WES was combined with homozygosity mapping, if this was 
not the case a trio-sequencing strategy was applied. This approach led to the 
identification of ESR2 as a novel candidate disease gene for 46,XY DSD and the 
identification of a recurrent NR5A1 mutation in cases with 46,XX DSD.  
In study 2, the identification of three ESR2 mutations is reported in three unrelated 
cases with syndromal and isolated 46,XY DSD. Functional characterization of these 
variants was done using transcriptional activation assays. Structural analysis provided 
additional evidence for functional consequences on the protein level. Furthermore, the 
expression of ER-β was assessed in an 8-week old male fetus.  
In study 3, we implicated a recurrent NR5A1 mutation in the pathogenicity of 46,XX 
testicular and ovotesticular DSD. Immunohistochemistry on patient-derived gonadal 
tissue showed SRY-independent SOX9 expression in the testicular regions of the 
gonads and FOXL2 expression in the ovarian parts. Transcriptional activity and 
subcellular localization experiments showed no consistent changes however. 
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Therefore, we proposed a theoretical working hypothesis for this mutation, which we 
aim to explore in future research.  
Objective 3: To explore the concept that DSD genes may underlie a spectrum of 
reproductive disorders in males and females: identification of a novel disease gene 
for POI starting from a case of 46,XY DSD 
Insights in the pathogenesis of rare conditions such as DSD can extend our knowledge 
on the mechanisms underlying more common reproductive disorders like POI. For 
instance, NR5A1 mutations were first identified in 46,XY DSD cases, but later 
implicated in POI and male infertility. In study 4, we report on the identification of 
FOG2/ZFPM2 mutations, previously implicated in the pathogenesis of 46,XY DSD, in 
a large cohort of POI women. First, a maternally inherited FOG2 deletion was 
identified in a boy with isolated 46,XY DSD. AMH assessment in the mother suggested 
a decreased ovarian follicle pool, leading to the hypothesis that FOG2 is a disease gene 
for POI, which is supported by literature data. Targeted resequencing of FOG2 in a 
large POI cohort revealed four heterozygous variants with likely pathogenic effect 
(4/388, 1%), for which we assessed transcriptional activity using luciferase 
experiments. 
Objective 4: To explore the role of non-coding genetic variation as a mechanism for 
DSD 
Despite the identification of novel DSD disease genes, the majority of cases remains 
unsolved, suggesting the involvement of other mechanisms in the pathogenesis of 
DSD. Over the years several reports on non-coding variation in DSD have been 
published. Study 5 provides a review of these findings and the different action 
mechanisms involved.  
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ABSTRACT 
Background: One in 4 500 children is born with ambiguous genitalia, milder 
phenotypes occur in one in 300 newborns. Conventional time-consuming hormonal 
and genetic work-up provides a genetic diagnosis in around 20-40% of 46,XY cases 
with ambiguous genitalia. All others remain without a definitive diagnosis. The 
investigation of milder cases, as suggested by recent reports remains controversial. 
Methods: Integrated clinical, hormonal and genetic screening was performed in a 
sequential series of 46, XY children, sex-assigned male, who were referred to our 
pediatric endocrine service for atypical genitalia (2007–2013). 
Results: A consecutive cohort of undervirilized 46,XY children with external 
masculinization score (EMS) 2–12, was extensively investigated. In four patients, a 
clinical diagnosis of Kallmann syndrome or Mowat-Wilson syndrome was made and 
genetically supported in 2/3 and 1/1 cases respectively. Hormonal data were 
suggestive of a (dihydro)testosterone biosynthesis disorder in four cases, however no 
HSD17B3 or SRD5A2 mutations were found. Array-CGH revealed a causal structural 
variation in 2/6 syndromic patients. In addition, three novel NR5A1 mutations were 
found in non-syndromic patients. Interestingly, one mutation was present in a fertile 
male, underlining the inter- and intrafamilial phenotypic variability of NR5A1-
associated phenotypes. No AR, SRY or WT1 mutations were identified. 
Conclusion: Overall, a genetic diagnosis could be established in 19% of non-
syndromic and 33% of syndromic cases. There is no difference in diagnostic yield 
between patients with more or less pronounced phenotypes, as expressed by the 
external masculinisation score (EMS). The clinical utility of array-CGH is high in 
syndromic cases. Finally, a sequential gene-by-gene approach is time-consuming, 
expensive and inefficient. Given the low yield and high expense of Sanger sequencing, 
we anticipate that massively parallel sequencing of gene panels and whole exome 
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sequencing hold promise for genetic diagnosis of 46,XY DSD boys with an 
undervirilized phenotype. 
Keywords: 46,XY DSD, Undervirilization, Integrated screening, Diagnosis, Array-
CGH, MLPA, NR5A1 mutations 
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BACKGROUND 
The birth of a child with ambiguous 
genitalia is a rare event with a 
prevalence of one in 4 500 live births and 
poses a challenge to the parents and the 
medical team1. Specialized 
multidisciplinary medical care, aiming 
at addressing concerns and 
uncertainties regarding gender 
assignment, underlying etiology and 
management, as well as providing 
adequate psychological support is 
essential2. Extensive and time-
consuming hormonal and genetic work-
up provides a genetic diagnosis in 20-
40% of cases3,4. Less pronounced 
atypical development of male external 
genitalia is more prevalent and is 
noticed in the newborn period in around 
one in 300 males; 75% of cases are 
associated with hypospadias5. These 
milder forms of undervirilization, such 
as isolated or combined cryptorchidism 
and hypospadias have been related to 
environmental factors, low birth weight 
and multiple gene polymorphisms 
rather than single gene mutations6-8. 
However, mutations in the Androgen 
Receptor (AR), Nuclear Receptor Subfamily 
5 Group A Member 1 (NR5A1) and Wilms 
Tumor 1 (WT1) genes - classically 
associated with genital ambiguity or 
more severe forms of undervirilization - 
have recently been identified in cases 
with isolated proximal or even distal 
hypospadias, combined cryptorchidism 
and (distal) hypospadias or anorchia, 
and sequencing of these genes has been 
advocated in such cases9-14. On the other 
hand, copy number variations in genes 
involved in the process of sexual 
development have effectively been 
detected by whole genome (array 
comparative genomic hybridization, 
array-CGH) or targeted (multiplex 
ligation-dependent probe amplification, 
MLPA) copy number analysis15-17, and 
both techniques have become widely 
available in recent years. However, 
whether a systematic extensive genetic 
work-up is indicated in the 46,XY 
newborn with a milder degree of 
undervirilization, as indicated by a 
higher Prader or External 
Masculinization Score (EMS) remains a 
matter of debate18. Current screening 
methods are time consuming and have a 
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low efficiency. The introduction of 
genome-wide technologies such as 
whole exome sequencing (WES) holds 
promise for future clinical decision 
making in a routine diagnostic setting 
for these rare, genetically heterogeneous 
conditions. In order to gain insight in the 
appropriateness and diagnostic yield of 
a systematic genetic work-up in 46,XY 
infants with atypical external genitalia, 
we performed a standardized genetic 
screening panel in all 46,XY neonates 
and infants who were referred to our 
pediatric endocrine service for atypical 
male or ambiguous genitalia in the 
period 2007–2013 and who received 
male sex assignment. This screening 
consisted of consecutive Sanger 
sequencing of the AR, NR5A1 and WT1 
genes, high-resolution (180 K) array-
CGH and a commercially available 
MLPA kit with probes for Sex 
Determining Region Y (SRY), SRY-box 9 
(SOX9), Nuclear Receptor Subfamily 0 
Group B Member 1 (NR0B1), Wingless type 
4 (WNT4) and NR5A1. Additionally, 
sequencing of SRY was performed in 
cases with hormonal results consistent 
with the presence of (partial) gonadal 
dysgenesis, and sequencing of 
Hydroxysteroid 17-β Dehydrogenase 
(HSD17B3) or Steroid-5-α-Reductase, 
(SRD5A2) was performed in cases with 
suspicion of a (dihydro)testosterone 
biosynthesis defect. Results were 
interpreted in the light of clinical and 
hormonal findings.  
RESULTS 
Clinical investigation 
Consanguinity was present or suspected 
in 4/32 cases (12.5%). Another four cases 
had a family history of subfertility or 
atypical genitalia. Nine children (28.1%) 
were born small for gestational age 
(SGA), defined as a BW< −2 Standard 
Deviation (SD) for gestational age, with 
a mean BW of −2.8 SD; mean BW of 
children born appropriate for GA was 
−0.36 SD. EMS scores ranged from 2/12 
to 12/12. In 6/32 children (18.7 %) 
dysmorphic features were noticed. 
Patient details are represented in Table 
1). Three out of 32 patients (P26, P28, 
P29) were diagnosed with KS based on 
clinical and hormonal data (day 14–90). 
Patient 26 (EMS 12) was referred for an 
atypically looking short penis (with 
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bilateral descended testes). At physical 
examination, stretched penis length 
(SPL) measured 30 mm, but his penis 
was extremely thin and weak, 
reminiscent of agenesis of the corpora 
cavernosa, which was excluded by 
Magnetic Resonance Imaging (MRI) of 
the penile structures. Hormonal data 
concordant with hypogonadotropic 
hypogonadism (HoH) (Table 2) and 
MRI  revealing a hypoplastic bulbus 
olfactorius were both consistent with a 
diagnosis of Kallmann syndrome. An 
etiological diagnosis was sought by 
targeted resequencing of several known 
KS genes (KAL1, FGFR1, FGF8, CHD7, 
PROK2, PROKR2, HS6ST1, WDR11, 
SEMA3A, GNRH1, GNRHR, KISS1, 
KISS1R, TAC3 and TACR3); no causal 
mutations were identified. The second 
patient with KS (P28, EMS 8) presented 
with mild craniofacial dysmorphism 
(ptosis, plagiocephaly), general 
hypotonia, developmental delay, 
micropenis (SPL 15 mm) and bilateral 
inguinal testes. Low gonadotrophins in 
association with a low AMH was 
suggestive of HoH. Array-CGH 
revealed a causal hemizygous deletion 
on the X chromosome including the 
Kallmann syndrome 1 (KAL1) gene, as 
discussed below. Patient 29 (EMS 9) was 
diagnosed with KS based on the 
presence of micropenis (SPL 21 mm) and 
a positive family history for KS: the 
father had been diagnosed with KS and 
was able to conceive following 
gonadotrophin therapy. Hormonal data 
confirmed HoH in the index patient. The 
diagnosis was supported genetically by 
the identification of a heterozygous 
FGFR1 mutation, c.1042G>A (p.G348R), 
in both the patient and his father. This 
mutation has been described 
previously273. Patient 30 was diagnosed 
with Mowat-Wilson syndrome (MWS), 
he presented with typical external ear 
abnormalities (Figure 1), hypotonia, 
persistent ductus arteriosus, ventricular 
septum defect, facial dysmorphism, 
Hirschsprung disease, penoscrotal 
inversion and hypospadias. MWS is 
caused by heterozygous de novo 
mutations in ZEB2. Sequencing of this 
gene revealed a heterozygous one 
basepair frameshift deletion, c.2856delG 
(p.Arg953Glufs*24).
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Table 1: Medical history and phenotypic details of patients 
 Code GA 
(weeks) 
BW 
(g) 
BW 
(SD) 
EMS Pregnancy Dysmorphic 
features 
Consanguinity Family history  
           
 1 32 900 -3.15 2/12 CS IUGR No Unremarkable  
           
 2 41 3.260 -1.12 3/12 Normal Large ears 
Broad nose 
Mild frontal 
bossing 
No Unremarkable  
 3 40 4.150 1.12 2,5/12 Normal / No Maternal aunt: 
difficulties to 
get pregnant, 
one child with 
congenital 
abnormalities 
 
 4 41 3.060 -1.6 3/12 Normal 
Minoxidil 
treatment 
/ No Unremarkable  
 5 34 1.320 -2.93 7,5/12 CS IUGR No Unremarkable  
 6 40 3.380 -0.59 9/12 Normal / No Grandfather 
with 
hypospadias, 
maternal aunt 
with POF 
 
 7 30 510 -3.8 6/12 Induced 
delivery 
Twins 
IUGR No Paternal 
grandmother: 
cleft lip 
 
 8 39 3.690 0.45 10/12 IVF / No Unremarkable  
 9 38 3.310 0.01 8/12 Normal / No Unremarkable  
 10 39 2.850 -1.53 9/12 Placental 
infarction 
Microcepha
ly 
No Unremarkable  
107 
 
Mild facial 
dysmorphis
m 
 11 40 3.000 -1.51 3/12 Normal Macrocepha
ly 
Facial 
dysmorphis
m 
Short neck 
Developme
ntal delay 
(speech) 
No Unremarkable  
 12 40 3.850 0.47 6/12 Normal / Yes Mother: fertility 
problems, 
irregular 
menses 
 
 13 35 2.530 -0.26 6/12 Preeclampsia 
and 
hypertension 
Obesity  
Twins 
Sectio 
/ No Unremarkable  
 14 32 945 -2.98 3/12 Bleeding  
CS 
/ No Unremarkable  
 15 40 NA NA 3/12 Normal / No Unremarkable  
 16 28 860 -1.26 7/12 Eclampsy 
Prematurity 
Atrial 
septum 
defect 
No Unremarkable  
 17 34 1.450 -2.52 6/12 CS Ventricular 
septum 
defect 
Yes Cousin 
(deceased)with 
Jeune 
syndrome 
 
 18 34 1.400 -2.68 2/12 CS / No 
 
Unremarkable  
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Antidepressa
nt Paroxetine 
 19 41 2.805 -2.24 3/12 Normal / No Unremarkable  
 20 39 2.880 -1.45 6/12 Normal / Possible Unremarkable  
 21 36 1.585 -3.39 7/12 Preeclampsia / No Unremarkable  
 22 39 2.640 -2.07 6/12 Normal / No Unremarkable  
 23 40 3.250 -0.9 8/12 Normal  / No Unremarkable  
 24 37 3.290 -0.43 6/12 Normal  / Yes Unremarkable  
 25 38 2.800 -1.20 6/12 Preeclampsia  / No Mother: brother 
deceased from 
SIDS 
Maternal 
grandfather: 
depression 
Maternal 
grandmother: 
recurrent 
miscarriage 
Father: late 
puberty 
Paternal uncle: 
retractile testes, 
normal fertility 
 
 26 39 3.770 -0.63 12/12 Preterm 
contractions 
Hypoplastic 
bulbus 
olfactorius 
/ Unremarkable  
 27 26 700 -1.26 10/12 IVF 
Twins 
Placental 
rupture 
Persisting 
ductus 
arteriosus  
Periventricu
lar 
leukcomala
cy 
/ Unremarkable  
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 28 36 2.570 -0.72 8/12 Previous 
abortions 
Preterm 
contractions 
Bleeding 
X-linked 
ichthyosis 
Hypotonia 
Developme
ntal delay 
Abnormal 
liver 
function 
tests 
/ First child was 
stillborn 
Three 
miscarriages 
between month 
1 and 2 
 
 29 39 3.230 -0,6 9/12 Pregnancy 
after 
gonadotroph
in treatment 
father 
/ / Father with 
Kallmann 
syndrome, 
pregnancy after 
gonadotrophins 
 
 30 38 3.782 1.04 8/12 Normal Mowat-
Wilson 
syndrome 
/ Unremarkable  
 32 39 2780 -1.70 7/12 Normal No No Unremarkable  
 GA: gestational age, BW: birth weight, EMS: external masculinization score, IUGR: intra uterine growth 
retardation, POF: premature ovarian failure, SIDS: sudden infant death syndrome; CS: Caesarian section, 
IVF: in vitro fertilization 
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Table 2: Hormonal and genetic data of patients 
 Code FSH 
(U/l)# 
(ref) 
AMH  
(µg/l) 
(ref)$ 
T 
(ng/dl)*/*
*  
AR NR5A1 WT1 SRY Array-CGH MLPA Other   
 1 3.2 
(1-12) 
59.8 
(46.8-
173) 
136* Nl Nl Nl FISH 
Nl 
Nl Nl HSD1
7B3 
 
 2 14.0 
(1-12) 
62.7 
(46.8-
173) 
63.8*/579
** 
/ Nl Nl Nl Nl Nl HSD1
7B3, 
ATRX 
N 
 
 3 6.6 
(1-12) 
10.8 
(105-
270) 
4.7* / c.253_254del  / Nl / /   
 4 1.6 
(1-12) 
118 
(46.8-
173) 
195* Nl Nl Nl / Nl Nl   
 5 NA 152 
(67.4-
197) 
526** Nl c.437G>C 
(tolerated) 
/ FISH 
Nl  
/ /   
 6 3.3 
(1-12) 
64.5 
(62-130) 
184* Nl c.630_637del / FISH 
Nl 
/ Nl   
 7 1.5 
(1-12) 
57.6 
(105-
270) 
222* Nl Nl Nl / 7q36.3q36.3 
(158189154-
158343770)x1
, maternal 
Nl   
 8 NA 10.6  
(38-180) 
275** Nl Nl Nl Nl Nl Nl   
 9 NA 231 
(46.8-
173) 
 
NA Nl Nl Nl / Xp22.33p22.3
3 (839417-
1179089)x3, 
maternal 
Nl   
 10 NA 244 
(46.8-
173) 
NA Nl Nl Nl / Nl Nl ATRX 
Nl 
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 11 5.5 
(1-12) 
NA 158*/511*
* 
/ / / / 3p25(RP11-
385A18→RP
11-
334L22)x3, 
9p24.3 
(RP11-
48M17→RP1
1-320E16)x1 
 
/   
 12 2.5 
(1-12) 
147 
(46·8-
173) 
109* / Nl Nl / / Nl   
 13 NA 72.7 
(46.8-
173) 
280* 
 
 
 
/ Nl Nl FISH 
Nl 
Nl Nl   
 14 1.2 
(1-12) 
8.6  
(105-
270) 
248* Nl / / / / /   
 15 NA 132.9 
(42-185) 
 
NA Nl c.1109 G>A 
(p 
Cys370Tyr) 
/ FISH 
Nl 
16p12.3p12.3 
(18894303-
19162153)x3,
maternal 
(normal 
variant)  
 
/   
 16 1.3 
(1-12) 
298 
(67.4-
197) 
337* Nl Nl Nl FISH 
Nl 
Xq13.3q13.3 
(74285912-
75325119)x2, 
maternal 
 
Nl   
 17 NA 72 
(38-180) 
NA / Nl Nl FISH 
Nl 
/ Nl HSD1
7B3 
 
 18 2.6 
(1-12) 
82.2 
(23.8-
124) 
NA Nl Nl Nl / 2p16.3p16.3 
(5073244-
50894316)x1; 
Nl   
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16p13.11p13.
11(15830681-
16270149)x3 
 
 19 1.8 49.1 
(23.8-
124) 
35.3*/390
** 
Nl Nl Nl FISH 
Nl 
Xq13.3q13.3(
74380482-
74567915)x2, 
maternal  
 
Nl   
 20 2.8 
(1-12) 
194 
(105-
270) 
104* Nl Nl Nl FISH 
Nl 
Nl Nl   
 21 1.9 
(1-12) 
28.8 
(55.3-
187) 
NA Nl Nl Nl Nl  / Nl   
 22 2.1 
(1-12) 
94.1 
(105-
270) 
151* Nl Nl Nl Nl  5p14.3p14.3(
21438696-
21490654)x1, 
maternal,  
14q21.2q21.3
(42908541-
43293564)x3, 
maternal  
 
Nl   
 23 NA 11.27 
(55.3-
187) 
404** Nl Nl Nl Nl Nl Nl   
 24 NA 43 
(105-
270) 
152*/474*
* 
/ Nl Nl Nl Nl 
 
Nl SRD5
A2 N 
 
 25 1.0 
(1-12) 
156 
(105-
270) 
207.3* Nl Nl Nl / Nl Nl   
 26 0.17 
(1-12) 
65.9 3.3*/90.8 
** 
/ / / / Nl /   
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(105-
270) 
 27 NA 245 
(55.3-
187) 
951** Nl 
 
Nl Nl / / Nl   
 28 NA 14.03 
(55.3-
187) 
NA / / / / Xp22.32p22.3
1(5405569-
9222059)x0, 
maternal 
/   
 29 0.57 
(1-12) 
NA 3.2* / / / / / / FGFR
1 
c.1042
G>A 
 
 30 1.2 
(1-12) 
159 
(105-
270) 
502* / / / / Nl / ZEB2 
c.2856
delG 
 
 32 11 
(1-12) 
25 
(105-
270) 
191.9* Nl Nl Nl Nl Nl Nl   
 Symbols and abbreviations: NA: not available, FSH: follicle stimulating hormone; AMH: anti-Müllerian hormone;  ref: 
age-specific reference value; T: testosterone; Nl: normal 
#: Determined between day 14-90; $: age-specific AMH reference values may differ according to the commercial kits that 
have been used during the course of the study; *: Basal testosterone value between day 14-90 / ** : Testosterone value after 
HCG stimulation (1500 U, blood sampling after 72h).  
Genomic coordinates based on build hg18 (2006), except for patient 32, where build hg19 (2009) is used. 
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Figure 1: Mowat-Wilson syndrome, 
facial characteristics. The typical large 
and uplifted earlobes in Patient 30, who 
was diagnosed with Mowat-Wilson 
syndrome based on clinical data. 
Hormonal work-up 
With the exception of cases with KS, 
where FSH was low, serum FSH was 
within the reference range in all cases. 
AMH, representing Sertoli cell function, 
was low in 11/32 cases (34,3%), 
including 2/3 cases with KS (in the third 
KS case, AMH could not be determined) 
and 4/9 cases (44%) born SGA. Low 
AMH was associated with low T values 
(a marker for Leydig cell function) in 
only two cases (P3, subsequently 
diagnosed with a NR5A1 mutation and 
P26, with KS). Two of three patients 
with NR5A1 mutations had an AMH 
value within the reference for age. 
Ratios of T/A and T/DHT were 
determined to identify possible cases of 
(dihydro)testosterone biosynthesis 
disorders. The T/A ratio, measured 
during mini-puberty was suggestive of 
17β-HSD deficiency in two patients 
(case 1: T/A ratio 0,19; case 2: T/A ratio 
0,52) and after HCG stimulation in one 
case (case 17: T/A ratio 0,08)20,21. 
HSD17B3 sequencing was performed in 
all three cases but revealed no causal 
mutations. In patient 2 a heterozygous 
missense variant was identified, c. 
866G>A (p.Gly289Asp), although 
mutation prediction programs indicated 
this variant to be tolerated. In patient 24, 
a T/DHT ratio of 10,8 was found at basal 
sampling during mini-puberty but 
SRD5A2 sequencing revealed no 
mutations. 
Genetic work-up 
Array-CGH was done in 23/32 patients 
to screen for larger genomic 
rearrangements. In 10 of them, CNVs 
115 
 
were identified as shown in Table 2. 
Seven of these rearrangements were 
maternally inherited, making their 
clinical significance questionable. In 
patient 11, we identified a partial 
chromosome 9 deletion (9p24.3), 
encompassing the Doublesex and Mab3 
related transcription factor 1 (DMRT1) 
gene. In patient 28, a deletion was found 
on the X chromosome (Xp22.31-
Xp22.32). This region includes the STS 
region and the genes KAL1 and 
Neuroligin 4, X-linked (NLGN4X). This 
deletion was also present in the patient’s 
mother. In addition, we performed 
MLPA for 23/32 patients to screen for 
deletions and/or duplications on the 
exon level, however no additional CNVs 
were identified. AR (20/32) and WT1 
(22/32) sequencing did not reveal any 
mutations. NR5A1 sequencing was done 
in 26/32 patients, leading to the 
identification of three novel mutations, 
which will be discussed below. In cases 
with serum AMH below the reference 
value for age (8/32), suggestive of 
gonadal dysgenesis, SRY was 
sequenced, however no mutations were 
found.  
Identification of three novel NR5A1 
mutations 
NR5A1 sequencing revealed three novel 
mutations (Figure 2A). In patient 3 a 
heterozygous frameshift deletion was 
identified: c.253_254del, resulting in a 
premature stopcodon (p.Ala85*). No 
other family members were available for 
segregation analysis. A second 
heterozygous frameshift deletion of 8 bp 
was identified in patient 6, c.630_637del, 
(p.Tyr211Profs*12). RT-qPCR in the 
patient’s lymphoblasts indeed showed a 
lower expression of NR5A1 mRNA 
(Figure 2B). Segregation analysis 
indicated that this mutation was present 
in (1) the asymptomatic patient’s 
mother, (2) maternal aunt, who had 
been diagnosed with POF at the age of 
35, and (3) grandfather, who had been 
operated for proximal hypospadias, but 
spontaneously fathered two children 
(pedigrees in Figure 2C). The third 
mutation was found in patient 15, c.1109 
G > A, (p.Cys370Trp). This mutation was 
predicted to have a deleterious effect on 
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Figure 2: Three novel NR5A1 mutations. (A) Schematic overview of the positions of 
the mutations and electropherograms. (B) RT-qPCR showed a lower NR5A1 
expression in the maternal grandfather of the index patient (I:1), and in the mother of 
the index patient (II:2). We did not include the index case in this experiment as no fresh 
blood could be collected. Two negative control samples (NC) without the mutation 
were included for comparison. To exclude technical variations, expression of the 
reference genes GADPH, HMBS and TBP were also measured, showing stable 
expression in all patients. (C) Pedigrees for the patients with a NR5A1 mutation. The 
genotype of the analysed individuals is shown under their symbol. Full black squares 
indicate affected males with hypospadias, partially black circles indicate females with 
POF and circles with a black dot correspond with asymptomatic carrier females. 
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protein function according to several 
prediction programs (SIFT, Polyphen 
and MutationTaster). The affected amino 
acid is located in the ligand-binding 
domain and is highly conserved (up to 
zebrafish). Segregation analysis revealed 
that the mutation was present in the 
patient’s mother, who had no symptoms 
of POF at the age of 24. 
DISCUSSION 
To gain insight into the appropriateness 
and diagnostic yield of a systematic 
integrated work-up in 46,XY 
undervirilized cases who are sex-
assigned male, we used a standardized 
screening panel in a series of 32 cases 
referred to our DSD clinic. An overview 
of the approach is shown in Figure 3A. 
Difficulties in blood collection in 
newborns and infants made it impossible 
to perform the complete screening in 
every case, resulting in missing data. 
Low EMS scores (EMS < 7, n = 17) did not 
yield a higher diagnostic success as 
compared to higher EMS scores (EMS ≥ 7, 
n = 15). As reported earlier, no causal 
genetic variations were identified in 
children born SGA (n = 9) in our series22.  
Clinical investigation and hormonal data 
were sufficient to diagnose Kallmann 
syndrome and Mowat-Wilson syndrome in 
respectively three and one patients 
Familial, hormonal and/or phenotypic 
data were sufficient to suspect KS in 
three patients (P26, 28 and 29) and MWS 
in patient 30. As suggested in a paper by 
Grumbach et al. our study confirms that 
in boys, the period of physiological 
gonadotrophin surge (the so-called 
“mini-puberty”) represents a unique 
opportunity to diagnose KS early in cases 
with a suggestive phenotype (micropenis 
+/− cryptorchidism in the absence of 
hypospadias)23. In these patients a 
targeted approach to identify the 
underlying molecular cause was used. 
Here, we ended up with a higher 
diagnostic success rate, the molecular 
cause was identified in 75% (3/4) of 
patients.  
Despite suggestive hormonal results, we 
could not identify any HSD17B3, SRD5A2 or 
SRY mutations 
 Accumulation of A or T due to 17β-HSD 
deficiency or 5α-reductase deficiency 
respectively may lead to  markedly low 
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T/A (in case of 17β-HSD deficiency) or 
elevated T/DHT (in case of 5α-reductase 
deficiency) ratios. In contrast to previous 
reports, sequencing of the HSD17B3 and 
SRD5A2 genes in cases with aberrant T/A 
and T/DHT ratios respectively revealed 
no mutations20,21,24,25. However, for 
practical reasons, stimulated A and T 
values, which are generally considered 
more accurate than basal values during 
mini-puberty, had been obtained in only 
one of three patients with T/A < 1. 
Another possible explanation might be 
the different detection methods used for 
the various androgens 
(Radioimmunoassay for A versus 
LC/MSMS for T). Simultaneous detection 
of A, T and DHT by LC/MSMS, as 
described recently, is expected to be more 
reliable but is not routinely available 
yet26. Low serum AMH has been 
reported previously in infants with KS3,27, 
and has been attributed to a lack of FSH-
driven stimulus28,29. In all cases in which 
serum AMH was below the age-specific 
reference values (n = 10), sequencing of 
SRY was performed but revealed no 
mutations, confirming that SRY 
mutations are a relatively rare cause of 
46,XY partial gonadal dysgenesis in 
contrast to 46,XY complete gonadal 
dysgenesis, where SRY mutations are 
thought to account for up to 15% of 
cases3,30. 
Genetic screening: targeted resequencing 
and copy number analysis 
Following a number of recent reports in 
which NR5A1, AR and WT1 mutations 
and CNVs have been identified as the 
cause of isolated hypospadias and/or 
cryptorchidism10,12,31-37, a standardized 
genetic screening protocol was applied to 
identify the underlying genetic cause of 
the observed atypical genital 
development in all cases where clinical 
and hormonal data did not suggest a 
specific diagnosis, irrespective of the 
EMS scores. The screening consisted of 
array-CGH, MLPA and SRY-specific 
FISH to screen for genomic 
rearrangements, and sequencing of the 
AR, WT1 and NR5A1 genes.
 
119 
 
Array-CGH is a valuable diagnostic tool in 
46,XY undervirilization newborns with 
dysmorphic features and allowed the 
identification of two causal CNVs in our 
cohort 
Array-CGH was used to screen for 
larger genomic rearrangements and led 
to the identification of two deletions 
with clinical significance, both found in 
syndromic patients. Patient 11 (EMS = 3) 
presented with penoscrotal 
hypospadias and transposition. Besides 
these genital characteristics, this patient 
also showed macrocephaly, facial 
dysmorphism and developmental 
delay. Hormonal results revealed 
normal T levels, AMH was not available; 
array-CGH revealed a partial 
chromosome 9 deletion, encompassing 
the DMRT gene cluster. These genes 
encode transcriptional regulators 
involved in sex development, and 
monosomy of the distal part of 
chromosome 9p, mostly DMRT1, has 
been associated with 46,XY DSD in 
several cases38,39. Patient 28 (EMS = 8) 
showed symptoms of KS. Other 
phenotypic characteristics included: X-
linked ichthyosis, hypotonia, recurrent 
kidney stones and developmental delay. 
Liver function tests showed abnormal 
results, of hitherto unknown etiology. In 
this patient a part of the X-chromosome, 
including the genes KAL1 and NLGN4X, 
was deleted. KAL1 deletions or 
mutations are an established cause of X-
linked KS and can explain the genital 
phenotype seen in this patient40. 
NLGN4X, has been associated with X-
linked mental retardation and X-linked 
autism spectrum disorders41, and might 
explain the observed developmental 
delay. Previously, a link between KS, 
ichthyosis and Xp deletions has been 
described by Bick et al.42. No evident 
association could be found between the 
identified deletion and the elevated liver 
enzymes and recurrent kidney stones. 
This deletion was inherited from the 
mother, who had mild mental delay but 
no symptoms of KS. This deletion is 
therefore characterized by incomplete 
penetrance. In total, array-CGH 
revealed 10 CNVs in 22 patients, seven 
of them were inherited from the mother; 
making their clinical relevance 
questionable. Array-CGH resulted in a 
definite genetic diagnosis in 2/22 
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patients, (9%). When only considering 
the syndromic cases, array-CGH 
renders a diagnostic yield of 2/6 patients 
(33%). Although our series is small we 
can conclude that array-CGH is a 
valuable diagnostic tool in 46,XY DSD 
with associated dysmorphic features 
however larger patient groups should 
be investigated to make more definite 
conclusions. Because of the limited 
resolution of array-CGH, we performed 
MLPA to screen for deletions or 
duplications on the exon level for SOX9, 
NR5A1, WNT4 and NR0B1. In total 23 
patients were screened, however no 
additional CNVs were identified. 
Likewise, FISH analysis of SRY could 
not reveal any deletions. Although the 
mutation uptake of targeted CNV 
detection (MLPA) was limited in our 
cohort, it still remains an important 
addition to a genetic work-up of 46,XY 
undervirilized or 46,XY DSD patients. 
Different reports showed NR5A1 
microdeletions as a cause of both 46,XY 
DSD and POF43,16. 
We identified three novel NR5A1 
mutations, one of them was present in an 
affected male with preserved fertility 
Recently Kohler et al. reported a WT1 
mutation rate of 7.5% in children with 
severe hypospadias and Wang et al. 
identified AR mutations in 6.6% of their 
patient cohort with isolated 
hypospadias and micropenis, indicating 
a role for both WT1 and AR in minor 
forms of undervirilization32,44. Sanger 
sequencing of AR and WT1 was done in 
respectively 20 and 22 patients of our 
cohort. In contrast to these series, no 
significant sequence changes in these 
genes were identified. The relatively 
high frequency in previous cohorts 
might be attributed to a selection bias. 
Therefore, we conclude that the 
incidence of mutations in AR and WT1 
mutations is probably overestimated in 
patients with milder forms of 
undervirilization. On the other hand, 
NR5A1 was sequenced in 26 patients 
and revealed mutations in three of them 
(11.5%). This is in line with other series, 
where mutations were identified in 
approximately 15% of patients. In our 
cohort, two frameshift mutations and 
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one missense mutation were identified. 
The missense mutation, c.1109G > A, 
found in patient 15 (EMS = 3), targets an 
amino acid in the functionally important 
ligand binding domain (p.Cys370Trp) 
and is predicted to alter protein function 
(SIFT, Polyphen, MutationTaster). This 
mutation was also found in the patient’s 
mother. In addition to causing 46,XY 
DSD, NR5A1 mutations are a known 
cause of premature ovarian failure 
(POF)45. The patient’s mother had 
regular menses at the age of 30, however 
she is at risk for developing POF. The 
first frameshift mutation (patient 3), 
c.253_254del induces a premature stop 
codon at position 85 (p.Ala85*). There 
were no additional family members 
available for segregation analysis. The 
second frameshift mutation (patient 6), 
c. 630_637del, also leads to a premature 
stop codon (p. Tyr211Profs12*). This 
mutation was also present in the mother 
of the patient, a maternal aunt and the 
maternal grandfather. The aunt had 
recently been diagnosed with POF at the 
age of 35 years and underwent several in 
vitro fertilization (IVF) cycles, the 
patient’s mother (age 39) declared to 
have regular menses. Interestingly, the 
grandfather had been treated for 
hypospadias as a child. Preserved 
fertility in males with NR5A1 mutations 
has only exceptionally been reported so 
far46,47. These findings support the 
extreme intrafamilial variability seen 
with NR5A1 mutations. At the moment 
the mechanism behind this phenotypic 
variability and incomplete penetrance 
resulting from NR5A1 mutations 
remains elusive; they likely result from 
the effects of multiple genetic variations 
(modifiers) and/or their interactions 
with environmental factors. Variable 
expressivity, reduced penetrance and 
even more complex inheritance patterns 
such as digenic models have been 
reported in other developmental 
conditions such as Kallmann syndrome 
and may be explained in part by the 
overall ‘mutational load’ in different 
genes playing arole in common 
signaling pathways48-50.  
The integrated story: clinical, hormonal 
and genetic data 
Taken together, in spite of extensive 
clinical, hormonal and genetic 
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screening, the molecular cause of 46,XY 
atypical male genital development 
could only be identified in seven out of 
32 patients (21.8%). When comparing 
the diagnostic success rate between 
patients with low (<7, n = 17) or high (≥7, 
n = 15) EMS scores, we identified the 
underlying molecular defect in 
respectively three and four patients, 
leading to a diagnostic success rate of 
respectively 17.6% and 26.5% for 
patients with low versus higher EMS 
scores, suggesting that the decision to 
perform a detailed diagnostic work-up 
in 46,XY patients with atypical genitalia 
should not be based on the severity of 
the phenotype alone. Array-CGH 
revealed the causal CNV in two out of 
six syndromic patients, leading to a 
diagnostic yield of 33% in patients with 
additional phenotypic characteristics. 
When we included non-syndromic 
cases, the success rate drops to 9%, 
indicating that array-CGH is still an 
appropriate diagnostic tool in 
syndromic forms of 46,XY DSD, but is 
less efficient in non-syndromic cases. 
Sequencing of AR, WT1 and SRY did not 
reveal any mutations. Besides the low 
diagnostic yield of this sequential 
sequencing approach, cost and time 
efficiency should be considered. Sanger 
sequencing has an average cost of $2400 
per million bases, whereas the emerging 
next generation sequencing 
technologies (NGS) are much cheaper. 
With the Illumina platform, there is only 
a $0.07 sequencing cost per million bases 
(number based on Hiseq2000)51. The 
next step in the diagnostic work-up of 
46,XY boys wit atypical genitalia should 
be the implementation of targeted NGS 
panels covering clinically relevant genes 
with a known role in sex development 
and steroid biosynthesis pathways. A 
flexible and automated NGS workflow 
used for targeted resequencing of 
disease gene panels has been reported 
by us and allows parallel and cost-
effective analysis of a sizeable number of 
genes in a clinical setting52. While this 
approach seems to be very useful in 
some heterogeneous disorders, their 
clinical utility in 46, XY DSD is 
debatable, since the known disease 
genes in these phenotypes only account 
for 20–40% of patients. Therefore we 
anticipate that whole exome sequencing 
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(WES), which is increasingly put 
forward as a clinical diagnostic test in 
genetically heterogeneous disorders53,54, 
will gain importance in the diagnostic 
work-up of 46,XY DSD, both in a clinical 
and research context. However, in cases 
where associated phenotypic 
characteristics or cases where clinical 
and hormonal data suggest a specific 
gene defect, it remains advisable to 
perform targeted resequencing of the 
specific disease gene(s).
 
CONCLUSION 
In this study we examined a large consecutive cohort of undervirilized 46,XY neonates 
and infants. Following this protocol, we were able to genetically diagnose 19% of non-
syndromic patients and one third of the syndromic cases. There was no significant 
difference between the diagnostic success rate in patients with low EMS compared to 
higher EMS. In syndromic cases, array-CGH had a high diagnostic yield. Serial gene 
screening resulted in several novel NR5A1 mutations, although the overall diagnostic 
yield was rather low. Interestingly, we identified a novel NR5A1 mutation that was 
also present in a related male with preserved fertility, which has only exceptionally 
been reported. Given the low diagnostic yield of the sequential approach, parallel 
screening technologies such as targeted resequencing of clinically relevant disease 
genes and WES will be a preferred choice in future screening protocols. However, in 
cases where associated phenotypes are present, a more targeted approach remains the 
preferential strategy.
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Figure 3: Overview of the integrated investigation approach. (A) Results in the 46,XY 
undervirilization cohort. Clinical and hormonal investigation was sufficient to suspect 
a diagnosis in 4/32 cases. For two Kallmann syndrome patients the diagnosis was 
genetically confirmed, as shown in the CNV analysis and targeted resequencing boxes. 
A ZEB2 mutation was identified in the Mowat-Wilson syndrome patient. 
Subsequently a genetic work-up was performed for the remaining patients, guided by 
hormonal results. Sequencing of HSD17B3 and SRD5A2 in patients with a possible 
testosterone biosynthesis disorder did not reveal mutations. Genetic screening 
consisting of array-CGH, DSD MLPA and sequential gene-by-gene sequencing led to 
the identification of two causal CNVs (of which one KS, see above) and three novel 
NR5A1 mutations, respectively. (B) Suggested clinical algorithm for the investigation 
of 46,XY male neonates or infants referred for atypical genitalia. Upper section 
(orange): clinical investigation, including pregnancy history, medical history and 
physical examination, enables categorization in cases with and without syndromic 
features. Mid-section (blue): In all cases, clinical investigation should be followed by a 
hormonal work-up, which in turn can be suggestive of gonadal dysgenesis (GD), 
disorders of the steroid hormone biosynthesis pathway and/or rare forms of CAH (*: 
Only forms characterized by defective androgen production are implicated here), 
partial androgen receptor defects or KS. Insights in hormone levels can guide selection 
of target candidate genes. Lower section (green): After thorough evaluation of clinical 
and hormonal data, a decision can be made to sequence specific gene panels or to 
proceed to clinical whole exome sequencing to identify the underlying molecular 
cause and thereby support the clinical diagnosis. The boxes between brackets (with 
squared filling) represent single gene tests which can be replaced be the 
aforementioned gene panels In cases with syndromic features, array-CGH is still a 
recommended method to identify CNVs. 
 
PATIENTS & METHODS 
Patients  
All 46,XY children younger than two years who were referred to our pediatric 
endocrinology service for the evaluation of atypical genitalia (e.g. hypospadias, 
micropenis) and who were sex assigned male, between 2007-2013 were included (n=32) 
(Table 1). Medical history included pregnancy details, birth weight (BW), 
consanguinity and a familial history of disorders of sex development (DSD), sub- or 
infertility, premature ovarian failure (POF) or atypical genitalia. Phenotypic 
description consisted of a physical examination with special attention to 
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dysmorphism; EMS scores were calculated based on the aspect of the external 
genitalia55. None of the patients had proteinuria or renal insufficiency. 
Biochemical analyses 
Hormonal levels were obtained between day 14–90 after birth or after HCG 
stimulation (Pregnyl®, 1500U, with blood sampling at baseline and after 72 hours). 
The following hormone levels were measured: anti-Müllerian Hormone (AMH) by 
enzyme linked immunosorbent assay (Beckman Coulter Company), Androstenedione 
(A) by Radioimmunoassay (DiaSource Company), Testosterone (T) and 
Dihydrotestosterone (DHT) by liquid chromatography/tandem mass spectrometry 
(UPLC Waters Quattro premier). LH and FSH by electrochemoluminescence assay 
(Roche Diagnostics E170 Modular). 
Genetic analyses 
Array-CGH using the Agilent 180 K array was used as a genomewide screen for copy 
number variations (CNVs) with an overall mean probe spacing of 14 kb, or 11 kb when 
only taking into account the Refseq genes. Hybridization was done according to the 
manufacturer’s protocol, followed by visualization of the results in arrayCGHbase56. 
Fluorescent in situ hybridization (FISH) was performed for SRY to search for SRY 
rearranging translocations and mosaicism. To screen for CNVs on the exon level, 
MLPA was done using the SALSA MLPA P185 Intersex probemix (MRC-Holland) 
containing probes for NR0B1, NR5A1, SOX9, SRY and WNT4. Sanger sequencing of 
the coding exons and untranslated regions (UTRs) was used to identify mutations in 
AR, NR5A1 and WT1. SRY sequencing was included for patients suspected to have 
gonadal dysgenesis, based on an AMH level below the reference range. HSD17B3 and 
SRD5A2 were sequenced in cases with suspicion of a testosterone biosynthesis 
disorder based on a T/A ratio <1 for 17β-HSD deficiency and a T/DHT ratio > 8.5 for 
5α Reductase Deficiency (Table 2)274,275. Primers for AR, WT1 and SRY were designed 
using PrimerXL (http://www.primerxl.org/, available on request). Primer sequences 
for NR5A1, HSD17B3 and SRD5A2 can be found in supplemental data (Additional file 
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1: Table S1). Zinc Finger E-Box Binding Homeobox 2 (ZEB2) sequencing and sequencing 
of the Kallmann syndrome (KS) gene panel, consisting of six genes (KAL1, CHD7, 
FGFR1, PROK2, PROKR2, FGF8) was done at the Henri Mondor Hospital (Paris, 
France). Fibroblast Growth Factor Receptor 1 (FGFR1) sequencing was performed at the 
CHU Hospital Cochin (Paris, France). 
Cell culture, RNA extraction and cDNA synthesis 
Lymphocytes were isolated by Lymphoprep™ (STEMCELL Technologies) and 
cultured in RPMI medium with 10% FCS; interleukin-2 and phytohemagglutin were 
added. Cells were incubated at 37°C and 5% CO2. RNA was extracted using the 
RNeasy Plus Mini kit (Qiagen), followed by cDNA synthesis with the iScript™ cDNA 
synthesis kit (Biorad). 
Expression analysis 
Expression levels of NR5A1 were measured through real-time quantitative PCR (rt-
qPCR), using following primers: NR5A1-F 5′ caggagtttgtctgcctcaa 3′ and NR5A1-R 5′ 
agtggcacagggtgtagtca 3′. After in silico validation primers were tested using a dilution 
series. The experiment was done with the SsoAdvanced SYBR supermix (Bio-rad). 
Analysis of rt-qPCR results was done with qbase + software (Biogazelle). 
The study was approved by the local medical ethical committee (Registration number 
B670201110608) and all parents signed a written informed consent. 
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ABSTRACT 
Background:  Disorders/differences of sex development (DSDs) are rare congenital 
conditions characterized by atypical sex development. The molecular cause remains 
unknown in 50% of cases. Whole exome sequencing (WES) can uncover novel genes 
implicated in sexual differentiation.  
Methods: Homozygosity mapping and WES revealed an ESR2 variant in an individual 
with syndromic 46,XY DSD. Additional cases with 46,XY DSD underwent WES and 
targeted next-generation sequencing of ESR2. Functional characterization of the 
identified variants included luciferase assays and protein structure analysis. 
Immunostaining of ER-β was performed in an eight-weeks old human male embryo. 
Results: We identified a homozygous ESR2 variant, c.541_543del p.(Asn181del), 
located in the highly conserved DNA-binding domain of ER-β, in an individual with 
syndromic 46,XY DSD. Two additional heterozygous missense variants, c.251G>T 
p.(Gly84Val) and c.1277T>G p.(Leu426Arg), located in the N-terminus and the ligand-
binding domain of ER-β, were found in unrelated, non-syndromic 46,XY DSD cases. 
A significantly increased transcriptional activation and an impact on protein 
conformation was shown for the p.(Asn181del) and p.(Leu426Arg) variants. ER-β 
expression was demonstrated in developing intestine and eyes. 
Conclusion: Our study supports a role for ESR2 as a novel disease gene for 46,XY DSD. 
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INTRODUCTION 
In humans, gonadal fate is determined 
by the presence or absence of sex-
specific gene expression. In the 
bipotential stage of development, 
transcription factors such as Wilm’s 
Tumor 1 (WT1), Nuclear Receptor 
Subfamily 5 Group A member 1 
(NR5A1) and GATA binding protein 4 
(GATA4) lead to upregulation of Sex 
determining Region Y (SRY) in the male 
embryo, thereby initiating the male 
developmental signaling cascade, with 
the expression of other male-specific 
genes like SRY-box 9 (SOX9)1. In 
addition, several reports indicate an 
important role for the Mitogen 
Activated Protein Kinase (MAPK) 
pathway in the early phases of (male) 
sex determination2-4. In female embryos, 
lacking the Y chromosome, female-
specific genes like R-spondin 1 (RSPO1) 
and Forkhead box L2 (FOXL2) are 
expressed amongst others1,5. Animal 
studies have revealed multiple and 
long-lasting interactions between these 
male and female pathways; for instance 
loss of Foxl2 or Dmrt1 in murine adult 
granulosa and Sertoli cells respectively 
result in trans-differentiation to an 
opposite cell fate6,7.  
Subtle imbalances of this strictly 
regulated sex-specific gene network can 
lead to disorders/differences of sex 
development (DSD)1,5. Currently, 
mutations in genes known to be 
involved in sex development explain the 
molecular pathogenesis in only a 
minority of 46,XY DSD1,8. Next-
generation sequencing-based 
approaches such as whole exome 
sequencing (WES) improve the 
identification of causal genetic defects, 
and the discovery of new genes and 
signaling pathways implicated in sex 
development9,10. Elucidating the 
underlying causes of DSD can facilitate 
sex assignment, and lead to improved 
management, a better prognosis and a 
more accurate evaluation of gonadal 
function and gonadal germ cell cancer 
risk11,12. 
So far, mutations in genes encoding 
nuclear receptors such as NR5A1 (also 
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known as Steroidogenic Factor 1 or SF1)13 
and Androgen Receptor (AR, NR3C4)14, 
have been implicated in DSD 
pathogenesis as well as the duplication 
of Nuclear Receptor Subfamily 0 Group B 
Member 1 (NR0B1, DAX1)15. Here, we 
identified biallelic and monoallelic 
Estrogen receptor 2 (ESR2) mutations in 
one syndromic and two non-syndromic 
46,XY DSD cases respectively, putting 
forward ESR2 as a novel disease gene 
for 46,XY DSD and expanding the 
spectrum of nuclear receptors 
implicated in 46,XY DSD etiology.  
RESULTS 
Identification of a homozygous ESR2 
variant in Case 1 with syndromic 46,XY DSD 
Given the possible parental 
consanguinity, we performed 
homozygosity mapping to identify runs 
of homozygosity containing the 
putative underlying genetic cause of the 
syndromic 46,XY DSD phenotype in 
Case 1. Twenty-one homozygous 
regions larger than 1 Mb were identified 
(Supplemental data, Table S6). The 
largest one, 20 Mb in length, is located 
on chromosome 14, and contains 465 
genes, none of them are known DSD 
genes. The gene encoding 5α-reductase, 
SRD5A2, was present in another small 
homozygous region (3.6 Mb), however 
no potentially pathogenic variants were 
found in its coding region. Variant 
prioritization ranked ESR2 as the top 
candidate gene (Supplemental data, 
Table S7). Sequencing of ESR2 revealed 
a homozygous 3-bp deletion in exon 9, 
c.541_543del, leading to an in-frame 
deletion, p.(Asn181del) (Figure 1A-B). 
This deletion affects a highly conserved 
amino acid, located in the DNA-binding 
domain (DBD) (Figure 1A-B). The 
deletion was found to be absent in 92 
tested ethnically matched control 
chromosomes and in 320 other tested 
control chromosomes. This variant is 
reported at very low frequencies in 
publicly available databases (ESP, ExAC 
0.3.1, gnomAD), however no 
homozygotes have previously been 
identified (variant details in 
Supplemental data, Table S8). 
Segregation analysis showed that both 
parents (Figure 1B, I:1 and I:2) and one 
healthy 46,XX sibling (Figure 1B, II:2) 
are heterozygous carriers of the 
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deletion, another 46,XX sibling (Figure 
1B, II:3) is homozygous for the wild type 
allele. WES made the presence of other 
potentially pathogenic coding variants 
in the index case and her parents very 
unlikely. An overview of the variant 
filtering, performed as previously 
described16, is given in Supplemental 
Tables S3-4.  
Identification of two heterozygous ESR2 
missense variants in Case 2 and 3 with non-
syndromic 46,XY DSD  
Targeted resequencing of the ESR2 
coding region in a Belgian 46,XY DSD 
cohort (n=73) and in a Brazilian 46,XY 
DSD cohort (n=40) revealed two 
heterozygous missense variants in two 
unrelated cases with non-syndromic 
46,XY DSD. In Case 2 a heterozygous 
ESR2 variant c.251G>T was found in 
exon 2, leading to a missense variant 
p.(Gly84Val) affecting a highly 
conserved amino acid (up to fruitfly) 
located in the N-terminal domain, which 
contains the first activation function of 
the receptor (Figure 1A). The 
physicochemical difference between Gly 
and Val is moderate (Grantham distance 
of 109). Several prediction programs 
(SIFT, PolyPhen-2 and MutationTaster) 
suggest a deleterious effect on protein 
function. The variant is absent in 412 
tested control chromosomes and in 
genomic databases such as dbSNP, ESP, 
and ExAC. In gnomAD it occurs in 
0,000396% (no homozygotes) (Table 3). 
WES did not reveal any other potentially 
pathogenic variants in Case 2, an 
overview of the different filtering steps 
and variants is given in Supplemental 
Tables S3 and S5. In Case 3 a 
heterozygous missense variant was 
found, c.1277T>G in exon 8 of ESR2, 
leading to the missense variant 
p.(Leu426Arg) in the ligand-binding 
domain (LBD) and affecting a highly 
conserved amino acid (up to Tetraodon). 
The Grantham distance between Leu 
and Arg is moderate (i.e. 102) and 
several prediction programs show a 
potential deleterious effect. This variant 
is not present in the consulted genomic 
databases (dbSNP, ESP, ExAC, 
gnomAD) nor in 214 Brazilian controls 
(Table S8). Figure 1 shows a schematic 
overview of the location and 
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Figure 1: Identification of three ESR2 variants. (A) Schematic overview of the ER-β protein 
with detailed representation of the DNA-binding domain (DBD). Light grey circles: P-box 
amino acids. Dark grey circles: dimerization interface. Red circle: deleted amino acid in Case1. 
(B) Protein alignment (left) indicating the deleted amino acid Asn181 (N181) found in Case 1, 
conserved up to Tetraodon and in human ER-α. Electropherogram (middle) and pedigree 
(right). Affected individual: black symbol. M: mutation.(C) Protein alignment (left) indicating 
the affected amino acid in Case 2, Gly84 (G84) conserved up to fruitfly. Electropherogram 
(middle) and pedigree (right). NA: not available.(D) Protein alignment (left) indicating the 
affected amino acid in Case 3, Leu426 (L426) conserved up to Tetraodon. Electropherogram 
(middle) and pedigree (right). NA: not available.
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characteristics of the identified ESR2 
variants. 
Structural analysis of the ER-β variants  
The ER-β DBD binds to DNA as a 
homodimer. We built homology models 
for the wild type and p.(Asn181del) 
mutant homodimer. Residue Asn181 is 
part of a longer extended loop that 
connects the main DNA binding helix to 
a zinc coordination site, which is part of 
the homodimer interface. The Asn181 
deletion shortens this connecting loop 
and causes a 15° tilt of the main DNA-
binding helix (Figure 2, panel A-B). 
Molecular dynamics simulation, 
followed by energy minimization 
suggests that this slightly affects the 
orientation between the two DBDs in the 
homodimer, with an increased number 
of contacts between the two domains 
(Figure 2, panel A-B). It is therefore very 
likely that the Asn181 deletion affects 
homodimerization and/or DNA binding 
of the ER-β. 
To assess the possible influence of the 
p.(Leu426Arg) missense variant on ER-β 
protein structure, we made in silico 
calculations of ΔΔG with foldX and tried 
to model the best rotamer position for 
each variant with UCSF Chimera17. 
There was no template available for 
remodeling of the p.(Gly84Val) variant, 
and no decent homology models could 
be obtained. The p.(Leu426Arg) variant 
is located in the LBD, which was 
previously characterized by X-ray 
crystallography18. Leu426 is a buried 
residue of helix 9 (Figure 2A). FoldX 
energy calculations using the 
BuildModel command indicate that the 
p.(Leu426Arg) mutation affects the 
folding energy of the protein and has a 
destabilizing effect (in silico ΔΔG= 2.3 
kcal/mol)18. Leu426 fits in a hydrophobic 
pocket and engages in interactions with 
Leu322, Leu330, Leu406 and Met410 
(Figure 2B). Modeling the best fitting 
Arg rotamer at the position of Leu426 in 
UCSF Chimera shows that this mutation 
abolishes most of these hydrophobic 
interactions, while even the best fitting 
rotamer of the Arg sidechain introduces 
strong steric clashes in the absence of 
drastic energy minimization (green 
lines) (Figure 2C). The p.(Leu426Arg) 
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Figure 2: Structural analysis of mutated and WT ER-β. (A) Effect of the Asn181 deletion on a 
dimer of the ER-β DNA binding domain. A model for a dimer of both the wild type (blue) and 
Asn181del mutant (red) DNA-binding domain (DBD) are shown. Monomer 1 of both dimers 
is superposed. The Asn181 (N181) deletion shortens a long loop between the DNA-binding 
helix and the zinc-binding site at the dimer interface. As a result, the DNA-binding helix tilts 
towards the dimer interface. The red arrow indicates an upward shift of the second monomer 
versus the first monomer in the mutant dimer. The molecules are rotated 90° compared with 
panel B and the DNA-binding helices are directed towards the viewer. (B) Model of the wild 
type ER-β DBD bound to DNA. The position of Asn181 is indicated. (C) Position of the Leu270 
(L270) and Leu426 (L426) residues in the ER-β LBD structure. Atoms of L270 and L426 are 
shown as grey spheres. (D) L426 is buried in a hydrophobic environment in the LBD structure. 
(E) When L426 is mutated to the best fitting Arg rotamer in UCSF chimera, the Arg sidechain 
clashes with residues D326 and M410 (red lines)17.
142 
 
variant is likely to affect the stability or 
folding of the LBD domain. Folding of 
the p.(Leu426Arg) variant estrogen-
bound LBD domain into a wild type-like 
structure would at least require drastic 
structural changes in the environment of 
residue 426, which could hamper LBD 
dimerization, as helix 9 and the loop 
between helix 8 and 9 (which interacts 
with Leu426 via Met410) are both part of 
the symmetrical LBD dimer interface. 
ER-β expression in a human male embryo 
In a human male embryo, eight weeks 
gestational age, ER-β expression was 
demonstrated in the developing eye, 
especially the corneal epithelium and 
endothelium, primitive lens neurons, 
primitive retinal cells and the retinal 
pigment epithelium, the mucosa of the 
developing intestine and in the neuronal 
system, specifically the primitive 
neurons of the germinal matrix. No ER-
β expression could be demonstrated in 
the developing testis at this stage of 
development (Supplemental data, 
Figure S1).  
Transcriptional activation assays and 
localization studies 
The impact of the identified variants on 
transcriptional activation was assessed 
using luciferase assays with TK-3xERE-
promoter constructs. The p.(Asn181del) 
variant resulted in a significantly 
increased transcriptional activation after 
stimulation with the ER-β specific 
ligand, DPN (p<0.001). For the two 
missense variants, p.(Gly84Val) and 
p.(Leu426Arg), no significant alterations 
of ligand-dependent transcriptional 
activation were observed (Figure 3). 
Interestingly, the p.(Leu426Arg) variant 
shows a higher transcriptional 
activation compared to WT ER-β when 
the cells are not stimulated with DPN 
(p=0.0014), suggesting a higher baseline 
activity. Localization studies for wild 
type, p.(Asn181del) and p.(Gly84Val) 
constructs in HEK293T cells showed no 
differences in subcellular localization 
between the wild type and mutagenized 
constructs. Both ER-β variants showed 
nuclear translocation upon stimulation
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Figure 3: Transcriptional activation assays. Results are shown as means  standard error for 
relative luciferase intensity units (R.L.U.). The analysis involved the fitting of a hierarchical 
generalized linear model (HGLM) to the R.L.U. data, as implemented in Genstat v1819, with 
transfection and  stimulation as fixed terms (Poisson distribution; log link) and replicates (n = 
4 or higher) nested within experimenter as additional random terms (Gamma distribution; log 
link). **: p < 0.01; ***: p < 0.001. with the ER-βspecific ligand DPN (Supplemental data, 
Figure S2).
DISCUSSION 
The identification of three distinct 
potentially pathogenic variants in ESR2 
in unrelated individuals with 46,XY 
gonadal dysgenesis suggests an 
unanticipated role for ER-β in early 
gonadal development. Previously, 
polymorphic ESR2 variants have been 
associated with milder variations in 
sexual development such as 
hypospadias and micropenis20-24 and a 
heterozygous ESR2 variant c.1295C>A 
leading to a missense change 
p.(Ala432Asp) in the LBD of ER-β was 
recently reported in a girl with primary 
amenorrhea25.  
Here, we identified a biallelic in-frame 
deletion in a girl with syndromic 46,XY 
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DSD and two monoallelic missense 
variants in two unrelated cases with 
non-syndromic 46,XY DSD. The data of 
Case 1 is suggestive of absent gonadal 
development, while data of Case 2 and 3 
are compatible with partial and 
complete gonadal dysgenesis. Both 
population frequencies and in silico 
predictions support a pathogenic role of 
the three variants found (Table S8). 
Structural analyses support a 
deleterious effect of the p.(Asn181del) 
and the p.(Leu426Arg) variant on 
protein conformation, but are not 
available for the p.(Gly84Val) variant 
due to the absence of a suitable model 
for this region. A significant increase in 
transcriptional activation was shown for 
p.(Asn181del) and the p.(Leu426Arg) 
variant resulted in increased activity in 
the absence of an ER-β specific ligand; 
both effects might hint towards a gain-
of-function effect.  
Immunohistochemistry in an eight-
weeks old male human embryo 
confirmed ER-β expression in the 
developing intestine, eye and neuronal 
systems26 which reflects the 
extragonadal organs affected in Case 1. 
However, no testicular expression was 
observed at this time of development, 
suggesting an earlier role of ER-β, at the 
stage of gonadal determination, in line 
with the absence of gonads observed in 
Case 1. Non-classical estrogen signaling 
has been shown previously to interact 
with the MAPK pathway27; a signaling 
pathway involved in the earliest stages 
of gonadal development, although the 
operating mechanisms are different in 
humans and mice. In humans, MAPK 
signaling is essential for tilting the gene 
expression balance towards SOX9 
expression; gain-of-function mutations 
of MAP3K1 lead to a higher 
phosphorylation of downstream targets, 
causing a decreased expression of SOX9 
and an increased expression of female-
specific genes like β-catenin2,28,29. In mice, 
the Mapk pathway acts through direct 
upregulation of Sry; homozygous loss-
of-function variants of Map3k4 are 
reflected in a male-to-female sex 
reversal phenotype3,29.  
Nuclear receptor family members, to 
which the ERs belong, are known to 
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exert their functions through different 
action mechanisms. The classical, 
genomic pathway involves ligand 
binding and receptor dimerization, 
followed by nuclear translocation and 
activation or repression of target gene 
expression27,30. Estrogen binds on both 
ER-α and ER-β receptors, however, 
binding results in partially overlapping 
but also differential transcriptional 
effects31,32. Alternative action 
mechanisms involve interactions with 
other transcription factors, ligand-
independent receptor activation and 
activation of different signaling 
pathways. For instance, it has been 
shown that ER-β can activate specific 
MAPK pathways in human colon cancer 
cell lines. The scarce experimental data 
on these alternative pathways indicate 
that these processes are highly cell 
specific27. We hypothesize that ESR2 
gain-of-function variants, as assumed 
for p.(Asn181del), can lead to increased 
activation of the MAPK pathway via a 
non-genomic working mechanism, 
thereby shifting the expression balance 
from SOX9 to β-catenin signaling, and 
resulting in resulting in decreased SOX9 
activation and failure of testicular 
development (Figure 4). For the 
p.(Leu426Arg) variant, we observed a 
significantly higher activation of the 
unstimulated ER-β receptor compared 
to WT unstimulated ER-β, suggestive of 
a hyperactive ER-β receptor that can be 
activated by estrogen levels that are 
otherwise insufficient. Maternal 
estrogen that typically has no obvious 
effect on male sex development, might 
have activated the hyperactive receptor 
in this case and induce a gain-of-
function effect as well. Experimental 
validation of these hypotheses is 
challenging given the cell-type 
specificity of these alternative pathways 
and the fact that no relevant cell line 
resembling the undifferentiated gonad 
is available. Furthermore, it remains 
complex to acquire an experimental set-
up that resembles the earliest phases of 
sex development as all available 
gonadal cell lines have already 
differentiated.  
The differential action modes of MAPK 
signaling in mice and humans can also 
explain the absence of a sex reversal 
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Figure 4: Suggested action mechanism for gain-of-function mutations in ESR2.  Green boxes: 
testis promoting factors, orange boxes: ovary promoting factors, arrows represent interactions 
that promote action of downstream targets, bars represent interactions that inhibit action of 
downstream targets. (A) Suggested role of the ESR2 gene in normal male development. 
Besides the classical genomic action mechanism, ESR2 can also exert its effect by cell-type 
specific, non-genomic responses via other pathways like the MAPK pathway. The MAPK 
pathway has previously been implicated in gonadal development by the identification of gain-
of function mutations in MAP3K1. This pathway shifts the gene expression balance towards 
SOX9 upregulation via interactions with downstream targets (e.g. MAP3K4) and their co-
factors (GADD45γ). Once SOX9 is activated, it maintains its own expression via a FGF9 
regulated positive feedback loop. In physiological circumstances, MAP3K1 activity also leads 
to phosphorylation of p38 and ERK1/2, leading to inhibition of the female specific β-catenin 
pathway. (B) We hypothesize that ESR2 gain-of function variants can act on gonadal 
development in a similar way as MAP3K1 variants. Previous research has shown that gain-of-
function MAP3K1 mutations may mimic the ovary determining pathway and lead to increased 
binding of co-factors RHOA and Rock, inhibiting SOX9 expression. In addition, it induces 
hyperphosphorylation of p38 and ERK1/2, neutralizing and even reversing β-catenin 
inactivation. Beta-catenin signaling can then activate FOXL2, thereby further repressing SOX9 
activation. This way MAP3K1 mutations, and hence ESR2 mutations according to our 
hypothesis, can attenuate the testis-determining signal induced by SRY (grey box). Hypothesis 
and figure are based on data reported by Loke et al. (2014) and Ostrer et al. (2014) 28,29.
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phenotype in ER-β knock-out mouse 
models. Over the years, several ER-β KO 
mice have been generated. A first mouse 
knockout model was characterized by 
female sub- or infertility and normal 
reproductive capacity in males33. This 
mouse was generated through insertion 
of a neomycin resistance gene into exon 
3 of the Esr2 gene by homologous 
recombination in embryonic stem cells. 
Several transcripts were still being 
processed however, leading to an 
incomplete knockout. Moreover, ER-β 
knock-out mice originating from the 
same initial ER-β mutant but raised and 
examined in different laboratories 
presented with a range of different 
phenotypes. A new ER-β knock-out 
mouse used Cre/LoxP mediated 
excision of the third exon of Esr2, 
resulting in complete absence of any 
Esr2 transcript. These mice show 
infertility in both sexes, but no sex 
reversal. A similar situation has been 
reported for another nuclear receptor 
NR0B1 (DAX1), where duplications lead 
to male-to-female sex reversal in 
humans, but to delayed testis 
development in mice34. 
Differences in zygosity have been 
shown for the missense ESR2 variants 
found here, and may relate to the milder 
and different phenotype in the two 
monoallelic cases compared to the 
biallelic case (non-syndromic versus 
syndromic; complete and partial 
testicular dysgenesis versus gonadal 
agenesis). Moreover, a different 
working mechanism cannot be excluded 
for the monoallelic missense variants 
found, although they may all act via the 
same dysregulated MAPK pathway. 
Differences in zygosity and mutation-
dependent action mechanisms have 
been described for other nuclear 
receptors, such as NR2E3, implicated in 
both autosomal dominant and recessive 
retinal dystrophies with clinically 
distinct phenotypes35.
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GENERAL CONCLUSION 
We identified biallellic and monoallelic variants in ESR2 in patients with syndromic 
and non-syndromic 46,XY DSD respectively, putting forward ESR2 as a novel 
candidate gene for 46,XY DSD etiology. It is interesting to speculate about an 
unanticipated role for ER-β in early gonadal development, i.e. the development and 
stabilization of the bipotential gonad and/or its differentiation into a functional testis, 
for instance through the MAPK signaling pathway, as has been demonstrated for 
MAP3K1 mutations. 
 
PATIENTS AND METHODS 
Study subjects 
Laboratory and clinical investigations of cases 1-3 are summarized in Table 1. Cases 
and/or parents provided written informed consent for the study. Detailed case reports 
can be found in Supplemental data, Case reports S1-S3. 
Genetic studies 
Homozygosity mapping was performed by genome-wide SNP genotyping in Case 1 
and in two unaffected siblings, using the HumanCytoSNP-12 BeadChip platform 
(Illumina). Plink software, integrated in ViVar, identified homozygous regions > 1 Mb 
which were ranked according to their length and the number of SNPs, as described16. 
Only homozygous regions unique to the index case were selected. The presence of 
relevant known DSD genes was excluded using Biomart filtering. Next, different gene 
prioritization tools (Endeavour, GeneDistiller, GeneWanderer, PosMed, SUSPECTS 
and ToppGene) were used to identify candidate genes in the selected regions36. For 
this purpose, known DSD genes were used as training genes (Supplemental data, 
Table S1). 
Sanger sequencing and targeted next-generation sequencing. Primers were developed 
for PCR amplification and sequencing of all coding exons, intron-exon boundaries and 
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untranslated regions of ESR2 (Supplemental data, Table S2). Sanger sequencing (Case 
1 and 2) was done on the ABI 3730XL DNA Analyzer (Applied Biosystems) using the 
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) followed by data-
analysis with SeqScape v2.5 (Life Technologies). Targeted NGS (Case 3) with a MiSeq 
instrument was performed using a workflow as described37. CLC Genomics 
Workbench (CLCBio, Aarhus, Denmark) was used for the mapping of the reads and 
data-analysis of the variants. Segregation analysis for the ESR2 variant found in Case 
1 was performed in the available family members. Apart from the mother, no family 
members were available for further analysis in case 2. For case 3, no parental DNA was 
available for segregation analysis. 
Whole exome sequencing was performed to exclude the presence of other possibly 
pathogenic variants in Cases 1 and 2. Exome enrichment was performed with the 
Nextera Rapid Capture Exome kit (Illumina), followed by paired-end sequencing on 
HiSeq 2000 (2x100 cycles) (Illumina). Reads were mapped against the human reference 
genome sequence (NCBI, GRCh37/hg19) with the CLC Genomics Workbench v6.4 
(CLC bio) followed by post-mapping duplicate read removal, coverage analysis, and 
quality-based variant calling. More thorough variant annotation was executed with 
the Alamut-HT v1.1.5 software (Interactive Biosoftware) and complementary 
literature search after extensive screening (Supplementary Table S3-5). 
Structural analysis of the ER-β variants  
Models for the wild type ER-β DNA binding domain were built using the standard 
homology modeling procedure in YASARA structure (http://yasara.org/products). We 
used the structure of the ER-β bound to a DNA response element (pdb code 1HCQ) as 
a template38. We built models for dimers of the wild type DNA binding domain with 
and without DNA. A model for the p.(Asn181del) (N181del) mutation (found in Case 
1) was built in YASARA structure based on the wild type model, by deleting residue 
N181, introducing a new peptide bond between residues 180 and 182, followed by 
energy minimization (em_runclean protocol in YASARA structure). The homodimer 
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models for the wild type and N181del mutant DNA binding domains were further 
subjected to 500 ps of molecular dynamics with the YASARA2 forcefield, followed by 
energy minimization using the md_refine procedure39.  
Using FoldX and the estrogen-bound ER-β ligand binding domain (LBD) structure 
with pdb code 3OLL, we calculated an in silico estimate of the Gibbs energy of protein 
folding for the mutant and wild type LBD using the RepairPDB and BuildModel 
commands18,40. For each mutant, we report the average ΔΔG for folding of mutant 
versus wild type of 20 BuildModel calculations. The 3OLL protein structure was 
visualized in UCSF Chimera17. The effect of the p.(Leu426Arg) (L426R) mutation 
(found in Case 3) was visualized by replacing L426 with the best fitting arginine 
rotamer in the Dunbrack backbone dependent rotamer library. 
Immunohistochemistry 
Tissue slides (4 µm) were prepared from a formalin-fixed, paraffin embedded eight-
weeks old male fetus obtained after spontaneous abortion. Prior to 
immunohistochemistry a heat induced antigen retrieval (HIAR) step (Tris-EGTA 
pH9.00) was included. We used a standard ABC-protocol for detection of ER-β. After 
blocking of endogenous peroxidase and biotin (Avidin/Biotin Blocking Kit Catalog 
Number: SP-2001), and overnight incubation with mouse anti-ER-β (dilution 1/50, 
Dako M7292), detection was performed with a biotinylated rabbit anti-mouse antibody 
(dilution 1/150, 30 minutes, Dako E413) followed by 30 minutes of incubation with 
Avidin-Biotin-HRP labeled complex (VECTASTAIN Elite ABC HRP Kit Catalog 
Number: PK-6100). Visualization was done with DAB/H2O2 and hematoxylin 
counterstaining.  
Luciferase assays and localization studies 
Plasmid construction. Plasmids containing the ESR2 variants were constructed with 
site-directed mutagenesis starting from a pcDNA-flag-ER-β plasmid (35562, 
Addgene). Mutagenesis primers were designed using the NEBaseChanger software 
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(http://nebasechanger.neb.com/). After amplification, the plasmids were digested with 
DpnI to remove non-mutated DNA. After verifying that mutations had correctly been 
inserted via sequence analysis, mutated plasmids were transformed in chemically 
competent E. coli (DH10b cells) and subsequently isolated with the NucleoBond Xtra 
Midi/Maxi kit (Macherey-Nagel). 
Cell culture and luciferase assays. HEK293T cells were cultured in Dulbecco’s minimal 
essential medium (DMEM) without phenol red, supplemented with 10% charcoal 
stripped fetal bovine serum (DCC-FBS) (Life Technologies) and 10 µg/ml Gentamycin 
at 37°C and 8% CO2. A total of 300 000 cells per well were plated in 6-well plates. Cells 
were transfected with a total of 2 µg of DNA using a standard calcium phosphate 
transfection method. After 24h, cells were washed with phosphate buffered saline 
(PBS) and subsequently stimulated with 2,3-Bis(4-hydroxyphenyl)propionitrile (DPN) 
to a final concentration of 10 nM. Following lysis with 1x CCLR lysis buffer (25mM 
Tris-phosphate pH7.8, 2mM DTT, 2mM CDTA, 10% Glycerol, 1% Triton X-100), 
luciferase activity measurements were done 24 hours after stimulation on a TopCount 
luminometer (Canberra-Packard). To normalize for differences in transfection 
efficiency, a plasmid constitutively expressing β-galactosidase was co-transfected in 
all experiments (Tropix Galacto-star system, Applied Biosystems). Each transfection 
was replicated in at least three independent experiments.  
Subcellular localization experiments. Coverslips were coated with poly-L-Lysine and 
150,000 cells were seeded per well in DMEM (without phenol red), supplemented with 
10% DCC-FBS. Flag-tagged ER-β constructs were transfected as described for the 
luciferase assays and cells were stimulated with DPN after 4 hours of starvation. After 
24 hours, cells were fixed using 4% paraformaldehyde, permeabilized with methanol 
and blocked with blocking buffer (20mM phosphate buffer, 100mM NaCl, 0.23% Triton 
X-100, 10% donkey serum). This was followed by overnight incubation with a primary 
mouse anti-FLAG antibody (monoclonal anti-flag M2, Sigma #F3165, 20µg/ml). The 
next day, subsequently to washing steps with PBS with 0.1% TX-100, an anti-mouse 
secondary antibody (Alexa Fluor 488 donkey anti-mouse IgG H+L, 2µg/ml) (Life 
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Technologies) was added and nuclei were counterstained with DAPI. Visualization 
was done with a motorized inverted IX81 FluoView FV1000 laser scanning confocal 
microscope (Olympus) and three fields of on average 15 cells were scored. 
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SUPPLEMENTAL DATA 
SUPPLEMENTAL NOTES: Case reports 
Case report S1. Clinical case report of Case 1. 
Case 1 was referred to the pediatric endocrinology service at the age of 15 because of 
absence of pubertal development. She was born after an uneventful pregnancy, birth 
weight was 2850 g. She has two healthy sisters, family history was unremarkable but 
both parents originated from the same village, suggesting a potential consanguineous 
background (Figure 1B). Anal atresia, a rectovestibular fistula and a vaginal dimple 
were observed at birth, external genitalia appeared female. Anal reconstructive 
surgery was performed eight days after birth and at the same time 
sigmoidovaginoplasty was performed. Retrospective data on the basis of ultrasound 
(US) imaging regarding the presence of Müllerian structures are inconclusive. The girl 
was additionally diagnosed with blepharophimosis and ptosis for which she 
underwent oculoplastic surgery at the age of three. She developed nystagmus, severe 
degenerative myopia and left esotropia, and was operated for retinal detachment at 18 
years. At the time of evaluation (15 years), dysmorphism was observed (Table 1). 
Breast and pubic hair were concordant with Tanner stages B1 and P3 respectively and 
skeletal maturation was markedly delayed. Breast development under estradiol 
supplementation reached a small sized Tanner 5 after 2 years and at follow-up 
consultations. Laboratory work-up showed normal electrolytes and renal function and 
elevated liver enzymes (about 2-3 times) of unknown etiology at repeated occasions. 
Hepatitis, CMV, EBV serology and autoimmune and tumor markers were negative. 
Abdominal US revealed minimal hepatomegaly. A pelvic US was repeated at the age 
of 10 years, no gonads could be visualized at that occasion but instead, a big cystic 
lesion was seen in the right adnexal region, which was confirmed by pelvic magnetic 
resonance imaging. Excision biopsy of the lesion revealed a serous cyst containing 
Wolffian duct remnants, liver biopsy at that time was unremarkable and no gonads 
were found at laparoscopy. Hormonal investigation suggested absence of functional 
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gonads, results are summarized in Table 1. Karyotyping and FISH revealed an SRY 
positive 46,XY karyotype. In view of the ocular manifestations, sequencing and copy 
number analysis of the FOXL2 gene was performed but revealed no mutation. Gender 
identity developed as female and puberty was induced at 15 years with 17-β-estradiol 
in increasing doses.  
Case report S2. Clinical case report of Case 2. 
Case 2 is a 20-year old woman from Bosnian origin, born with atypical genitalia 
(clitoromegaly, urogenital sinus, bilateral palpable gonads in the groins). Birth weight 
was 3550 g, birth length was 52 cm. A female sex was assigned at birth. She underwent 
gonadectomy, vulvovaginoplasty and clitoris reduction at the age of seven years, 
histology of the gonads revealed dysgenetic testicular tissue. Unfortunately, no 
medical records or gonadal specimen from this period are available; the family moved 
to Belgium when she was ten years old. Upon arrival, US showed absence of a uterus. 
The girl had no dysmorphic features and had a normal psychomotor development. 
Gender identity was female and from 12.5 years onwards, puberty was induced, first 
with ethinylestradiol, then with 17-β-estradiol in increasing doses. Bone age at the start 
of puberty induction was 11.5 years and had increased with one year after three years 
of hormone supplementation. Gonadotropins were mostly within the high-normal 
follicular range. In spite of good compliance with medication, breast development was 
poor and the patient sought breast augmentation surgery at the age of 18 years. 
Vaginoscopy performed at the age of 16 years revealed a 5 cm long blind ending 
vagina. Vaginal dilation therapy was proposed but the patient preferred intercourse 
as a first-line approach. She started university studies and withdrew from further 
medical follow-up at the age of 19 years. Karyotyping and FISH revealed an SRY 
positive 46,XY karyotype. No mutations were found in the AR and NR5A1 genes.    
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Case report S3. Clinical case report of Case 3. 
Case 3 is a 24 years old Brazilian woman who was referred at the age of 24 for primary 
amenorrhea. Her parents were first cousins. There were no remarkable medical events 
during infancy or at birth. The woman had no dysmorphic features and had a normal 
psychomotor development. At first evaluation, she had breast development Tanner 1, 
female external genitalia and pubic hair Tanner 4. Her karyotype was 46,XY and her 
hormonal profile was characterized by high serum gonadotropins and undetectable 
testosterone and estrogen levels, compatible with a diagnosis of complete gonadal 
dysgenesis. Pelvic US showed an infantile uterus and no visible gonads. Gonadectomy 
was performed and bilateral dysgenetic gonads were confirmed by histology analysis. 
The left gonad had a 1 cm gonadoblastoma in combination with germ cell neoplasia in 
situ.
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SUPPLEMENTAL TABLES 
Table S1:  List of DSD genes used as training genes for gene prioritization in IBD-regions 
AKR1C1 CHD7 DHCR7 FGFR1 GPR54 LEP MAP3K1 PROP1 SRD5A2 
AKR1C2 CTNNB1 DHH FKBP4 HESX1 LEPR NELF PSMC3IP SRD5A2 
AKR1C4 CYB5 DMRT1 FOG2 HHAT LGR8 NOBOX RSPO1 SRY 
AMH CYP11A1 EAP1  FOG2 HOXA13 LHCGR NR5A1 SEMA3A STAR 
AMHR2 CYP11B1 EMX1 FOXL2 HSD17B1 LHX1 NR5A2  SOX2 TSPYL1 
AR CYP17A1 EMX2 FSHR HSD17B3 LHX3 NR0B1 SOX3 WDR11 
ARX CYP19A1 FAM58A FSHβ HSD3B2 LHX4 PBX1 SOX8 WNT4 
ATRX CYP1B2 FBLN2 GATA4 INSL3 LHX9 POR SOX8 WT1 
BMP15 CYP21A2 FGF8 GATA4 KAL1 LHβ PROK2 SOX9 WWOX 
CBX2 DAX1  FGF9 GnRHR KISS1 MAMLD1 PROKR2 SRD5A1 
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Table S2: Primer sequences for PCR amplification and sequencing of ESR2. 
 Exon  Forward 5'->3' Reverse 5'-> 3' UCSC Length  
 ESR2_1 ccgggagggaggacagttt cgggtgacaaaatccagact chr14:64804890-64805346 457 bp   
 ESR2_2 cgctggaaggagtgtcagagc accgtcagaaacggcttgta chr14:64804548-64804996 449 bp  
 ESR2_3 cgctcccacttagaggtcacg ctcaacacgactggtttctca chr14:64760670-64761230  561 bp  
 ESR2_4 cggatgtatttgtaatctcatacaaacg tttgggtgctgtaagtaaactatg >chr14:64749208-64749908  701 bp  
 ESR2_5 cggaaccctggaggaaaaaga gtgccaaacaggccagtagt >chr14:64746596-64746989 394 bp  
 ESR2_6 ctcagctggaaagtgttatcagtg ctcttttcccggctacctgt >chr14:64735424-64735724 301 bp  
 ESR2_7 ccccacaggctccagaaaata tctaggcacagctcatggac >chr14:64727063-64727557 495 bp  
 ESR2_8 cttgcgcagcttaacttcaaa cagcacccaggactttgttc >chr14:64723863-64724263  401 bp  
 ESR2_9 ctcagatgaacatgttacaagatgaaa cgaagtccaaaaggaaacca >chr14:64716134-64716512  379 bp  
 ESR2_10 ccaaagcaacccagatcacct ttgcagacacttttcccaaa >chr14:64701598-64701974 377 bp  
 ESR2_11 cgtggggtagactggctctga tcaaatgtgccctctgctaa >chr14:64699642-64700142 501 bp  
 ESR2_12 tgcagctcacaaaagtcctg catggattacaatgatcccaga >chr14:64694167-64694742  576 bp  
 ESR2_13 ctcggtggcctaaagaaaaa ctcaactgatctgcccacct >chr14:64693640-64694238 599 bp  
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Table S3: Whole Exome Sequencing (WES) data analysis in Case 1 and Case 2. After quality control, variants with a coverage (cov) below 5 and 
a minor allele frequency above 5% were discarded. Variants were filtered and listed based on their coding effect. Only splicing variants in the 20 
bp proximity of regular splice sites (SS) were included. Three different strategies were used: (1) variants in known Disorders of Sex Development 
(DSD) genes, (2) variants in homozygous regions (only for patient 1) en (3) variants in the entire exome.  
 DSD genes (heterozygous and homozygous)  Case 1 Case 2  
  Nonsense variants (cov>5, MAF<0.05) 0 0  
  Frameshift variants (cov>5, MAF<0.05) 2 1  
  In-frame variants (cov>5, MAF<0.05) 3 4  
  Missense variants (cov>5, MAF< 0.05) 18 10  
  Splicing variants (cov>5, MAF<0.05, nearest SS: +- 20) 4 6  
 Homozygous regions (homozygous)     
  Nonsense variants (cov>5, MAF<0.05) 0 /  
  Frameshift variants (cov>5, MAF<0.05) 1 /  
  In-frame variants (cov>5, MAF<0.05) 4 /  
  Missense variants (cov>5, MAF< 0.05) 22 /  
  Splicing variants (cov>5, MAF<0.05, nearest SS: +- 20) 4 /  
 Whole exome (heterozygous and homozygous)   
  Nonsense variants (cov>5, MAF<0.05, VAF>0.2) 44 9  
  Frameshift variants (cov>5, MAF<0.05, VAF>0.2) 116 76  
  In-frame variants (cov>5, MAF<0.05, VAF>0.2) 115 128  
  Missense variants (cov>5, MAF<0.05) 2527 1016  
  Splicing variants (cov>5, MAF<0.05, VAF>0.2, nearest SS: +- 20) 204 157  
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Table S4: Sanger validation of variants found by Whole Exome Sequencing (WES) in Case 1. Variants that passed all filtering steps were 
confirmed with Sanger sequencing. When a variant was present in the patient’s father, no confirmation was done. *: variant present in other 
exomes (variant excluded without confirmation sequencing) +: variant with benign prediction in SIFT, Polyphen and Mutation Taster (variant 
excluded without confirmation sequencing) °: variant with a high MAF (3%<MAF<5%, variant excluded without confirmation sequencing), VAF: 
variant allele frequency. 
 Gene Coverage VAF Reference sequence: cDNA notation Protein notation Comments Confirmed  
 SRD5A2 
 
151  95 NM_000348.3:c.93dup p.Gly32Argfs*104 / Not confirmed  
 MAP3K1 56 32 NM_005921.1:c.2845_2847del p.Thr949del HeZ father° No Sanger  
 CYP21A2 74 34 NM_000500.6:c.26_28del p.Leu9del rs61338903, *° No Sanger  
 TSPYL1 42 60 NM_003309.3:c.526_528dup p.Val176dup rs78371471, ExAC 0.7628° No Sanger  
 ESR2 9 100 NM_001040275.1:c.541_543del p.Asn181del / Yes  
 HOXA13 5 20 NM_000522.4:c.869A>C p.Tyr290Ser / Not confirmed  
 POR 5 20 NM_000941.2:c.568T>G p.Tyr190Asp / Not confirmed  
 NOBOX  5 20 NM_001080413.3:c.1292G>T p.Ser431Ile / Not confirmed  
 CYP11B1 36 30 ENST00000377675.3:c.1370C>T p.Ala457Val rs4541+° No Sanger  
 CYP11B1 27 63 ENST00000377675.3:c.593C>A p.Thr198Lys rs9657020+ No Sanger  
 NR5A1 5 20 NM_004959.4:c.707A>C p.Asp236Ala / Not confirmed  
 LHX3 5 20 NM_014564.3:c.643G>C p.Ala215Pro / Not confirmed  
 LHX1 5 60 NM_005568.4:c.616A>C p.Thr206Pro rs201087752, HeZ father No Sanger  
 AR 5 20 NM_000044.3:c.343C>A p.Gln115Lys /* No Sanger  
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 AR 5 20 NM_000044.3:c.412G>T p.Ala138Ser /* No Sanger  
 ATRX 5 20 NM_000489.3:c.18G>T p.Met6Ile ExAC: 0.00003096 No Sanger  
 SOX3 5 20 NM_005634.2:c.1174G>T p.Ala392Ser / Not confirmed  
 SOX3 5 20 NM_005634.2:c.760G>T p.Val254Leu / Not confirmed  
 MAMLD1 5 20 NM_001177465.2:c.1109G>A p.Ser370Asn / Not confirmed  
 GPHB5 12 100 NM_145171.2:c.156dup p.Phe53Leufs*79 HoZ F, HoZ M No Sanger  
 TMIE 28 75 NM_147196.2:c.391_393del p.Lys131del HoZ M, benign No Sanger  
 ZNF816 37 84 NM_001031665.1:c.552_553insAGT p.Ile184_Gly185insSer / No Sanger  
 ZBTB8A 15 100 NM_001040441.1:c.1253G>C p.Gly418Ala rs704886, HoZ F No Sanger  
 NBPF14 497 83 NM_015383.1:c.1711C>T p.Arg571Cys rs11554534+ No Sanger  
 NBPF16 11 100 NM_001102663.1:c.1844A>C p.Gln615Pro rs6695216, HoZ F No Sanger  
 NBPF16 12 83 NM_001102663.1:c.1847C>T p.Ser616Leu rs75121840, HoZ F No Sanger  
 ANO2 32 96 NM_020373.2:c.2077A>G p.Ile693Val + No Sanger  
 FAM90A1 52 100 NM_018088.3:c.1043C>T p.Thr348Ile rs9668474, HoZ F No Sanger  
 KIAA0586 20 100 NM_014749.3:c.2300T>C p.Leu767Pro rs1748986, HoZ F No Sanger  
 KIAA0586 6 100 NM_014749.3:c.2938C>G p.Pro980Ala rs1617510, HoZ F No Sanger  
 TRMT5 10 100 NM_020810.2:c.649T>C p.Ser217Pro rs7142228+ No Sanger  
 AKAP5 23 100 NM_004857.3:c.608C>T p.Thr203Ile rs1256149, HoZ F No Sanger  
 GPX2 37 97 NM_002083.2:c.377C>T p.Pro126Leu rs17881652, HeZ F, HoZ 
reported 
No Sanger  
 SIPA1L1 23 100 NM_015556.1:c.119G>A p.Arg40Gln rs78621209, HeZ F, HoZ 
reported 
No Sanger  
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 ABCD4 14 100 NM_005050.3:c.1042C>T p.Arg348Trp rs147795328, HoZ F+ No Sanger  
 YLPM1 5 80 NM_019589.2:c.2431A>G p.Met811Val rs200333188, HoZ F No Sanger  
 MLH3 159 100 NM_001040108.1:c.2476A>G p.Asn826Asp rs175081, HoZ F No Sanger  
 ZSCAN29 11 100 NM_152455.3:c.595G>A p.Gly199Ser rs3917221, HoZ reported + No Sanger  
 PATL2 15 100 NM_001145112.1:c.262A>G p.Met88Val rs8026845, HoZ F No Sanger  
 ZNF611 28 96 NM_001161499.1:c.754_755delinsAT p.Pro252Ile / No Sanger  
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Table S5: Validation of variants found by Whole Exome Sequencing (WES) in known DSD genes in Case 2. Variants that passed all filtering 
steps were confirmed with Sanger sequencing. *: variant present in other exomes (variant excluded without confirmation sequencing) +: variant 
with benign prediction in SIFT, Polyphen and Mutation Taster (variant excluded without confirmation sequencing) °: variant with a high MAF 
(3%<MAF<5%, variant excluded without confirmation sequencing), VAF: variant allele frequency. 
 Gene Coverage VAF Reference sequence: cDNA 
notation 
Protein notation Comments Confirmed  
 SRD5A2 151  95 NM_000348.3:c.93dup p.Gly32Argfs*104 / Not confirmed  
 FAM58A 4 100 NM_152274.3:c.55_56insG p.Gln19Argfs*39 / Not confirmed  
 FAM58A 3 100 NM_152274.3:c.20dup p.Gly8Argfs*50 / Not confirmed  
 LHCGR 6 66 NM_000233.3:c.50_55dup p.Leu17_Gln18dup rs376653903° No Sanger  
 MAP3K1 612 78 NM_005921.1:c.2845_2847del p.Thr949del rs5868032 * Yes  
 CYP21A2 33 45 NM_000500.6:c.26_28del p.Leu9del rs61338903° No Sanger  
 TSPYL1 286 83 NM_003309.3:c.526_528dup p.Val176dup rs78371471 * Yes  
 LHCGR 73 46 NM_000233.3:c.872A>G p.Asn291Ser rs12470652 +° No Sanger  
 MAP3K1 670 5+ NM_005921.1:c.2816C>G p.Ser939Cys rs45556841 +° No Sanger  
 CYP21A2 51 35 NM_000500.6:c.305G>A p.Arg102Lys rs6474 +° No Sanger  
 CYP21A2 60 23 NM_000500.6:c.800C>T p.Pro267Leu rs142028935 +° No Sanger  
 NOBOX 106 37 NM_001080413.3:c.1991A>G p.Lys664Arg rs77802098 +° No Sanger  
 LHX1 145 47 NM_005568.4:c.1162G>T p.Ala388Ser rs145694637 +° No Sanger  
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Table S6: Overview of the homozygous regions larger than 1 Mb resulting from homozygosity mapping in Case 1. 
 Chromosome SNP start SNP stop Start (hg19) Stop (hg19) Length(bp)   
 1 rs35595182 rs655552 32,183,736 33,194,672 1,010,936   
 1 rs12117013 rs3855959 45,107,235 46,633,874 1,526,639   
 1 rs507630 rs12041774 77,149,207 81,482,945 4,333,738   
 1 rs1532399 rs7517566 147,381,444 15,0850,035 3,468,591   
 2 rs6729421 rs745007 30,575,898 34,272,097 3,696,199 SRD5A2  
 2 rs4449134 rs2848274 88,846,961 90,109,161 1,262,200   
 3 rs13325398 rs9874474 45,161,070 49,326,178 4,165,108   
 4 rs1504496 rs10517174 45,951,996 46,982,826 1,030,830   
 6 rs4502981 rs2474878 61,891,118 63,457,733 1,566,615   
 8 rs7839348 rs1562634 91,421,822 92,458,202 1,036,380   
 9 rs11795294 rs10907973 40,421,411 42,345,595 1,924,184   
 11 rs11038867 rs11570034 46,357,159 47,375,889 1,018,730   
 12 rs2041377 rs2719020 4,984,601 8,410,202 3,425,601   
 12 rs10770704 rs35939864 20,855,761 23,167,969 2,312,208   
 12 rs2204849 rs12831116 38,094,338 39,401,456 1,307,118   
 13 rs7320567 rs4150834 113,123,999 114,296,219 1,172,220   
 14 rs1189277 rs11623512 56,951,496 77,199,730 20,248,234 ESR2  
 15 rs12595426 rs12907793 26,029,193 27,982,953 1,953,760   
 15 rs1863601 rs12101736 43,495,212 46,289,459 2,794,247   
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 15 rs985868 rs10083634 71,915,278 73,165,722 1,250,444   
 19 rs2290745 rs7260411 52,909,303 54,444,972 1,535,669   
 
Table S7: Output of gene prioritization in the largest homozygous region on chromosome 14 resulting from homozygosity mapping in Case 
1. The different greens correlate with the amount of times a gene was highly ranked by the prioritization algorithms. ESR2 popped out 6 times, 
FOS 5 times, TGFB3 4 times, PSEN1 and ESRRB both popped out 2 times. 
 
Rank PosMed Endeavour ToppGene GeneWanderer SUSPECTS GeneDistiller 
 
 1 ESR2 ESR2 ESR2 FOS ESR2 KCNH5  
 2 SGPP1 ESRRB FOS PSEN1  FOS PARP1P2  
 3 PSEN1 PSEN1 ESRRB MED6  ESRRB RHOJ  
 4 LTBP2 TGFB3 TGFB3 ESR2  TGFB3 GPHB5  
 5 FOS CHX10 MAX EIF2S1  LTBP2 PPP2R5E  
 6 VSX2 SFRS5 RBM25 SLC10A1  ADAM20 RPL31P5  
 7 GPHN ZBTB25 VSX2 TGFB3  CHX10 GCATP1  
 8 RGS6 MAX MED6 FUT8  PGF WDR89  
 9 MTHFD1 FOS DPF3 DLST  RDH12 HSPE1P2  
 10 NPC2 MTHFD1 EIF2B2 EIF2B2 ADAM21 SGPP1  
 11 ABCD4 EIF2S1 SRSF5 RDH11  RDH11 EIF2S2P1  
 12 SLC10A1 ACTN1 ACTN1 RDH12  TM21_Human RPS28P1  
 13 GPX2 ZFP36L1 C14orf169 ATP6V1D SLC39A9 SYNE2  
 14 PGF ENSG00000140044 CHURC1 MLH3  C14orf114 MIR548H1  
 15 HSPA2 C14orf1 C14orf43 MTHFD1  HSPA1 ESR2  
 16 EIF2S1 BATF SIPA1L1 AKAP5  MTHFD1 TEX21P  
 17 RHOJ NEK9 YBX1P1 BATF ENTPD5 MTHFD1  
 18 ARG2 DLST|DLSTP RAP1AP SYNJ2BP  SLC8A3 LOC100506245  
 19 GPHB5 RBM25 ADAM21P1 NUMB  CHURC1 AKAP5  
 20  MAP3K9 COX7A2P1 HSPA2  PCNX LOC100506266  
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Table S8: Detailed overview of the identified ESR2 mutations 
 Variant cDNA Protein Conservation Amino acid 
conservation 
CADD-score SIFT PolyPhen-2 Mutation 
Taster 
Grantham 
distance 
Public databases  
 1 c.541_543del p.(Asn181del) Nucleotide: / Highly 
conserved: 
Zebrafish 
/ / / / / dbSNP: rs750091675 
ESP: Eur. Am.: C=0.04% 
ExAC: ALL:0.041%, no 
homozygous cases 
reported 
GnomAD:       ALL: 
0.0368%, no 
homozygous cases 
reported 
 
 2 c.251G>T p.(Gly84Val) Moderately 
conserved: 
phyloP: 4.22 
Highly 
conserved: 
Fruitfly 
26.9 Tolerated Probably 
damaging 
Disease 
causing 
109 Absent in dbSNP, ESP 
and ExAC 
GnomAD:     ALL: 
0.000396% (singleton) 
 
 3 c.1277T>G p.(Leu426Arg) Highly 
conserved: 
phyloP: 8.70 
Highly 
conserved: 
Tetraodon 
23.4 Deleterious Probably 
damaging 
Disease 
causing 
102 Absent in dbSNP, ESP 
and ExAC, GnomAD 
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SUPPLEMENTAL FIGURES 
 
Figure S1: Immunohistochemical analysis of ER-β in an 8-week old male embryo. Brown staining indicates ER-β expression. (A-
B) No expression is seen in the developing testis. (A: 10x, B: 20x) (C-D) Positive staining is present in mucosa of the developing gut. 
(C: 1.25x, D: 10x) (E-F) Developing eye, especially the corneal epithelium and endothelium, primitive lens neurons, primitive retinal 
cells and the retinal pigment epithelium. (E: 5x, F: 20x) (G) Developing brain, specifically the primitive neurons of the germinal 
matrix (20x) (H) Placental tissue positive control for ER-β-expression. (20x) (I) Overview of the entire embryo (0.5x). 
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Figure S2: Subcellular localization of wild-type and mutant (p.(Asn181del) and p.(Gly84Val)) ER-β proteins using a 
fluorescent anti-ER-β antibody. The left panel shows the localization of wild type (WT) ER-β, the middle and right panel show the 
unaltered subcellular localization of both mutant ER-β proteins. 
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ABSTRACT 
Purpose: We aimed to identify the genetic cause in a cohort of 11 unrelated cases and 
two sisters with 46,XX SRY-negative (ovo)testicular disorders of sex development 
(DSD). 
Methods: Whole-exome sequencing (n = 9), targeted resequencing (n = 4), and 
haplotyping were performed. Immunohistochemistry of sex-specific markers was 
performed on patients’ gonads. The consequences of mutation were investigated using 
luciferase assays, localization studies, and RNA-seq. 
Results: We identified a novel heterozygous NR5A1 mutation, c.274C>T p.(Arg92Trp), 
in three unrelated patients. The Arg92 residue is highly conserved and located in the 
Ftz-F1 region, probably involved in DNA-binding specificity and stability. There were 
no consistent changes in transcriptional activation or subcellular localization. 
Transcriptomics in patient-derived lymphocytes showed upregulation of MAMLD1, a 
direct NR5A1 target previously associated with 46,XY DSD. In gonads of affected 
individuals, ovarian FOXL2 and testicular SRY-independent SOX9 expression 
observed. 
Conclusions: We propose NR5A1, previously associated with 46,XY DSD and 46,XX 
primary ovarian insufficiency, as a novel gene for 46,XX (ovo)testicular DSD. We 
hypothesize that p.(Arg92Trp) results in decreased inhibition of the male 
developmental pathway through downregulation of female antitestis genes, thereby 
tipping the balance toward testicular differentiation in 46,XX individuals. In 
conclusion, our study supports a role for NR5A1 in testis differentiation in the XX 
gonad. 
Keywords: gonadal development; NR5A1; ovotesticular DSD; testicular DSD; 46,XX 
DSD 
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INTRODUCTION 
Although several genetic mechanisms 
leading to 46,XY disorders of sex 
development (DSD) have been 
elucidated in recent years, little is 
known about the developmental 
pathways that may induce testicular 
development in 46,XX individuals when 
dysregulated. Approximately 80% of all 
46,XX testicular DSD cases are explained 
by a translocation of the Sex Determining 
Region Y (SRY) gene1,2. Duplications of 
SRY-box 9 (SOX9) or its regulatory 
region are a rare cause of 46,XX 
testicular DSD3,4. Copy number 
variations disrupting the regulatory 
region of SRY-box 3 (SOX3), a putative 
ancestor of SRY, have also been found in 
patients with 46,XX DSD5,6. In line with 
this, 46,XX DSD phenotypes have been 
associated with partial duplications of 
human chromosome 22q13 containing 
SRY-box 10 (SOX10)7,8. Studies in mice 
overexpressing Sox10 strongly implicate 
gain-of-function of SOX10 in 46,XX 
DSD9. In addition to these gain-of-
function changes of male sex-
determining genes, loss-of-function 
mutations of female sex-determining 
genes can give rise to 46,XX DSD. This is 
illustrated by biallelic loss-of-function 
mutations in R-Spondin 1 (RSPO1), 
which have been reported in a rare 
syndrome characterized by 46,XX 
testicular DSD, palmoplantar 
hyperkeratosis, and susceptibility to 
development of squamous cell 
carcinoma10,11. Interestingly, 
intrafamilial phenotypical variability 
and incomplete penetrance have been 
described, ranging from unaffected 
mutation carriers to cases with 46,XX 
testicular DSD or ovotesticular DSD, 
indicating that these conditions may 
represent a phenotypic spectrum of the 
same underlying defect12-14. Here, we 
aimed to identify the underlying 
molecular genetic cause in 11 unrelated 
individuals and 2 sisters with 46,XX 
testicular and ovotesticular DSD; the 
latter was defined as the combined 
presence of testis and ovarian tissue in 
the same individual. In three of them, 
we identified a novel and recurrent 
heterozygous variant, c.274C>T 
p.(Arg92Trp), in the Nuclear Receptor 
family 5 subfamily A member 1 gene 
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(NR5A1, AD4BP). The impact of this 
variant was further studied by 
structural remodeling of the affected 
amino acid, luciferase and localization 
studies in cellular systems, RNA-seq on 
patient-derived lymphocytes, and 
immunohistochemistry of patients’ 
gonads. 
RESULTS 
Novel and recurrent missense mutation in 
NR5A1 in three patients with 46,XX 
(Ovo)Testicular DSD 
Eleven unrelated patients and two 
sisters with 46,XX ovotesticular or 
testicular DSD were included in this 
study. Nine underwent WES and four 
underwent resequencing of the coding 
region of NR5A1 because they were 
included at a later time. When exome 
data were available, all variants were 
filtered against a list of known 46,XX 
and 46,XY DSD genes (Supplementary 
Data, Supplementary Table S2), 
annotated, and manually curated. All 
variants in DSD genes, identified in 
cases 1–9, are listed in Supplementary 
Data and Supplementary Tables S3–S11. 
We identified a heterozygous missense 
variant in exon 4 of NR5A1 c.274C>T 
p.(Arg92Trp) in cases 1–3. Prediction 
programs SIFT, Polyphen-2, and 
MutationTaster suggest a possible effect 
on protein function. The 
physicochemical distance between Arg 
and Trp is moderate (Grantham score of 
101) and the variant is absent in genomic 
databases such as dbSNP, ESP, ExAC, 
GoNL, and 1000 Genomes and in an in-
house exome database. The affected 
amino acid and surrounding region are 
highly conserved up to zebrafish and is 
part of the Ftz-F1 region (Figure 1B)15. 
Segregation analysis of the three 
families showed incomplete penetrance 
in four 46,XX family members (Figure 
1A). In case 1, the mutation was 
paternally inherited (family 1: II:2); in 
the other two families, the mutation was 
transmitted by the mother (family 2: I:2; 
family 3: I:2). The gynecological history 
for these unaffected women as well as 
for the older sister of case 1, who also 
carries the mutation (family 1: III.1), was 
unremarkable (Supplementary Data, 
Supplementary Table S12). 
Microsatellite analysis showed a 
haplotype of approximately 1.5 Mb 
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Figure 1: Pedigrees and haplotypes of mutation-positive families and schematic 
representation of the NR5A1 protein, mutation location, and conservation. (A) Pedigrees for 
families 1–3. Affected individuals heterozygous for NR5A1 mutation c.274C>T p.(Arg92Trp) 
are indicated by filled symbols. Asymptomatic individuals with NR5A1 mutation 
p.(Arg92Trp) are represented by a black spot in the symbol. In total, 29 microsatellite markers 
were used to assess the haplotypes; only the ones building up the common haplotype and 
flanking markers are shown here. The common haplotype (in red box) shared by the three 
mutation carriers has a maximum size of 1.5 Mb. (B) The different domains found in NR5A1, 
a DNA-binding domain at the C-terminus, followed by the Ftz-F1 region, which is important 
for DNA-binding stability, a hinge region, and a ligand-binding domain. An electropherogram 
showing the c.274C>T substitution is depicted below. The protein alignment of p.(Arg92Trp) 
and its surrounding amino acids is shown on top. The affected amino acid and the surrounding 
region are conserved up to zebrafish.
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shared among cases 1–3 (Figure 1A), 
pointing to a founder effect. Given the 
incomplete penetrance, we assessed the 
WES data for other variants that might 
contribute to the phenotype. Variant 
lists with de novo variants for case 1 and 
rare variants (minor allele frequency < 
0.01) for cases 2 and 3 were added to the 
Supplementary Data and 
Supplementary Tables S13–S16. 
Protein structure modeling of NR5A1 
p.(Arg92Trp) and p.(Arg92Gln) 
We performed protein structural 
modeling, starting from a model of 
NR5A1 bound to the α-inhibin 
promoter, for the following mutations: 
p.(Arg92Trp) found here in the three 
cases with 46,XX DSD and p.(Arg92Gln) 
previously found in 46,XY DSD16.  FoldX 
calculations predict that the mutations 
do not affect the stability of the isolated 
NR5A1 DNA-binding domain17. In the 
models of mutants bound to DNA, the 
tryptophan and glutamine side chains 
do not penetrate as deeply into the 
minor groove as does the wild-type 
arginine side chain. Although the Arg92 
side chain makes a hydrogen bond with 
a deoxycytosine base, no hydrogen 
bonds are formed by the mutant side 
chains. The (enthalpic) in silico binding 
energy for interaction of the DNA-
binding domain of NR5A1 with the 
DNA segment is 9% lower for both 
mutants. This suggests that both 
mutations can affect the interaction of 
NR5A1 with its response elements, 
although effects may be variable and 
specific for different response elements 
(Figure 2). 
Transcriptional activity and subcellular 
localization of NR5A1 mutants 
p.(Arg92Trp) and p.(Arg92Gln) 
We assessed the impact of following 
mutations on transcriptional 
activity and subcellular localization in 
different cellular systems: c.274C>T 
p.(Arg92Trp) and the previously 
reported adjacent mutation c.275G>A 
p.(Arg92Gln). For the latter mutation, 
partial loss of DNA-binding and 
transcriptional activity have previously 
been shown16. We cotransfected WT or 
mutagenized NR5A1 plasmids with 
different NR5A1 responsive promoters 
(TESCO, SOX9, AMH, CYP11B1) in 
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Figure 2: Structural analysis of NR5A1 (PDB code 2FF0). Position of Arg92 (R92) in the wild-
type NR5A1 DNA-binding domain (DBD). (A) R92 is part of the C-terminal A-box and its 
side chain fits in the minor groove, making a hydrogen bond with a deoxycytosine base. 
Models of the p.(Arg92Trp) (Trp=W) (B) and p.(Arg92Gln) (Gln=Q) (C) mutants show how this 
mutated side chain binds in the DNA minor groove without hydrogen bond formation to the 
DNA. The affected amino acid R92 is located in a region C-terminal to the classical DBD with 
its two zinc (Zn) fingers. This additional domain is found in family members of NR5A1, 
including NGFI-B, and was called the A-box or Ftz-F1 box18. This A-box domain has been 
implicated in interactions with the minor groove of the target DNA. Prior to structure 
determination, binding studies with NR5A1 and NGFI-B mutants showed that this interaction 
is important for their binding specificity toward different DNA targets. For NR5A1, this 
specificity is determined by amino acids 91–93, which are predicted to interact with three 
specific basepairs 5ʹ of the classical half-site bound by the Zn fingers. The results of this study 
are in line with those for the later NMR structure of the NR5A1 DBD bound to a DNA fragment 
of the inhibin-alpha subunit promoter. In this structure, the side chain of R92 inserts deeply 
into the minor groove, and its guanidine head group binds to two of the three basepairs at the 
5ʹ of classical half-sites. Mutation R92A abolished DNA-binding and signaling via the inhibin-
alpha subunit promoter in this study18 by removing the interaction with the basepairs of the 
minor groove. The p.(Arg92Trp) mutation is not allowed in the structure without gross 
structural rearrangements; the W side chain cannot insert into the minor groove and cannot 
be accommodated in the current DNA-bound structure without inducing steric clashes
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different cell lines (HeLa, KGN). These 
experiments were repeated with FOXL2 
cotransfection because it was shown 
previously that FOXL2 inhibits NR5A1-
mediated SOX9 expression during 
female development19. The results of 
these assays were inconclusive, and only 
the results for the TESCO-luc constructs 
are shown (Supplementary Data, 
Supplementary Figure S1). These 
experiments reproduced the previously 
described lower transcriptional activity 
of the c.275G>A p.(Arg92Gln) variant. 
The c.274C>T p.(Arg92Trp) variant, 
however, led to decreased activity in 
HeLa cells but not in KGN cells, 
showing that the transcriptional activity 
of a variant might be influenced by the 
cellular environment. Subcellular 
localization assays in HeLa cells showed 
nuclear expression without aggregate 
formation for both WT and mutant 
NR5A1 (Supplementary Data, 
Supplementary Figure S2). 
Transcriptome analysis in patients’ 
lymphocytes 
RNA-seq generated an average of 39 
million reads per sample. Differential 
expression analysis with default settings 
showed a total of 1,420 genes with 
significant differential expression 
(corrected value < 0.05) when 
comparing the patient and control 
groups (Supplementary Data, 
Supplementary Table S17). This gene set 
was filtered against a list of DSD-
associated genes (Supplementary Data, 
Supplementary Table S2), the coverage 
of which was low in general. This 
filtering resulted in three (LEPR, 
MAMLD1, and IRF2BPL) genes with 
differential expression (Supplementary 
Data, Supplementary Table S18). 
MAMLD1, a direct target gene of 
NR5A120 that was previously reported 
to be involved in 46,XY DSD21, was 
upregulated (log 2-fold change = 1.637, 
= 0.03) in patients compared with 
controls. BioGPS, an online available 
expression database, shows expression 
in both testis and ovaries in mice. LEPR 
and IRF2BPL (EAP1) are genes involved 
in hypogonadotropic hypogonadism, 
which we considered not directly 
relevant in the context of the phenotypes 
observed here.
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Figure 3: Immunohistochemistry on gonadal biopsies. (A) Case 1. Testis. Supportive cells 
have differentiated as Sertoli cells as indicated by SOX9 positivity. SOX9 staining, 200×. (B) 
Case 1. Scarce germ cells (stained in brown) populate the testis tubules. DDX4 staining, 200×. 
(C) Case 2. Ovotestis. Sertoli cells in the testicular component (right) express SOX9; no SOX9 
expression is seen in the ovarian part (left). SOX9 staining, 200×. (D) Same gonad. Ovarian 
granulosa cells but not testicular Sertoli cells display FOXL2 positivity. FOXL2 staining, 200×. 
(E,F) Germ cells (ova, black arrows) are only present in the ovarian and not in the testicular 
part. DDX4 staining, 200×. (G) Case 3. In this patient, bilateral infantile testes with a Sertoli 
cell–only pattern were observed. All Sertoli cells are SOX9-positive. SOX9 staining, 200×. (H) 
Same gonad. FOXL2 staining is negative. FOXL2, 200×. (I) Case 3. DDX4 staining indicates 
absence of germ cells, thus confirming the Sertoli cell–only pattern. DDX4 staining, 200×
Immunostaining of SOX9, FOXL2, and DDX4 
on patients’ gonads 
Gonadal biopsy specimens from cases 1 
and 3 and a gonadectomy specimen 
from case 2 were available. In case 1, a 
dysgenetic testis with scarce germ cells, 
as identified by DDX4 immunostaining, 
was found. Biopsy specimens for case 3 
revealed bilateral immature testes with 
Sertoli cell–only tubules (i.e., no germ 
cells present). Case 2 had bilateral 
ovotestes, including the presence of 
primordial and primary follicles in the 
ovarian part, located at the pole of the 
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gonad, and next to immature 
seminiferous tubules without germ 
cells, located in the central testicular part 
of both gonads. Immunohistochemistry 
with SOX9 and FOXL2 antibodies, 
identifying Sertoli and granulosa cell 
differentiation, respectively, revealed 
exclusive SOX9 expression in testicular 
parts in all three cases and exclusive 
FOXL2 expression in ovarian parts of 
case 2 (Figure 3). Hematoxylin and eosin 
staining of ovarian tissue, removed after 
ovarian torsion at age 41 years in the 
mother of case 2, was unremarkable and 
showed an aging ovary with some 
residual primordial follicles and stromal 
tissue (Supplementary Data, 
Supplementary Figure S3). 
DISCUSSION 
A few NR5A1 mutations have been 
identified in females with 46,XY 
complete gonadal dysgenesis and 
adrenal failure16. Interestingly, one of 
these was an adjacent homozygous 
mutation, c.275G>A p.(Arg92Gln), in the 
same codon as the c.274C>T 
p.(Arg92Trp) mutation identified here. 
Lower transcriptional activity was 
shown for p.(Arg92Gln), suggesting a 
loss-of-function effect16. This mutation 
was also recently identified in a 46,XX 
female with adrenal insufficiency but no 
gonadal fenotype22. Subsequently, 
numerous NR5A1 mutations and copy 
number variations have been associated 
with isolated 46,XY gonadal dysgenesis, 
46,XY undervirilization, and male 
infertility23-26.  In 46,XX individuals, these 
loss-of-function mutations may cause 
primary ovarian insufficiency (POI)27. 
This broad range of phenotypes 
emphasizes that correct NR5A1 
functioning is essential for both male 
and female gonadal development and 
maintenance.  
Few data exist regarding the NR5A1 
expression pattern in human female and 
male fetuses. In humans, NR5A1 is 
upregulated in the undifferentiated 
stage and gonadal expression is 
maintained during the entire period of 
fetal development in both male and 
female fetuses, whereas in rodents it has 
been shown that Nr5a1 expression 
decreases in the ovary as sex 
differentiation progresses28,29. Indeed, 
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NR5A1 plays an important role in 
multiple stages of gonadal development 
because it is a key regulator of sex 
determination via SOX9 upregulation 
during male development and of sex 
differentiation in both sexes via 
upregulation of AMH and the different 
steroidogenic enzymes15,30,31. Both male 
and female Nr5a1 knockout (KO) mice 
lack gonadal and adrenal 
development32,33. Recently, a 
CRISPR/Cas9 amino acid substituted 
mouse model was generated for 
p.(Arg92Trp); however, no phenotypic 
data were provided34.  
Here, the NR5A1 mutation p.(Arg92Trp) 
was found in three unrelated patients 
with 46,XX (ovo)testicular DSD. A 
potential founder effect was suggested 
by haplotype analysis. The mutation 
was found in XX unaffected individuals 
in each of the three families, suggesting 
incomplete penetrance, as has been 
observed in other NR5A1-associated 
phenotypes35,36 and in other large 
families with 46,XX (ovo)testicular 
DSD12,13. In a 46,XY DSD mouse model 
(B6 XYpos), incomplete penetrance has 
been shown to result from differences in 
spatiotemporal expression37. Of note, the 
geographical distribution of testicular 
and ovarian regions in the ovotestes of 
case 2 supports the involvement of 
analogous (temporospatial) 
mechanisms and corresponds to 
observations in the B6 XYpos mouse37.  
During normal ovarian development, 
FOXL2 actively represses SOX9, thereby 
inhibiting the male developmental 
cascade38. During male development, it 
is well established that NR5A1, together 
with other transcription factors, binds to 
the regulatory domain of SOX9 thereby 
inducing a positive feedback loop in 
which SOX9 maintains and enhances its 
own expression, resulting in Sertoli cell 
recruitment and differentiation30. 
NR5A1 loss-of-function mutations lead 
to a decrease in activation of SOX9 and 
other transcriptional targets, resulting in 
undervirilization and 46,XY DSD. Our 
initial hypothesis that p.(Arg92Trp) 
leads to more stable binding of NR5A1 
to the SOX9 promoter, thereby directly 
inhibiting FOXL2-mediated repression 
of , as described by Uhlenhaut et 
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al.19, is not supported by the cellular 
transactivation assays performed. This 
is possibly because the adult cell lines 
that were used are not representative for 
early stages of gonadal development. In 
addition, transcriptome analysis of 
patient-derived lymphocytes did not 
reveal an upregulation of early male-
specific genes. However, it did show 
upregulation of another NR5A1 target, 
MAMLD1. Whether this finding 
represents a direct effect resulting from 
p.(Arg92Trp) or whether it is secondary 
to the male environment from which 
cells were taken is currently unclear.  
A more attractive hypothesis is that 
NR5A1, apart from its well-known role 
in inducing testicular development, also 
triggers the activation of early ovarian 
genes such as WNT4, a pathway that 
ultimately leads to FOXL2 activation 
and definitive suppression of the 
NR5A1-SOX9 tandem. Repression of the 
Nr5a1 cofactor Cited2 in XX mice entails 
reduced Nr5a1 activity, which has been 
shown to result in decreased Wnt4, 
Rspo1, and Foxl2 levels and increased 
mesonephric cell migration and Fgf9
levels, leading to transient activation of 
the male pathway in XX gonads39. It is 
conceivable that in our patients, 
p.Arg92Trp interferes with this early 
ovary-promoting function of NR5A1, 
ultimately resulting in insufficient 
and/or delayed upregulation of FOXL2
and, thus, (partial) escape from its testis-
suppressing activity. In our patients, 
NR5A1 is directly affected, which might 
explain the permanent and more severe 
gonadal phenotype as compared to the 
mouse model. Given the fact that the 
mutation affects the Ftz-F1 domain, 
which is important for DNA-binding 
specificity and stabilization, an altered 
expression of specific targets might be 
expected. In addition, this hypothesis 
fits with the incomplete penetrance and 
phenotypic heterogeneity, as seen in our 
families, depending on timing and 
spatial thresholds.  
Two animal models support this 
hypothesis. It was shown very recently 
that CRISPR/Cas9-induced Nr5a1
mutations cause female-to-male sex 
reversal in the XX Nile Tilapia. Nr5a1 
depletion leads to reduced Cyp19A1 
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expression and low estradiol levels. 
Because ovarian differentiation in fish is 
mediated by estradiol, the lack of sex 
steroid production here was proposed 
as the possible trigger for changing the 
initial gonadal fate40. Temporal 
expression studies of Nr5a1 and Foxl2 in 
this model underscore the critical 
importance of threshold levels of Foxl2 
to downregulate Nr5a1 in the XX gonad. 
A second animal model is the polled 
intersex syndrome (PIS) goat, which is 
characterized by absence of horns in 
heterozygous and homozygous animals 
and female-to-male sex reversal in 
homozygous XX animals. This 
phenotype is caused by the 11.7-kb 
regulatory deletion that is located 300 kb 
upstream of the goat FOXL2 gene. 
Knockout experiments have shown that 
FOXL2 depletion leads to reduced 
CYP19A1 expression and that it is 
responsible for inhibiting ovarian 
development41 similarly to the fish 
model. However, if testis formation in 
this species is, similarly to the Nile 
Tilapia, mediated by reduced Nr5a1 
activity, then its influence on the female 
gonadal pathway remains to be 
elucidated. These two alternative 
hypotheses may explain the different 
phenotypes observed for the two 
adjacent NR5A1 mutations. Mutation 
c.275G>A (p.Arg92Gln) has a direct 
negative influence on SOX9 expression 
and leads to aberrant male gonadal 
development and adrenal failure16. 
Variant p.Arg92Trp has no direct effect 
on SOX9 expression but is hypothesized 
to interfere with hitherto unrecognized 
female-promoting activity of NR5A1, 
ultimately resulting in loss of stable 
SOX9 repression by FOXL2. Both 
mutations are located in the same codon 
that is part of the Ftz-F1 box, which is
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Figure 4: Schematic overview of the sex development gene regulation network. Blue: testis-
promoting activity of NR5A1. Orange: counteractive connections to suppress the opposite 
pathway. Green: ovary-promoting activity of NR5A1 as hypothesized here and supported by 
other works39,40. (A) General scheme: NR5A1 is known to initiate the male developmental 
pathway through upregulation of SOX9 (synergistically with SRY). SOX9 then maintains its 
own expression via Fgf9 signaling. In the female embryo, in the absence of SRY, NR5A1 
induces WNT4 and RSPO1 expression as shown by Combes, leading to upregulation of FOXL2 
and other ovary-specific genes. High FOXL2 expression results in stable repression of SOX9 
and, possibly, NR5A1, and hence the male pathway. (B) Possible mechanism by which 
c.274C<T leads to ovotesticular disorders of sex development. We hypothesize that this novel 
mutation affects the activation of female-specific genes such as WNT4/β-catenin (as indicated 
by the dotted lines), leading to decreased FOXL2 expression. In this way, FOXL2 can no longer 
prosecute its pro-ovarian functions and, at the same time, male-promoting genes escape firm 
suppression, ultimately resulting in NR5A1-mediated and/or independent SOX9 upregulation 
and enhancement of testicular differentiation.
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important for DNA-binding specificity. 
The newly introduced amino acid might 
determine which NR5A1 targets are 
affected by the mutation and which 
pathways are perturbed. Structural 
models show that both mutations have 
problems entering the DNA minor 
groove, although they cannot predict 
which targets will be affected. Our 
results suggest that temporal, spatial, or 
quantitative changes disturbing the 
balance between the male and female 
pathways in the XX gonad may shift the 
ovarian developmental program to the 
testicular pathway, probably through 
autocrine and paracrine reinforcing 
signals37 (Figure 4). The exact 
mechanisms behind these processes 
need to be substantiated by additional 
experimental work.
 
CONCLUSION 
Taking these findings together, we propose NR5A1 as a novel disease gene for 46,XX 
(ovo)testicular DSD. Our study suggests SRY-independent SOX9 expression at the 
gonadal (testicular) level, most likely not through the canonical NR5A1-SOX9 
interaction, but rather through downregulation of the pro-ovarian Wnt4/β-catenin 
pathways, thus tipping the balance toward male development. In addition, we 
demonstrated that testicular and ovotesticular DSD may represent different 
phenotypes resulting from a common cause. We conclude that NR5A1, a well-
established gene for male gonadal development, is also involved in correct female 
gonadal development, the exact molecular mechanisms of which are still elusive.
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MATERIALS AND METHODS 
Subjects 
Case 1, the second child of two healthy, non-consanguineous parents, was born after 
an uneventful pregnancy. Mild hypertrophy of the clitoris was noticed at birth. 
Vaginoscopy and laparoscopy detected the presence of a cervix and possibly a right 
hemi-uterus, a left epididymis, and male vasculature. Both inguinal gonads were 
biopsied. The left gonad revealed testicular differentiation with germ cells present; the 
right gonad contained only fibrotic tissue. A human chorionic gonadotropin (hCG) 
stimulation test (1,500 IU administrated intramuscularly with blood sampling after 72 
h) was performed on the seventh day after birth, resulting in a testosterone level of 
2.52 nmol/l (baseline: 0.72 nmol/l); anti-Müllerian hormone (AMH) was between the 
male and female references (99.9 pmol/l). Based on these results and the child’s 
phenotype, a female sex was assigned. Microarray-based comparative genomic 
hybridization (array CGH) showed a normal female pattern, and fluorescence in situ 
hybridization (FISH) with SRY-specific probes excluded SRY translocation. The results 
of quantitative polymerase chain reaction for the regulatory RevSex locus, upstream 
of SOX9, and MLPA for different sex development–related genes (P185 Intersex, MRC 
Holland, Amsterdam, The Netherlands) were normal. 
Case 2 is a 22-year-old woman who had been diagnosed with 46,XX ovotesticular DSD. 
She had ambiguous genitalia at birth and a short, blind-ending vagina. At age 4, she 
underwent clitoroplasty and bilateral gonadectomy of abdominal gonads, which both 
turned out to be ovotestes, including primordial and primary follicles in the ovarian 
part and Sertoli cell–only tubules in the testicular part. SRY-specific FISH was 
negative, and array CGH revealed a small duplication reported to be a benign variant 
(hg19: chr 8: 132161619 – 132812388). RevSex locus-specific quantitative polymerase 
chain reaction was normal. She has one younger sister, who displayed normal puberty; 
family history was unremarkable. 
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Case 3 is a 23-year-old man with 46,XX testicular DSD. At birth, a micropenis, penile 
hypospadias, and bilateral scrotal but atrophic testes were noticed. Gonadal biopsies 
at the age of 2 years revealed bilateral testicular differentiation with immature 
seminiferous tubules without germ cells and limited intertubular fibrosis. When he 
was 12 years old, a prolonged hCG test (2 × 1,500 IU per week for 3 consecutive weeks) 
led to a peak increase of serum testosterone to 6.0 nmol/l. Hypergonadotrophic 
hypogonadism developed rapidly thereafter, and testosterone supplementation was 
started at the age of 13. FISH with SRY and TSPY probes was negative, and array CGH 
and quantitative polymerase chain reaction for the RevSex locus were normal. He is 
the oldest of three brothers; familial history is unremarkable. All three patients are 
Caucasian. Cases 1 and 3 are from East-Flanders in Belgium, and case 2 originates from 
the south of the Netherlands, close to the Belgian-Dutch border. All families live near 
(within 70 km) each other. Pedigrees of the three families are shown in Figure 1a and 
phenotypic data for cases 1–3 are summarized in Table 1; phenotypic data for cases 4–
9 are presented in the Supplementary Data (Supplementary Table S1). 
Table 1: Phenotypic data cases 1-3. 
  Case 1 Case 2 Case 3  
 Clinical 
phenotype 
at birth 
 
Mild clitoris hypertrophy 
 
Ambiguous genitalia, 
blind-ending vagina 
Micropenis, hypospadias 
Scrotal, atrophic testes 
 
 Gonadal 
phenotype 
 
L: infantile testis 
R: fibrous streak 
L and R: ovotestes 
 
L and R: infantile testes  
 Germ cells 
 
Scarce Yes, in ovarian region No  
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 Genetic 
testing 
 
FISH SRY: negative 
Array CGH: normal 
female pattern 
FISH SRY: negative 
Array CGH: normal 
female pattern, no 
pathogenic CNVs found 
 
FISH SRY: negative 
Array CGH: normal 
female pattern 
 
 Family 
members 
carrying the 
mutation 
Father,  
paternal uncle, paternal 
grandfather 
Unaffected sister 
Unaffected mother and 
sister 
Unaffected mother and 
two brothers 
 
 
Genetic study 
Whole-exome sequencing (WES) was performed in nine patients with 46,XX 
(ovo)testicular DSD; in four additional patients, included later, the coding region of 
NR5A1 was sequenced. Enrichment for WES was performed with the SureSelectXT 
Human All Exon V5 kit (Agilent), followed by paired-end sequencing on HiSeq 2000 
(2 × 100 cycles) (Illumina). Reads were mapped against the human reference genome 
sequence (NCBI, GRCh37/hg19) with the CLC Genomics Workbench v6.4 (Qiagen), 
followed by postmapping duplicate-read removal, coverage analysis, and quality-
based variant calling. More thorough variant annotation was executed with Alamut-
HT v1.1.5 and Alamut Visual v2.7 software (Interactive Biosoftware). For case 1, 
because we had access to parental DNA, a trio-sequencing strategy was used. Variant 
filtering was performed with the Ingenuity Variant Analysis platform (Qiagen). 
Sanger sequencing was used to confirm potentially pathogenic variants identified by 
WES and to perform segregation analysis. Primers were designed with primer3plus. 
Sequencing was performed on the ABI 3730XL DNA Analyzer (Applied Biosystems) 
using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), 
followed by data analysis with SeqScape v2.5 (Life Technologies). Microsatellite 
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analysis with 29 markers (deCODE, Généthon, and Marshfield) was performed to 
assess disease haplotypes in the three mutation-positive cases. Data analysis was 
performed with the GeneMapper v3.7 software (Applied Biosystems). 
In silico modeling of the p.(Arg92Trp) and p.(Arg92Gln) mutations 
All modeling and calculations were performed using model 1 of the NMR structure of 
the NR5A1 DNA binding domain (PDB code: 2ff0)18. The effect of the mutations on the 
stability of the protein was calculated using the FoldX RepairPDB and BuildModel 
commands, with 20 replicate calculations17. Models for p.(Arg92Trp) and, for 
comparison, p.(Arg92Gln) mutants of the NR5A1 DNA-binding domain in complex 
with DNA were built using the YASARA structure with the swap and optimize 
commands to replace R92 by a tryptophan or glutamine, followed by energy 
minimization with the YASARA forcefield in explicit solvent42. The in silico binding 
energy between the NR5A1 LBD and the DNA fragments was calculated using the 
YASARA BindEnergy command42. Models and structures were visualized via UCSF 
chimera43. 
Plasmid construction 
We constructed a GFP-tagged NR5A1 wild-type (WT) construct starting from the 
Gateway pcDNA-DEST47 vector (Invitrogen, Life Technologies) and a WT NR5A1 
open reading frame (ORF)-containing entry clone using a Gateway LR-recombination 
reaction (Invitrogen, Life Technologies). The mutations undergoing study were 
inserted using the Q5 site-directed mutagenesis kit (New England Biolabs), and 
mutation-specific primers were designed with the NEBaseChanger software (New 
England Biolabs). Mutated plasmids were transformed in One Shot TOP10 competent 
cells (Invitrogen, Life Technologies) and subsequently isolated with the NucleoBond 
Xtra Midi/Maxi kit (Macherey-Nagel). The entire NR5A1 insert and the surrounding 
backbone were sequenced and selected plasmids were grown to obtain larger 
quantities. 
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Luciferase assays 
Luciferase assays were performed in two cell lines: HeLa and KGN. Cells were grown 
in DMEM-F12 medium supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. One day before transfection, 5,000 cells/well were seeded in a 
96-well plate. Each experiment was performed in six independent replicates. Cells 
were transfected with 187 ng of a DNA mixture using calcium phosphate transfection, 
after which they were washed with phosphate-buffered saline and ethylene glycol 
tetra-acetic acid to remove remaining precipitates. After 48 h, cells were washed with 
phosphate-buffered saline again before lysis and luciferase activities were assessed 
with the Dual-Glo Luciferase Assay System (Promega). Results are reported as relative 
light units (R.L.U., i.e., the ratio of the Renilla luciferase to firefly luciferase activities). 
Each value is the mean of six independent experiments, and the standard error bar 
represents the standard error of the mean. 
Subcellular localization 
Cells were seeded in 24-well plates containing sterile coverslips at a concentration of 
30,000 cells per well 1 day before transfection. A total of 1,250 ng DNA per well was 
transfected using the calcium phosphate method. At 48 h after transfection, cells were 
washed with phosphate-buffered saline and fixed with 4% paraformaldehyde at room 
temperature for 15 min. Nuclei were stained with Hoechst (1/500) and coverslips were 
mounted on slides with Vectashield mounting medium (Vector Laboratories). 
Subcellular localization was assessed using fluorescence microscopy. All transfections 
were performed in duplicate, and at least 100 cells were counted per transfection. 
RNA-seq 
RNA-seq was performed on cultured lymphocytes from two patients (cases 1 and 3) 
and four female control samples. Lymphocytes were isolated from EDTA blood using 
Lymphoprep (Stemcell Technologies), cultured in Roswell Park Memorial Institute 
medium with 10% fetal bovine serum, and substituted with interleukin-2 and 
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phytohemagglutinin. RNA was isolated with the QiaAmp RNeasy Mini-Kit (Qiagen), 
followed by sample preparation with the TruSeq Stranded mRNA sample preparation 
kit (Illumina), subsequent cluster generation, and single-end sequencing with the 
NextSeq 500 High Output Kit V2 (75 cycles) (Illumina). To obtain equally large patient 
and control groups, patient samples were run in duplicate. First, all reads were 
mapped against the human GRCh38 reference genome with TopHat (v.2.1.0)44, 
followed by transcriptome assembly with Cufflinks (v.2.2.1)45. Subsequently, a read 
count matrix was generated using HTSeqcount (v.0.6.1p1)46. Trimmed mean of M-
values normalization and differential gene expression were assessed with the Limma 
software package47. The statistical significance of each observed change in expression 
was tested between the patient group (two patient samples, two replicates per patient) 
and the control group (four control samples) with a false discovery rate threshold of 
5%. 
Immunohistochemistry 
Slides with thicknesses of 4 μm were prepared from formalin-fixed (10%), paraffin-
embedded tissue and pretreated for 5 min with 3% H2O2 to block endogenous 
peroxidase. After heat-induced antigen retrieval at pH 9, slides were blocked for biotin 
(SP-2001, Vector Laboratories, Burlingame, CA). After overnight incubation at 4 °C 
with SOX9 (dilution 1/250, AF3075, R&D systems), FOXL2 (dilution 1/350, a gift from 
Marc Fellous), and DDX4 primary antibody (dilution 1/100, Ab13840, Abcam), 
detection was performed by 30-min incubation at room temperature with a biotin-
labeled secondary antibody, followed by another 30-min incubation with horseradish 
peroxidase (HRP)-conjugated Avidin-Biotin complex. Visualization was performed 
using 3,3-diaminobenzidine (DAB)/H202, (SOX9 and DDX4), and aminoethyl 
carbazole (AEC)/H202 (FOXL2); counterstaining was performed with hematoxylin. 
General morphology was assessed on adjacent slides after hematoxylin and eosin 
staining. 
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SUPPLEMENTARY MATERIAL 
Supplementary material is linked to the online version of the paper at 
http://www.nature.com/gim/journal/vaop/ncurrent/full/gim2016118a.html#suppleme
ntary-information 
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SUPPLEMENTAL DATA 
Figure S1 Results of transcriptional activation assays. Transcriptional activation was 
assessed for two different mutations in HeLa and KGN cells. Four different promoter 
constructs were used, here only the results for TESCO are shown. A second luciferase gene 
(Renilla luciferase) was cotransfected and used to normalize the luciferase intensities, that are 
shown as relative light units (R.L.U.). Mean values ± STD are shown. (*) statistically significant 
with a p-value < 0.05. 
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Figure S2 Subcellular localization of wild type and mutant NR5A1. Subcellular localization 
of wild type (WT) and mutant NR5A1 proteins (p.Arg92Trp and p.Arg92Gln) in HeLa cells. 
DAPI (40,6-Diamidino-2-phenylindole) counterstain (blue) in the left panels shows staining of 
the nucleus. The middle panel shows the nuclear localization of GFP-fused NR5A1 protein, 
and the right panel is a merge. WT as well as mutated NR5A1 localize to the nucleus, no 
mislocalization or aggregates can be observed. 
 
 
Figure S3 H&E-staining of individual I:2 of family 2. Hematoxylin and eosin staining of the 
distorted ovary of the mother of case 2 (individual I:2 of family 2), removed at age 41 years, 
showing typical ovarian differentiation with age-related depletion of follicles. 
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Table S1 Summary of the phenotypic characteristics of Cases 4-9. 
  Case 4 Case 5 Case 6 Case 7 Case 8 Case 9  
 Clinical phenotype at 
birth / first 
presentation 
 
Presented at the age 
of 10 with proximal 
hypospadias, breast 
development (M3), 
left impalpable and 
right inguinal gonad . 
Presented at the age 
of 3 with clitoris 
hypertrophy, left 
impalpable and right 
labioscrotal gonad,  
hemivagina and hemi-
uterus 
 
Presented at birth 
with clitoris 
hypertrophy, single 
urogenital perineal 
opening, uterus 
    
 Gonadal phenotype 
 
R: ovotestis 
L: ovary 
R: testis 
L: ovary 
 
R: ovary  
L: testis 
R: NA 
L: ovotestis 
R: ovotestis 
L: ovary 
R: 
L: 
 
 Germ cells 
 
Germ cells present in 
ovarian part 
 
Germ cells present in 
ovarian part 
Germ cells present in 
ovarian part 
Germ cells present in 
ovarian part 
Germ cells present in 
ovarian and testicular 
part 
 
  
 Genetic testing 
 
46,XXSRYneg 
Array-CGH: 
duplication chr12 
(128440338-
128689778) 
46,XXSRYneg  
(also in gonads) 
Normal female array-
CGH 
46,XXSRYneg 
Array-CGH: 
duplication chr3 
(72772687-72915275), 
maternally inherited 
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Table S2 List of DSD genes used for filtering exome and RNA-seq data 
AKR1C1 CHD7 DHCR7 FGFR1 GPR54 LEP MAP3K1 PROP1 SRD5A2 
AKR1C2 CTNNB1 DHH FKBP4 HESX1 LEPR NELF PSMC3IP SRD5A2 
AKR1C4 CYB5 DMRT1 FOG2 HHAT LGR8 NOBOX RSPO1 SRY 
AMH CYP11A1 EAP1  FOG2 HOXA13 LHCGR NR5A1 SEMA3A STAR 
AMHR2 CYP11B1 EMX1 FOXL2 HSD17B1 LHX1 NR5A2  SOX2 TSPYL1 
AR CYP17A1 EMX2 FSHR HSD17B3 LHX3 NR0B1 SOX3 WDR11 
ARX CYP19A1 FAM58A FSHβ HSD3B2 LHX4 PBX1 SOX8 WNT4 
ATRX CYP1B2 FBLN2 GATA4 INSL3 LHX9 POR SOX8 WT1 
BMP15 CYP21A2 FGF8 GATA4 KAL1 LHβ PROK2 SOX9 WWOX 
CBX2 DAX1  FGF9 GnRHR KISS1 MAMLD1 PROKR2 SRD5A1 
 
 
Table S3 Overview of variants found in DSD genes in case 1 
 Gene Coverage VAF cDNA notation Protein notation Comments  ExAC  
 SRD5A2 101 0,97 NM_000348.3:c.90dup p.(Ser31Leufs*105) rs61748121 
mother HoZ 
0.1667  
 FAM58A 2 1 
 
NM_152274.3:c.17dup p.(Gly7Argfs*51) rs373552919 
mother HoZ 
1  
 MAP3K1 812 0,375 NM_005921.1:c.2845_2847d
el 
p.(Thr949del) rs5868032 0.7393  
 CYP21A2 22 0,636 NM_000500.7:c.29_31del p.(Leu10del) rs138498156 0.2934  
 TSPYL 351 0,84 NM_003309.3:c.526_528du
p 
p.(Val176dup) rs78371471 
mother HoZ 
0.7628  
 CYP21A2 33 0,576 NM_000500.7:c.308G>A p.(Arg103Lys) rs6474 0.3341  
 NR5A1 151 0,483 NM_004959.4:c.274C>T p.(Arg92Trp) not present in 
genomic 
databases 
  
 HHAT 86 1 NM_001170587.1:c.1248+19
G>C 
/ rs4297293 
mother HoZ 
0.9847  
Abbreviations used: VAF: variant allele frequency; HoZ: homozygous. 
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Table S4 Overview of variants found in DSD genes in case 2 
 Gene Coverage VAF cDNA notation Protein notation Comments  ExAC   
 SRD5A2 132 0,97 NM_000348.3:c.90dup p.(Ser31Leufs*105
) 
rs61748121 0.1667  
 FAM58A 9 100 NM_152274.3:c.17dup p.(Gly7Argfs*51) rs373552919 1  
 FAM58A 9 100 NM_152274.3:c.54dup p.(Gln19Alafs*39) rs371528168 0.998  
 CYP21A2 28 0,43 NM_000500.7:c.29_31del p.(Leu10del) rs138498156 0.2934  
 TSPYL 347 0,82 NM_003309.3:c.526_528du
p 
p.(Val176dup) rs78371471 0.7628  
 MAP3K1 65 0,51 NM_005921.1:c.764A>G p.(Asn255Ser) rs56069227 0.0203  
 CYP21A2 53 0,68 NM_000500.7:c.308G>A p.(Arg103Lys) rs6474 0.3341  
 NR5A1 129 0,472 NM_004959.4:c.274C>T p.(Arg92Trp) not present in 
genomic 
databases  
  
 MAMLD
1 
438 0,47 NM_001177465.2:c.2486C>
T 
p.(Ala829Val) rs186833799 0.0483  
 HHAT 76 1 NM_001170587.1:c.1248+19
G>C 
? rs4297293 0.9847  
 STAR 325 1 NM_000349.2:c.465+20A>C ? rs2720050 0.0343 
(1000 
genom
es) 
 
 AKR1C2 108 0,50 NM_205845.2:c.447+17G>A ? rs61856066 0.1263  
 WWOX 155 0,51 NM_016373.3:c.108-12G>T ? rs67493355 0.286  
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Table S5 Overview of variants found in DSD genes in case 3 
 Gene Coverage VAF cDNA notation Protein notation Comments  ExAC  
 KISS1 46 0,95 NM_002256.3:c.417del p.(*139Trpfs*8) rs71745629 0.2983  
 SRD5A2 101 0,96 NM_000348.3:c.90dup p.(Ser31Leufs*105
) 
rs61748121 0.1667  
 FAM58A 3 0,33 NM_152274.3:c.17dup p.(Gly7Argfs*51) rs373552919 1  
 FAM58A 2 1 NM_152274.3:c.54dup p.(Gln19Alafs*39) rs371528168 0.998  
 MAP3K1 555 0,81 NM_005921.1:c.2845_2847d
el 
p.(Thr949del) rs5868032 0.7393  
 TSPYL 255 0,83 NM_003309.3:c.526_528du
p 
p.(Val176dup) rs78371471 0.7628  
 MAP3K1 65 0,51 NM_005921.1:c.764A>G p.(Asn255Ser) rs56069227   
 CYP21A2 81 0,37 NM_000500.6:c.185A>T p.(His62Leu) rs9378252 100  
 NR5A1 124 0,444 NM_004959.4:c.274C>T p.(Arg92Trp) not present in 
genomic 
databases 
  
 AKR1C3 3 0,33 NM_001253908.1:c.754C>A p.(Pro252Thr) / /  
 BMP15 32 0,5 NM_005448.2:c.308A>G p.(Asn103Ser) rs41308602 0.0875  
 FAM58A 3 0,33 NM_152274.3:c.55C>G p.(Gln19Glu)  0.0017  
 FAM58A 3 0,33 NM_152274.3:c.50A>G p.(Glu17Gly) / /  
 HHAT 64 1 NM_001170587.1:c.1248+19
G>C 
? rs4297293 0.9847  
 STAR 297 1 NM_000349.2:c.465+20A>C ? rs2720050 0.0343 
(1000 
genom
es) 
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Table S6 Overview of variants found in DSD genes in case 4 
 
Gene Coverage VAF cDNA notation Protein notation Comments Exac  
 
 SRD5A2 40 1 NM_000348.3:c.90dup p.Ser31Leufs*105  /  0.1667  
 MAP3K1 505 0.601 NM_005921.1:c.2845_2847del p.Thr949del rs5868032  0.7393  
 BMP15 177 1 NM_005448.2:c.786_788dup p.Leu263dup rs531409392  0.06708  
 
AR 6 0.50 NM_000044.3:c.1412_1420del p.Gly471_Gly473del 
poly-Gly 
stretch 
 / 
 
 SOX3 14 0.36 NM_005634.2:c.1032_1091del p.Ala345_Ala364del  /  0.00004233  
 AMH 10 0.20 NM_000479.3:c.1094A>G p.Asp365Gly  /  /  
 LHB 10 0.40 NM_000894.2:c.104T>C p.Ile35Thr rs34349826  /  
 LHX4 121 0.51 NM_033343.3:c.1022T>C p.Ile341Thr rs372952844  0.00001647  
 DMRT1 127 0.99 NM_021951.2:c.1037A>G p.Lys346Arg rs35846503  0.006213  
 KAL1 137 0.47 NM_000216.2:c.1600G>A p.Val534Ile rs808119  0.5916  
 LHX3 13 0.30 NM_014564.3:c.46G>T p.Gly16Cys  /  /  
 AKR1C3 146 0.55 NM_001253908.1:c.197G>A p.Arg66Gln rs35961894  0.006901  
 SOX3 14 0.21 NM_005634.2:c.1036G>T p.Ala346Ser  /  /  
 ATRX 183 0.97 NM_000489.3:c.2785C>G p.Gln929Glu rs3088074  0.3924  
 CYP19A1 205 0.51 NM_000103.3:c.602C>T p.Thr201Met rs28757184  0.02425  
 AKR1C4 276 0.48 NM_001818.3:c.404G>A p.Gly135Glu rs11253043  0.008072  
 CHD7 284 0.49 NM_017780.3:c.3697G>A p.Gly1233Ser rs190548814  0.0007453  
 PSMC3IP 28 0.25 NM_013290.6:c.88C>A p.Gln30Lys  /  /  
 SOX3 41 0.58 NM_005634.2:c.127G>A p.Ala43Thr rs73637709  0.01584  
 AR 6 0.33 NM_000044.3:c.173A>T p.Gln58Leu rs200185441  /  
 AR 7 0.42 NM_000044.3:c.176A>T p.Gln59Leu  / /   
 SOX3 9 0.22 NM_005634.2:c.221C>T p.Pro74Leu  / /   
 
STAR 176 0.97 NM_000349.2:c.465+20A>G p.? 
Cryptic 
Donor 
Strongly 
Activated 
0.9796 
 
 
WT1 24 0.41 NM_001198551.1:c.-8_-7del p.? 
New Donor 
Site 
 / 
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Table S7 Overview of variants found in DSD genes in case 5 
 
Gene Coverage VAF cDNA notation Protein notation Comments Exac  
 
 NR0B1 28 0.32 NM_000475.4:c.207C>A p.Cys69*  /  /  
 SRD5A2 28 1 NM_000348.3:c.90dup p.Ser31Leufs*105  /  0.1667  
 MAP3K1 164 0.43 NM_005921.1:c.2845_2847del p.Thr949del rs5868032  0.7393  
 AR 30 1 NM_000044.3:c.234_239del p.Gln79_Gln80del  /  /  
 AR 22 1 NM_000044.3:c.1409_1420del p.Gly470_Gly473del  /  0.01489  
 MAMLD1 94 0.62 NM_001177465.2:c.1428_1430dup p.Gln477dup  / 0.001151  
 POR 32 0.47 NM_000941.2:c.376A>G p.Ser126Gly  /  /  
 CYP11B1 18 0.28 ENST00000377675.3:c.1370C>T p.Ala457Val rs4541  /  
 SOX8 10 0.3 NM_014587.3:c.979T>G p.Ser327Ala  / /   
 WWOX 29 0.45 NM_001291997.1:c.415C>G p.Pro139Ala rs75559202  /  
 AR 32 0.4 NM_000044.3:c.1960G>A p.Glu654Lys rs200737258  0.002680  
 ATRX 53 0.42 NM_000489.3:c.5773G>A p.Asp1925Asn  / /   
 
Table S8 Overview of variants found in DSD genes in case 6 
 
Gene Coverage VAF cDNA notation Protein notation Comments Exac  
 
 SRD5A2 40 1 NM_000348.3:c.90dup p.Ser31Leufs*105  /  0.1667  
 
AR 59 0.22 NM_000044.3:c.2418_2442dup p.Ser815Valfs*23 
 New 
Acceptor 
Splice Site 
/  
 
 MAP3K1 170 1 NM_005921.1:c.2845_2847del p.Thr949del rs5868032  0.7393  
 AR 27 0.96 NM_000044.3:c.234_239dup p.Gln79_Gln80dup  /  /  
 FBLN2 54 0.52 NM_001004019.1:c.244C>T p.Arg82Cys rs575900458  /  
 TSPYL1 73 0.41 NM_003309.3:c.1098C>A p.Phe366Leu rs140756663  0.00367  
 WWOX 64 0.41 NM_130791.3:c.532C>T p.Pro178Ser  / /   
 SOX3 7 0.29 NM_005634.2:c.1114T>G p.Ser372Ala  / /   
 FAM58A 25 0.4 NM_152274.3:c.338G>A p.Arg113His rs150562029  /  
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Table S9 Overview of variants found in DSD genes in case 7 
 
 
Gene Coverage VAF cDNA notation Protein notation Comment Exac  
 
 SRD5A2 30 1 NM_000348.3:c.90dup p.Ser31Leufs*105 / 0.1667  
 FAM58A 4 1 NM_152274.3:c.17dup p.Gly7Argfs*51 / /  
 MAP3K1 222 1 NM_005921.1:c.2845_2847del p.Thr949del rs5868032 0.7393  
 AR 14 0.36 NM_000044.3:c.1418_1420dup p.Gly473dup / /  
 DMRT1 27 0.44 NM_021951.2:c.442A>C p.Lys148Gln / /  
 LHX3 27 0.22 NM_014564.3:c.982G>C p.Ala328Pro / /  
 LHX3 24 0.25 NM_014564.3:c.979G>C p.Ala327Pro / /  
 EMX2 23 0.26 NM_004098.3:c.238A>C p.Asn80His / /  
 EMX2 30 0.2 NM_004098.3:c.244G>C p.Ala82Pro / /  
 SOX8 12 0.25 NM_014587.4:c.685A>C p.Thr229Pro / /  
 SOX8 13 0.23 NM_014587.4:c.688A>C p.Thr230Pro / /  
 SOX9 39 0.31 NM_000346.3:c.715A>C p.Thr239Pro / /  
 SOX9 42 0.26 NM_000346.3:c.718A>C p.Thr240Pro / /  
 KAL1 73 0.49 NM_000216.2:c.1600G>A p.Val534Ile rs808119 0.5916  
 ATRX 142 0.35 NM_000489.3:c.2785C>G p.Gln929Glu rs3088074 0.3924  
 
STAR 117 1 NM_000349.2:c.465+20A>G p.? 
Cryptic 
Donor 
Strongly 
Activated 
0.9796 
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Table S10 Overview of variants found in DSD genes in case 8 
 
 
  
 
Gene Coverage VAF cDNA notation Protein notation Comments Exac  
 
 
SRD5A2 59 1 NM_000348.3:c.90dup p.Ser31Leufs*105  / 0.1667 
 
 
FAM58A 3 1 NM_152274.3:c.54dup p.Gln19Alafs*39 rs371528168  / 
 
 
FAM58A 4 1 NM_152274.3:c.17dup p.Gly7Argfs*51  /  / 
 
 
MAP3K1 322 0.42 NM_005921.1:c.2845_2847del p.Thr949del rs5868032 0.7393 
 
 
BMP15 147 0.45 NM_005448.2:c.786_788dup p.Leu263dup rs531409392 0.06708 
 
 
AR 45 0.75 NM_000044.3:c.231_239dup p.Gln78_Gln80dup rs4045402 0.00002187 
 
 
HHAT 40 0.55 NM_001122834.3:c.997G>A p.Gly333Arg rs61744143 0.002738 
 
 
MAP3K1 8 0.25 NM_005921.1:c.479C>A p.Ala160Asp rs372955296  / 
 
 
POR 54 0.5 NM_000941.2:c.1709G>A p.Arg570His  / 0.0003066 
 
 
CYP11B1 36 0.5 ENST00000377675.3:c.1370C>T p.Ala457Val rs4541 0.07390  
 
 
NR5A1 99 0.44 NM_004959.4:c.779C>T p.Ala260Val  /  / 
 
 
SOX8 24 0.21 NM_014587.4:c.685A>C p.Thr229Pro  /  / 
 
 
SOX8 23 0.22 NM_014587.4:c.688A>C p.Thr230Pro  /  / 
 
 
LHB 13 1 NM_000894.2:c.104T>C p.Ile35Thr rs34349826  / 
 
 
ATRX 274 0.55 NM_000489.3:c.2785C>G p.Gln929Glu rs3088074   0.3924  
 
MAMLD1 158 0.54 NM_001177465.2:c.1439T>C p.Val480Ala rs61740566   0.01835  
 
STAR 142 1 NM_000349.2:c.465+20A>G p.? 
Cryptic 
Donor 
Strongly 
Activated 
0.9796 
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Table S11 Overview of variants found in DSD genes in case 9 
 
Gene Coverage VAF cDNA notation Protein notation Comments Exac  
 
 SRD5A2 53 1 NM_000348.3:c.90dup p.Ser31Leufs*105 / 0.1667  
 EMX2 35 0.26 NM_004098.3:c.233dup p.Pro79Alafs*62 /  /  
 MAP3K1 292 0.44 NM_005921.1:c.2845_2847del p.Thr949del rs5868032 0.7393  
 AR 20 1 NM_000044.3:c.1418_1420del p.Gly473del  /  0.001472  
 HSD3B2 136 0.5 NM_000198.3:c.707T>C p.Leu236Ser rs35887327  0.003687  
 CYP1B1 89 0.45 NM_000104.3:c.1328C>G p.Ala443Gly rs4986888  0.005280  
 FBLN2 64 0.45 NM_001004019.1:c.2658C>A p.Asn886Lys rs61731214  0.001426  
 PROP1 82 0.59 NM_006261.4:c.152G>C p.Gly51Ala rs2233783  0.01191  
 HOXA13 27 0.41 NM_000522.4:c.496C>A p.Pro166Thr /  0.03422  
 NOBOX 48 0.54 NM_001080413.3:c.1826C>T p.Pro609Leu rs115882574  0.001870  
 FGFR1 77 0.54 NM_023110.2:c.2314C>T p.Pro772Ser rs56234888  0.003822  
 CYP11B1 25 0.52 ENST00000377675.3:c.1370C>T p.Ala457Val rs4541  0.07390  
 DMRT1 59 0.39 NM_021951.2:c.1037A>G p.Lys346Arg rs35846503  0.006213  
 EMX2 29 0.24 NM_004098.3:c.244G>C p.Ala82Pro /  /  
 SOX8 20 0.35 NM_014587.4:c.676A>C p.Thr226Pro  /  /  
 SOX8 24 0.33 NM_014587.4:c.685A>C p.Thr229Pro  /  /  
 SOX8 30 0.27 NM_014587.4:c.688A>C p.Thr230Pro  /  /  
 WWOX 110 0.57 NM_001291997.1:c.274C>A p.His92Asn rs74860463  0.001764  
 SOX9 30 0.36 NM_000346.3:c.715A>C p.Thr239Pro  /  /  
 SOX9 23 0.43 NM_000346.3:c.718A>C p.Thr240Pro  /  /  
 PROKR2 86 0.47 NM_144773.2:c.151G>A p.Ala51Thr rs144994507  0.004192  
 ATRX 199 0.5 NM_000489.3:c.2785C>G p.Gln929Glu rs3088074    0.3924  
 MAMLD1 53 0.47 NM_001177465.2:c.966C>A p.His322Gln rs62641609  0.006742  
 MAMLD1 120 0.46 NM_001177465.2:c.1439T>C p.Val480Ala rs61740566   0.01835  
 
STAR 119 1 NM_000349.2:c.465+20A>G p.? 
Cryptic 
Donor 
Strongly 
Activated 
0.9796 
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Table S12 Overview of gynaecological examination in unaffected female carriers 
  Family 2  Family 3  
  I:2 II:2 I:2  
 Current age 
 
48 21 46  
 Age at menarche 
 
16 15.5 12  
 Early/excessive pubarche 
 
No No No  
 Acne  
 
No No No  
 Hirsutism 
 
No No No  
 Regular menses Regular, especially after 
pregnancies 
No: sometimes absent for 
several months, followed 
by menorrhagia  
Oral anticonception since 
age 16 
 
Prolonged menstrual 
cycle (1,5-2 months), 
long-term use of oral 
anticonception 
because of 
menorrhagia 
 
 Spontaneous pregnancies Yes None First 2 pregnancies 
spontaneous, last 
pregnancy by ICSI. 
Diagnostic testing at 
that time suggested 
male factor 
subfertility 
 
 
 Age at menopause 
 
45  NA  NA  
 Enlarged clitoris 
 
No No No  
 General medical problems 
 
No No No  
 Other remarks At age 41: acute 
ovariectomy because of 
ovarian cyst with torsion 
   
Abbreviations used: ICSI: intracytoplasmic sperm injection; NA: not applicable. 
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Table S13 List of rare variants (MAF<0.01) for patient 1, variants inherited from mother 
excluded (added in separate Excel file) 
Table S14 List of rare de novo variants (MAF<0.01) for patient 1 (added in separate Excel 
file) 
Table S15 List of rare variants (MAF<0.01) for patient 2 (added in separate Excel file) 
Table S16 List of rare variants (MAF<0.01) for patient 3 (added in separate Excel file) 
Table S17 Overview of all significantly differentially expressed genes (added in separate 
Excel file) 
Table S13-17 are available at: 
http://www.nature.com/gim/journal/vaop/ncurrent/full/gim2016118a.html#supplementary-
information 
Table S18 Overview of the significantly differentially expressed DSD related genes.  
 Default analysis       
 
gene Log fold change 
average 
expression 
T p-value adjusted p-value 
 
 LEPR -0.6681 6.123 -6.636 0.0001102 0.007119  
 MAMLD1 1.637 3.073 5.335 0.0005240 0.01289  
 IRF2BPL -0.7721 5.442 -4.092 0.002894 0.03156  
 Analysis with 
correction for 
fold change 
     
 
 
gene Log fold change 
average 
expression 
T p-value adjusted p-value 
 
 MAMLD1 1.637 3.073 4.478 0.0009225 0.03436  
 LEPR -0.6681 6.123 -4.023 0.001605 0.04671  
 
Fold change = ratio control group/ patient group; T = test-statistic value to compute significance of the observed 
change; p value = uncorrected p-value of the test statistic; adjusted p-value = the false discovery rate adjusted p-
value of the test statistic 
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ABSTRACT 
Background: Premature ovarian insufficiency (POI) is a major cause of female 
infertility. The genetic causes of POI remain unknown in most cases. Here, we 
hypothesized that haploinsufficiency of Friend of GATA2 gene (FOG2/ZFPM2) could 
contribute to the pathogenesis of POI, based on the identification of a heterozygous 
FOG2 deletion in a child with an isolated 46,XY disorder of sex development (DSD) 
and in his 25-year-old mother with low serum anti-Müllerian hormone (AMH) levels, 
suggestive of a decreased ovarian reserve. This hypothesis is supported by the role of 
the FOG2/GATA4 complex in mouse ovarian development.  
Methods: Copy number analysis of FOG2 in the index case was performed with array-
CGH followed by qPCR. Targeted next-generation sequencing of FOG2 was conducted 
in 31 Belgian and 357 French POI cases. Functional validation of the identified FOG2 
variants was performed by luciferase assays in HEK293T cells. 
Results: A heterozygous FOG2 deletion was found in a child with isolated 46,XY DSD 
and in his mother with putative POI risk. Subsequently, four novel likely pathogenic 
FOG2 variants were found in a heterozygous state in a large POI cohort (4/388, 1%), 
one frameshift duplication and three missense mutations. Luciferase assays showed 
significantly lowered transcriptional activation of the mutated FOG2/GATA4 complex 
for several of the identified variants.  
Conclusion: We demonstrate that FOG2 haploinsufficiency can lead to POI, 
supporting a role of FOG2 in human ovarian maintenance and contributing to the 
molecular pathogenesis of POI. Finally, we expand the phenotypic spectrum of FOG2 
mutations, thus far only associated with cardiac anomalies, congenital diaphragmatic 
hernia and 46,XY DSD.  
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INTRODUCTION 
Gonadal development and functioning 
is driven by strictly regulated 
spatiotemporal expression of several 
genes. Deviations from this tightly 
controlled process are known to cause 
disorders of sex development (DSD), a 
group of rare, congenital conditions 
characterized by atypical development 
of chromosomal, gonadal or phenotypic 
sex1. As many genes involved in 
gonadal development continue to be 
expressed in adult life, an emerging 
concept is that mutations in known DSD 
genes can underlie more frequent 
conditions such as male infertility or 
primary ovarian insufficiency (POI). An 
exemplary gene in this context is 
Steroidogenic factor-1 (SF-1, NR5A1), 
which was not only associated with 
46,XY DSD with or without adrenal 
failure2 but also with hypospadias male 
factor infertility3,4, POI and very recently 
with 46,XX (ovo)testicular DSD5-8. 
POI affects approximately 1% of women 
and is characterized by a triad of 
symptoms occurring before the age of 
40: amenorrhea for at least four months, 
sex steroid deficiency and follicle 
stimulating hormone (FSH) serum 
levels above 40 IU/L on at least two 
measurements and with an interval of at 
least one month9,10. Over the years, many 
tests have been developed to assess 
ovarian reserve, e.g. assessment of the 
number of antral follicles by 
transvaginal ultrasound (antral follicle 
count), and serum measurement of FSH, 
inhibin-B and anti-Müllerian hormone 
(AMH) concentrations. The advantage 
of AMH measurement is that it is an 
early marker of reduced ovarian reserve, 
independent of cyclic variation11-13. POI 
can be the result of either follicle 
dysfunction or follicle depletion. Many 
cases are iatrogenic, following chemo- 
or radiotherapy, or are due to 
autoimmune disorders9. In some 
patients POI is related to genetic defects 
such as structural or numerical 
abnormalities of the X chromosome (e.g. 
Turner syndrome) or mutations in POI 
genes (e.g. BMP15, FMR1, FOXL2, 
NR5A1)9. Although numerous genes 
have been identified, the genetic causes 
of POI remain unknown in the majority 
of cases.  
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In this paper we identified of a 
heterozygous, maternally inherited 
Friend of GATA2 gene (FOG2/ZFPM2) 
(MIM *603693) encompassing deletion 
in a boy with isolated 46,XY DSD. FOG2 
is a cofactor of the GATA-binding 
protein 4 (GATA4) transcription factor, 
and mutations and structural variations 
in FOG2 and GATA4 have previously 
been associated with 46,XY DSD and/or 
cardiac anomalies14-17. Hormonal work-
up was suggestive of gonadal 
dysgenesis in the boy and reduced 
ovarian reserve in the mother. Based on 
this, we hypothesized that 
haploinsufficiency of FOG2 could 
contribute to the pathogenesis of POI. 
Targeted next-generation sequencing of 
FOG2 in 31 Belgian and 357 French POI 
cases revealed four heterozygous 
potentially pathogenic FOG2 variants, 
which were functionally characterized.  
RESULTS 
Identification of a heterozygous, 
maternally inherited FOG2 deletion in a 
46,XY boy with gonadal dysgenesis 
A heterozygous deletion of 3.2 Mb was 
found in the index case with isolated 
46,XY DSD (chr 8: 104348705-107509840, 
GRCh37/hg19), encompassing several 
genes including FOG2, previously 
implicated in the pathogenesis of 46,XY 
DSD and cardiac malformations (Figure 
1A)17. The deletion was confirmed with 
FOG2-specific qPCR, Sanger sequencing 
of the entire FOG2 coding region 
excluded the presence of additional 
variants. Segregation analysis revealed 
that the deletion is of maternal origin 
(Figure 1B). Hormonal investigations in 
the 25-year-old mother revealed low 
serum AMH (0.57 µg/L, reference range 
before follicular phase, < 8.42 at age 25 
years, gradually decreasing to <0.3 at 
age 46 years). Low AMH serum 
concentrations are known to be early 
markers for decreased follicular reserve, 
AMH values can be decreased or 
undetectable while FSH still reaches 
normal levels. FSH and LH levels were 
within the reference limits (0.84 U/L and 
1.2 U/L respectively; reference range: 
FSH: 3-13 U/L, LH: 2-13 U/L); serum 
estradiol was below the detection limit 
of 12 ng/L (reference range: 12-166 
ng/µl).
219 
 
 
Figure 1: Identification of a FOG2 encompassing deletion in a patient with 46,XY DSD. (A) 
View of the UCSC genome browser (University of California, Santa Cruz) of the FOG2 
deletion, chr 8: 104348705-107509840, GRCh37/hg19. (B) qPCR results confirming the FOG2 
deletion in both the index patient and his mother. The patient’s father has two copies of the 
gene. Two reference genes were included for normalization. NC: negative control, SEM: 
standard error of the mean. (C) Schematic overview of the FOG2 protein and the location of 
the four novel variants identified in the Belgian/French POI cohort studied.  
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Table 1: Detailed overview of the identified FOG2 sequence variations. 
 Variant cDNA Protein Nucleotide 
conservation 
Amino acid 
conservation 
CADD-
score 
SIFT PolyPhen-2 Mutation 
Taster 
Grantham 
distance 
Public 
databases 
 
 1 c.848_851dup p.(Glu285Valfs*5) / / / / / / / Not present   
 2 c.3086A>T p.(Lys1029Ile) Highly 
conserved  
phyloP: 4.81 
Highly 
conserved: 
Tetraodon 
25.0 Deleterious  Probably 
damaging 
Disease 
causing 
102 ExAC: All: 
T = 0.032% 
GnomAD: 
T= 0.022% 
dbSNP: 
rs201729935  
 
 3 c.2501A>G p.(Lys834Arg) Highly 
conserved  
phyloP: 5.13 
Highly 
conserved: 
Tetraodon 
24,9 Deleterious Probably 
Damaging 
Disease 
causing 
26 ExAC: 
ALL:G= 
0.07222% 
GnomeAD: 
G= 0.0682% 
dbSNP: 
rs113289249 
 
 4 c.934G>C p.(Ala312Pro) Moderately 
conserved 
phyloP: 4.08 
Highly 
conserved: 
Fruitfly 
25.7 Deleterious  Probably 
damaging 
Disease 
causing 
27 Not present  
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Screening of a Belgian/French patient 
cohort revealed four potentially 
pathogenic FOG2 variants 
Targeted resequencing in a 
Belgian/French cohort (nBelgian=31, nFrench= 
357) revealed four heterozygous 
sequence variants. All of them were 
absent in publicly available exome 
databases like ExAC and 1000 genomes, 
or had a population frequency below 
1%. Variant 1 (V1) is a four nucleotide 
duplication c.848_851dup, leading to a 
frameshift and the introduction of a 
premature stop codon five amino acids 
later p.(Glu285Valfs*5), most likely 
undergoing nonsense mediated decay. 
The missense variants (V2-4) were 
predicted to have a deleterious effect on 
protein function according to several 
prediction algorithms like SIFT, 
PolyPhen-2 and Mutation Taster. The 
affected amino acids were moderately to 
highly conserved. Details about these 
variants are shown in Figure 1C and are 
listed in Table 1. 
 
 
Figure 2: Results of the luciferase transcriptional activation experiments. Blue bars: 
transcriptional regulation of the AMH promoter by FOG2. Orange bars: transcriptional 
regulation of the AMH promoter by FOG2 variants with cotransfection of wild type (WT) 
GATA4 and NR5A1. Results are reported as relative light intensity units (R.L.U). The error 
bars represent the standard deviation of the data. *: significant difference compared to the 
corresponding WT condition at the 0.05 level. **: significant difference compared to the 
corresponding WT condition at the 0.01 level.
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Luciferase assays show altered 
transcriptional activation.  
Different experimental set-ups were 
used to assess the transcriptional 
activation capacity of the FOG2/GATA4 
transcription complex on a human AMH 
promoter when FOG2 is mutated. Based 
on interactions described in literature, 
we co-transfected these FOG2 variants 
with wild type (WT) GATA4 and 
NR5A1. Transfection of FOG2 alone 
revealed discrete but significant 
differences for V1-V3 (pv1=0.0008, 
pv2=0.0088, pv3=0.0006). Co-transfection 
with WT GATA4 and NR5A1 vector on 
the other hand revealed a significantly 
lowered transcriptional activation for all 
variants except for V4 (pv1, pv2<0.0001, 
pv3=0.0154) (Figure 2).  
DISCUSSION 
FOG2 mutations were first identified in 
patients with structural congenital heart 
defects such as septum defects and 
tetralogy of Fallot15,18,19. However 
identification of a balanced 
t(8;10)(q23.1;q21.1) translocation, of 
which the chromosome 8 breakpoint 
disrupts FOG2, in a boy with an atrial 
septum defect and 46,XY gonadal 
dysgenesis (GD), provided a first 
argument for its involvement in human 
gonadal development as well. 
Expression analysis of neighboring 
genes showed no significant changes, 
relating the observed phenotype to 
FOG2 disruption20. A second 
t(8;18)(q22;q21) translocation, associated 
with a 16 Mb FOG2 encompassing 
deletion, was found in a syndromic case 
displaying a combined congenital heart 
defect and 46,XY gonadal dysgenesis18. 
In 2014, the first FOG2 point mutations 
associated with 46,XY gonadal 
dysgenesis and without cardiac 
abnormalities were reported. 
Segregation analysis revealed two 
asymptomatic female carriers. 
Functional validation of these variants 
showed reduced biological activity of 
the mutant proteins but the pathogenic 
mechanism was not revealed17.  
We first identified a FOG2 
encompassing deletion in a boy with 
isolated 46,XY GD and his mother with 
low AMH values, suggesting POI risk. 
Previously no genomic rearrangements 
affecting FOG2 have been found in 
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patients without a cardiac phenotype. 
The subsequent identification of four 
novel, heterozygous FOG2 mutations in 
a French-Belgian POI cohort confirmed 
our hypothesis that FOG2 mutations 
may underlie POI. No cardiac anomalies 
were reported in the medical history of 
these cases. The variants identified in 
this study are distributed over the entire 
FOG2 gene, which is, together with the 
deletion, suggestive of 
haploinsufficiency. As variants that 
were previously identified in patients 
with cardiac malformations are also 
scattered over the gene, it is not possible 
to establish reliable genotype-
phenotype correlations. Luciferase 
assays revealed a significant effect of the 
GATA4/FOG2 complex on 
transcriptional activation of a human 
AMH-promoter for variants V1-V3. 
Although these functional data are in 
favor of a pathogenic effect of the 
identified mutations, the precise 
pathogenic mechanism remains to be 
elucidated. 
Studies in knock-out mice propose a 
function for the Fog2/Gata4 
transcription complex in the earliest 
phases of gonadal development. Both 
knock-outs result in a similar phenotype 
in which testicular cord formation is 
abrogated. Early (i.e. pre-testicular) 
male specific genes like Nr5a1 and Wt1 
are no longer expressed, Sry expression 
is significantly reduced and 
downstream genes of Sry, such as Sox9 
and Amh are undetectable (Figure 3A)21-
24.  
Interestingly, several lines of evidence 
implicate the Fog2/Gata4 complex in 
ovarian development and functioning. 
Antonnen et al. have shown Fog2/Gata4 
expression in mice granulosa cells in 
different stages of follicle 
development25. Later it was shown that 
the absence of a functional Fog2/Gata4 
complex results in ectopic expression of 
Dkk1, a known Wnt signaling inhibitor, 
resulting in loss of expression of several 
genes of the Wnt pathway. In addition, 
loss of the Fog2/Gata4 complex leads to 
downregulation of Foxl2, which is one of 
the earliest markers of ovarian 
development (Figure 3A)26. Early 
embryonic death of both Gata4ki/ki - a 
knock-in model that abrogates the 
Fog2/Gata4 interaction and survives 
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longer than Gata4-/- mice - and Fog2-/- 
mice precludes evaluation of adult 
ovaries, however several sources of in 
vitro evidence implicate both factors in 
adult ovarian functioning. Together 
with Nr5a1, the Fog2/Gata4 complex is 
involved in transcriptional regulation of 
the Amh gene (Figure 3B). During 
follicular maturation, Amh is 
responsible for inhibiting excessive 
follicle recruitment by FSH27,28. Fog2 
appears to have a coordinating role in 
this pathway as it can act as a repressor 
of Gata4-induced Amh activation 
(Figure 3B)25. Besides Amh, the inhibin-α 
gene (Inha) is a second member of the 
transforming growth factor-β (TGF-β) 
family which is regulated by 
Fog2/Gata4. Inhibins form heterodimer 
glycoproteins that are involved in the 
control of pituitary FSH secretion29,30. In 
vitro evidence demonstrates that the 
Fog2/Gata4 complex can play a 
regulatory role in steroidogenesis as 
Gata4 binding sites have been found in 
the promoters of different genes 
encoding steroidogenic enzymes21. The 
involvement of the Fog2/Gata4 complex 
in both Amh regulation and 
steroidogenesis is reminiscent of the role 
of Nr5a1, which has also been 
implicated in 46,XY DSD and POI, sex 
development and adult ovarian 
functioning31. In agreement with 
NR5A1-associated POI, FOG2-
associated POI is also characterized by 
incomplete penetrance, as FOG2 
mutations previously identified in 
patients with 46,XY DSD, did not lead to 
POI in two female carriers17. 
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Figure 3: Suggested working mechanisms for the FOG2 mutations. Blue: male specific genes. 
Orange: female specific genes. (A) Mouse knock-out models suggest that the Fog2/Gat4 
complex is implicated in upregulation of Sry, thereby triggering the male developmental 
pathways22-24. In females, the Fog2/Gata4 complex inhibits Dkk1, a known inhibitor of the Wnt-
pathways26. (B) In vitro experiments are in favor of a postnatal role for the complex. Together 
with NR5A1, the FOG2/GATA4 complex can activate AMH, which is known to regulate FSH 
in order to prevent excessive follicle maturation25,28. The green crosses indicate that FOG2 
mutations can possibly inhibit the FOG2/GATA4 actions that are visualized by the black 
arrows.  
 
CONCLUSION 
We identified a heterozygous FOG2 encompassing deletion in a boy with 46,XY DSD 
and his mother with low AMH values, suggestive of a role of FOG2 haploinsufficiency 
in POI pathogenesis. Screening of a Belgian-French POI cohort revealed four 
potentially pathogenic FOG2 variants, with an effect on transcriptional activation. 
Based on our findings, the incidence of FOG2-associated POI is 1% (4/388). Our study 
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shows that FOG2 haploinsuffiency is implicated in a spectrum of conditions ranging 
from 46,XY gonadal dysgenesis, whether or not associated with cardiac 
malformations, to 46,XX POI. This phenotypic spectrum is reminiscent of the one 
previously identified for NR5A1 mutations and underlines the importance of correct 
functioning of sex developmental genes throughout adult life.   
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PATIENTS AND METHODS 
Patients 
The index case, currently four years old, was born at 38 weeks of gestation after an 
uneventful, spontaneous pregnancy. His birth weight was 2,575 kg and he measured 
47 cm. The boy displayed proximal penile hypospadias, a fused hypoplastic scrotum 
and impalpable gonads. Hormonal work-up at 3 months showed low serum AMH (3 
µg/L, reference range: 55.3-187 µg/L) and borderline increased FSH (12 U/L, reference 
range 1-12 U/L). Luteinizing hormone (LH) was within the reference range (1.2 U/L, 
reference range 1-9 U/L). At ten months, stretched penile length was 42 mm (mean of 
46.5 mm ± 4.7 mm), and gonads were still not palpable. Discrete dysmorphic features 
were observed: flat nasal bridge, low set ears, downslanting palpebral fissures. 
Psychomotor development was normal. Structural cardiac defects were excluded by 
cardiac ultrasonography, gonads were in an abdominal position. Gonadal biopsies, 
taken at the age of 13 months revealed dysgenetic testicular tissue on the left side, 
containing some spermatogonia, as indicated by positive DDX4 and negative OCT3/4 
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staining. On the right side no atypical testicularization was observed. Hypospadias 
was corrected in a two-stage procedure. Gonads could not be relocated in the scrotum 
and ultimately, gonadectomy was performed at the age of 2 years and 6 months in 
view of the increased gonadal germ cell cancer risk. Family history was negative for 
reproductive disorders. The mother had menarche at age 14 years and a normal 
menstrual cycle. She had two spontaneous pregnancies at age 23 and 25 (index case). 
The father is known with asthma, hypercholesterolemia and epilepsy.  
Belgian POI patients (n=31) were recruited in the fertility department of Ghent 
University Hospital (Ghent, Belgium), in a group who had successful pregnancies after 
oocyte donation between 2004-2013. Women with iatrogenic or auto-immune 
disorders were excluded. All of them signed informed consent. DNA samples from 
357 French POI patients were collected via the Service d’Endocrinologie et Médecine 
de la Reproduction, Hôpital Pitié – Salpêtriere (Paris, France). The study was approved 
by the ethical committee of the Ghent University Hospital (EC/2014/0592). 
Array-CGH and qPCR 
Microarray-based comparative genomic hybridization (array CGH) was performed 
with genome-wide arrays (180K, Agilent), with an overall probe spacing of 14 kb in 
general, 11 kb when only taking the RefSeq genes into account. Hybridization was 
performed as recommended by the company and results were visualized in ViVar32. 
Quantitative PCR (qPCR) for copy number detection was performed as described33. 
Primers were designed using Primer3plus and validated in silico and with a standard 
dilution series33.  The experiment was done with the SsoAdvanced SYBR supermix 
(Bio-Rad), and data-analysis was done with qbase+ software (Biogazelle). 
Targeted resequencing 
The coding exons and intron-exon boundaries of FOG2 were sequenced on a MiSeq 
instrument, using a standardized approach described by De Leeneer et al34. FOG2 
primers were designed with primer3plus (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi). Sanger sequencing was used to confirm potentially 
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pathogenic variants and was performed on the ABI 3730XL DNA Analyzer (Applied 
Biosystems) using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems), followed by data analysis with SeqScape v2.5 (Life Technologies). 
Plasmid construction 
We constructed a FOG2 and GATA4 wild type plasmid by using a Gateway LR 
recombination reaction (Invitrogen, Life Technologies), starting from gene specific 
pShuttle Gateway PLUS ORF clones (GC-U1317 and GC-Z5705, GeneCopoeia) and the 
Gateway pcDNA-DEST47 vector (Invitrogen, Life Technologies). Mutagenesis was 
performed using the Q5 site-directed mutagenesis kit (New England Biolabs), and 
mutation-specific primers were designed with the NEBaseChanger software (New 
England Biolabs). Mutation positive plasmids were grown up in One Shot TOP10 
competent cells (Invitrogen, Life Technologies) and subsequently isolated with the 
NucleoBond Xtra Midi/Maxi kit (Macherey-Nagel). All vectors were sequenced to 
ensure correct sequence. The luciferase reporter construct for AMH was a kind gift 
from dr. Nathalie Diclemente. 
Cell culture and luciferase assays 
HEK293T cells were cultured in DMEM supplemented with 10% FCS and 1% 
penicillin/streptavidin. One day before transfection 5000 cells/ well were seeded in a 
96 well plate. Cells were transfected with a total of 200 ng/ well using Dharmafect kb 
transfection reagent (GE healthcare) and washed with phosphate-buffered-saline 
(PBS) 24h later. After 48h, cells were washed a second time with PBS followed by cell 
lysis and assessment of the luciferase activities following the Dual-Glo Luciferase 
Assay System (Promega) protocol. Results are reported as relative light units (R.L.U., 
i.e., the ratio of the Renilla luciferase to firefly luciferase activities). Each value is the 
mean of six independent experiments, and the error bars represents the standard 
standard deviation of the data. 
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ABSTRACT 
Genetic studies in Disorders of Sex Development (DSD), representing a wide spectrum 
of developmental or functional conditions of the gonad, have mainly been oriented 
towards the coding genome. Application of genomic technologies, such as whole-
exome sequencing, result in a molecular genetic diagnosis in ∼50% of cases with DSD. 
Many of the genes mutated in DSD encode transcription factors such as SRY, SOX9, 
NR5A1, and FOXL2, characterized by a strictly regulated spatiotemporal expression. 
Hence, it can be hypothesized that at least part of the missing genetic variation in DSD 
can be explained by non-coding mutations in regulatory elements that alter gene 
expression, either by reduced, mis- or overexpression of their target genes. In addition, 
structural variations such as translocations, deletions, duplications or inversions can 
affect the normal chromatin conformation by different mechanisms. Here, we review 
non-coding defects in human DSD phenotypes and in animal models. The wide variety 
of non-coding defects found in DSD emphasizes that the regulatory landscape of 
known and to be discovered DSD genes has to be taken into consideration when 
investigating the molecular pathogenesis of DSD.
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INTRODUCTION 
Sex development, whereby the initially 
undifferentiated gonad is evolving to a 
testicular or ovarian fate, is undoubtedly 
one of the most intriguing processes of 
early embryonic life. Given the 
complexity of these processes, it is not 
surprising that they are prone to errors, 
leading to so-called Disorders of Sex 
Development (DSD)1. With a prevalence 
of around one in 2000–4500 births, they 
are among the most common birth 
defects2. In recent years, we have come 
to a better understanding of the 
molecular pathways involved in these 
complex processes and with the advent 
of next-generation sequencing 
technologies new genes and 
mechanisms have been identified3. 
Nevertheless, diagnostic approaches 
using targeted resequencing of DSD 
gene panels and whole-exome 
sequencing leave a majority of cases 
unsolved4. Genetic studies in DSD have 
mainly been oriented towards the 
coding portion of the genome. As many 
of the genes involved in sex 
development encode transcription 
factors (such as SRY, SOX9, NR5A1, 
FOXL2) requiring a rigorously regulated 
spatiotemporal expression, it can be 
expected that part of the unsolved cases 
are caused by a disturbed 
transcriptional or translational 
regulation of known or yet to be 
discovered DSD genes, resulting from 
non-coding genetic defects. Indeed, 
studies of developmental conditions 
such as DSD have uncovered a wide 
variety of non-coding mutations that 
affect regulatory elements and that 
result in reduced, mis- or 
overexpression of their target genes. 
Structural variations such as 
translocations, deletions, duplications 
or inversions can alter the normal 
chromatin conformation and can 
reposition enhancer elements which can 
lead to misexpression of their target 
gene. Such defects have been shown to 
be important in the pathogenesis of 
developmental conditions in general5-7. 
Here, we review regulatory defects that 
are known to be implicated in DSD, both 
in human as well as in other mammalian 
model organisms. 
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REGULATORY DEFECTS IN DSD 
SRY 
Two decades ago several individuals 
were described who had regulatory 
defects in Sex determining region Y (SRY) 
associated with 46,XY DSD; however for 
none of them the exact working 
mechanism could be elucidated8-11. 
Concomitantly, comparative sequence 
analysis revealed highly conserved 
motifs surrounding SRY, suggesting a 
function in transcriptional regulation12-
13. The first irrefutable evidence for the 
importance of correct SRY regulation in 
humans was provided by Assumpção et 
al. who identified a three basepair (bp) 
deletion located in the SRY promoter in 
a patient with 46,XY complete gonadal 
dysgenesis and the father, who had 
undergone several reconstructive 
surgeries for severe hypospadias in 
childhood. This deletion partially 
removes a Sp1 binding site from the SRY 
promoter. Previous research had 
showed that Sp1 is one of the 
transcription factors (together with 
NR5A1 and WT1) necessary for 
transcriptional activation of SRY14. In 
2008, a more extensive phylogenetic 
footprinting study showed four large 
conserved regions based on multiple 
sequence alignments. Two of the 
previously identified SRY regulatory 
defects8,11,12 proved to be located within 
one of these regions, supporting their 
association with gonadal dysgenesis. 
Intriguingly, it was noticed that mouse 
5′ sequences, as well as Sry coding 
sequences were different from those of 
other species, suggesting different 
regulatory mechanisms. This is reflected 
by a unique murine expression pattern 
of Sry15.  
SOX9 
The most extensively studied regulatory 
region involved in DSD is undoubtedly 
the SRY-box 9 (SOX9) region. Loss-of-
function coding mutations and 
regulatory defects including 
translocations, deletions and inversions 
can cause campomelic dysplasia (CD), a 
semi-lethal skeletal malformation 
syndrome with 46,XY DSD in 75% of 
male cases, while both coding and 
regulatory duplications are associated 
with 46,XX testicular DSD (called 
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RevSex)16,17. In addition, disruptions of 
specific long-range cis-regulatory 
elements are a known cause of Pierre 
Robin sequence (PRS), leading to 
craniofacial anomalies18,19. The situation 
is even more complex: SOX9 regulatory 
duplications that overlap with RevSex 
duplications but extend to the 
neighbouring KCJN genes do not result 
in female-to-male sex reversal but in 
Cooks syndrome, a condition 
characterized by brachydactyly and 
anonychia20. A comprehensive overview 
of reported regulatory rearrangements 
of the SOX9 region are listed in Table 1 
and depicted in Fig. 1. In an attempt to 
unravel the complex regulation of SOX9 
expression, several studies searched for 
conserved non-coding elements (CNEs) 
that might act as tissue-specific 
enhancers16,21-24 (Fig. 1). Different tissue-
specific enhancers have been identified 
(involved in neurodevelopment, 
chondrogenesis and craniofacial 
development); however the testis-
specific SOX9 regulation remains 
enigmatic25. In general, SOX9 regulatory 
rearrangements that are associated with 
specific phenotypes cluster in four main 
regions, although there are no clear-cut 
genotype–phenotype correlations. The 
first and most upstream interval (−1230 
to 1030 kb upstream of SOX9) is 
associated with PRS, the second (−932 to 
601 kb upstream of SOX9) with milder 
forms of CD and acampomelic 
campomelic dysplasia (ACD) and the 
third (−375 to 50 kb upstream of SOX9) 
with more severe CD, respectively (Fig. 
1). The shortest region of overlap (SRO) 
of the duplications found in 46,XX DSD, 
a 74-kb interval (−517 to −595 kb of 
SOX9), represents the critical region for 
this phenotype, called RevSex24. This 
region was further refined by Kim et al. 
to a 68-kb interval from 516 to 584 kb 
upstream of SOX9, called the XX sex 
reversal region (XXSR). Similarly, the 
authors identified the SRO of 46,XY DSD 
causing deletions, the XY sex reversal 
region (XYSR) of 32.5 kb, located 607.1–
639.6 kb upstream of SOX926. Almost 
simultaneously, Hyon et al. reduced this 
critical region to 41 kb27 (Fig. 1).  
Despite several efforts to identify 
gonadal-specific enhancers, the 
repositioning of which might cause sex 
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reversal, no such elements have been 
found to date. In this respect, a 
particular duplication that causes 46,XX 
DSD is of special interest. Benko et al. 
identified a 148 kb duplication in a 
46,XX ovotesticular DSD patient that 
was also present in the father and more 
surprisingly in the paternal, unaffected 
grandmother. It was hypothesized that 
changes in the regulatory region that 
harbors CNEs, could affect the 
chromatin state of the SOX9 promoter 
and more specifically of the testis-specific 
enhancer of SOX9 (TESCO) element, by 
alternative interactions between a 
specific regulatory element and TESCO. 
Chromatin profiling in fibroblasts 
showed that both the father and son had 
a more repressive signature in the 
region of the duplication and a more 
open chromatin state starting from the 
TESCO enhancer towards SOX9, 
compared with female controls, 
confirming this hypothesis. These 
epigenetic changes can be seen as a 
genetic background-based, 
superimposing regulatory element that 
can contribute to the observed 
incomplete penetrance28. 
More insights into the pathogenic 
mechanisms underlying different 
classes of SOX9 regulatory duplications 
were recently provided by Franke et al.29 
by chromosome conformation capture 
studies (capture Hi-C and 4C-seq). As 
mentioned above, small regulatory 
duplications encompassing the RevSex 
region lead to 46,XX DSD, while larger 
duplications including this region but 
extending to the KCNJ genes cause 
Cooks syndrome. In addition, a third 
class of duplications was described, 
containing the RevSex region and the 
gene desert between the SOX9 and 
KCNJ genes but not the genes 
themselves. Duplications of this type do 
not lead to a specific phenotype (Fig. 1). 
Franke et al. attribute these differential 
phenotypic expressions to different 
disruptions of topologically associated 
domains (TADs)29 that represent higher 
order chromatin structures in which 
interactions take place. They are 
separated from each other by 
boundaries, restricting the contacts that 
are established between enhancers and 
their target genes, and allowing intra-
TAD but no inter-TAD interactions30,31. 
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The first class of duplications, leading to 
female-to-male sex reversal, affects a 
single TAD and are called intra-TAD 
duplications. The other two classes 
affect two neighboring TADs and their 
boundary (inter-TAD duplications). 
Intra- and inter-TADs have a different 
impact on chromatin organization, 
leading to a distinct phenotypic 
expression. The intra-TAD duplication 
does not alter the original TAD structure 
but leads to an increased number of 
interactions in the duplicated region 
itself and with SOX9, causing increased 
SOX9 activity and thus testis 
development in an XX individual. The 
inter-TAD duplications have an impact 
on chromatin structure and create an 
additional TAD (neo-TAD). The 
duplication found in the phenotypically 
normal family forms a neo-TAD that is 
isolated from the rest of the genome and 
that does not interact with the 
neighboring SOX9 and KCNJ genes, 
which are not included in the 
duplication. Duplications found in 
Cooks syndrome lead to a neo-TAD 
containing the KCNJ2 gene that has 
ectopic contacts with the duplicated 
SOX9 regulatory elements and that is 
misexpressed, hence resulting in a 
developmental limb phenotype. As 
SOX9 is located in another TAD in the 
latter situation, there is no sex 
developmental phenotype29. The 
concepts of this study will have impact 
on the interpretation of copy number 
variations that are found by routine 
genetic testing in DSD-related 
phenotypes. 
SOX3 
SOX regulatory rearrangements in DSD 
patients are not restricted to the SOX9 
locus, but have also been described in 
the SOX3 region. Comparative sequence 
analysis and cytogenomic analyses led 
to the hypothesis that SRY arose from 
this gene32. Loss-of function mutations 
do not lead to sex determination defects, 
suggesting that SOX3 has no critical 
function in normal sex determination in 
humans. However, it was hypothesized 
that certain gain-of-function variants 
leading to ectopic SOX3 activation, 
could lead to female-to-male sex 
reversal. In 2011, Sutton et al. described 
three patients displaying 46,XX 
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testicular DSD in which distinct SOX3 
regulatory rearrangements were 
found32. In addition, a transgenic mouse 
model in which Sox3 is ectopically 
expressed in the developing XX gonads, 
is characterized by female-to-male sex 
reversal. These results show that 
gonadal SOX3 expression can act as a 
trigger for male sex development in the 
absence of SRY32. More recently an 
insertional translocation was reported in 
an individual with 46,XX ovotest/test 
DSD33, which was shown to result in 
robust SOX3 expression in patient-
derived lymphoblasts, while it was 
absent in XX and XY control 
individuals33. 
DMRT1 
Deletions of the short arm of 
chromosome 9 (9p) are associated with 
two distinct phenotypes. Telomeric 
deletions of 9p24.3 result in a genital 
phenotype ranging from isolated 
hypospadias to gonadal dysgenesis in 
XY individuals. More proximal 
interstitial deletions cause 9p-
malformation syndrome, that is 
characterized by intellectual disability, 
congenital hypotonia and a spectrum of 
craniofacial abnormalities34. The region 
associated with sex development 
encompasses 1 Mb starting from the 
telomeric end and spanning the DMRT 
gene cluster. On the basis of its 
expression pattern, haploinsufficiency 
of DMRT1 was hypothesized to be the 
underlying mechanism35,36. Only one 
telomeric 9p deletion that does not 
encompass the DMRT genes has been 
described in association with sex 
reversal37,38. According to a previous 
study, the critical DMRT1 regulatory 
region reaches out to 6.5 kb upstream of 
the gene39; however the deletion 
described by Calvari et al. has its 
breakpoint ∼40 kb upstream of 
DMRT137,38. The authors hypothesize 
that the more distal location, in closer 
proximity to the telomere, could also 
affect DMRT1 expression despite the 
intact proximal regulatory region38. 
Moreover, it cannot be ruled out that 
this deletion affects additional more 
remote regulatory elements. However, a 
more complex mechanism in which 
DMRT1 dysregulation together with 
other effects would lead to gonadal 
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dysgenesis, should also be considered. 
A combined dosage threshold effect 
could also explain the incomplete 
penetrance that was observed in several 
pedigrees38. 
DAX1 
The dosage sensitive Nuclear Receptor 
subfamily 0 group B member 1 (NR0B1, 
DAX1) gene is known to cause 
congenital adrenal hypoplasia (AHC) 
associated with hypogonadotropic 
hypogonadism when mutated or 
deleted, and 46,XY complete or partial 
gonadal (testicular) dysgenesis when 
duplicated40,41. DAX1 downregulates the 
Anti-Müllerian Hormone (AMH) gene 
during female development, therefore 
increased DAX1 expression can cause 
AMH repression during male 
development and lead to gonadal 
dysgenesis and an undervirilized 
phenotype in 46,XY individuals41,42. 
Smyk et al. reported a 46,XY female with 
a maternally inherited deletion of ∼250 
kb upstream of DAX142. In silico analysis 
of the deleted region identified several 
putative SF1-binding sites, 
evolutionarily conserved elements and 
cis-acting regulatory elements. The 
absence of adrenal insufficiency in this 
patient suggests that the deletion does 
not result in a loss-of-function effect. It 
was suggested that the deletion affects 
silencing cis-acting elements, thereby 
leading to increased activation of DAX1 
and thus 46,XY sex reversal42. Other 
possible mechanisms such as the loss of 
an insulator or the juxtaposition of a 
long-range, gonadal ridge-specific 
enhancer cannot be excluded; however 
the net result should be increased DAX1 
expression42. Interestingly, a large 
regulatory inversion, located about 4 kb 
upstream of DAX1, was identified in a 
patient with AHC43. This inversion 
relocates an SF1-binding site that was 
previously associated with murine sex 
development. These findings represent 
another example of defects that, by 
affecting different regulatory elements, 
can cause distinct phenotypes, as was 
also illustrated for the SOX9 region (see 
above). 
AR 
Additional interesting regulatory 
mechanisms were added to the 
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molecular pathogenesis of DSD, more 
specifically in the AR gene implicated in 
androgen insensitivity syndrome (AIS). 
First, a novel and recurrent 5’′ 
untranslated region (5′UTR) mutation 
was identified, confirming a 20-year-old 
hypothesis44. Indeed Mizokami and 
Chang had previously shown that 
certain regions of the AR 5’ UTR 
influence induction of translation 
without having an effect on 
transcription. It was hypothesized that 
mutations in this region might cause 
AIS, because they lead to a lower level of 
AR, without changing the transcript 
levels45. The identified variant 
introduces a new start codon to the AR 
5’ UTR, and together with an in-frame 
stop codon 183 nucleotides 
downstream, this creates a short 
upstream open reading frame (uORF). 
The short alternative transcripts 
resulting from this can reduce 
translation levels of the downstream 
translated gene by inhibiting ribosome 
progression or by complicating the 
binding of pre-initiation complexes to 
the original translation start site44. 
Functional validation of this variant 
showed expression of a short 
polypeptide, reduced levels of normal 
AR protein, while the mRNA levels 
remain unchanged. Overall, this is a 
novel mechanism explaining the 
complete AIS phenotype in these 
patients44. Very recently, Känsäkoski et 
al. identified a deep intronic AR variant 
(c.2450-118A>G) in two 46,XY sisters 
with complete AIS by whole-genome 
sequencing. This variant creates a de 
novo 5’ splice site and a putative exonic 
splicing enhancer motif, leading to the 
preferential formation of two aberrantly 
spliced transcripts. The de novo 5’ splice 
site leads to the activation of a 3’ splice 
site 84 bp upstream of the variant. In 
∼50% of the crypticly spliced transcripts 
a 202 nucleotide fragment downstream 
of the 3’ splice site is included. Both 
transcripts are predicted to cause a 
premature stop codon, predisposing 
them to nonsense mediated decay 
(NMD). Quantification of the normal AR 
transcript in patients’ genital fibroblasts 
showed 10% levels compared with 
controls. Despite normal amounts of 
total AR mRNA, the AR protein was 
undetectable in patients’ genital  
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Figure 1: Schematic overview of 5’ regulatory defects of the SOX9 region. UCSC genome 
browser, build GRCh37/hg19. At the top, in black; conserved non-coding elements (CNEs) 
based on sequence homology between different species16,21-24. Identified inversions, deletions, 
duplications and translocations are depicted in orange, red, green and blue respectively. In 
general four regulatory intervals can be distinguished, shown in grey at the top of the picture 
(references in Table 1). The first interval, from 1030-1230 kb upstream of SOX9 is associated 
with Pierre Robin Sequence (PRS); the second (601-932 kb upstream of SOX9) is associated 
with  acampomelic campomelic dysplasia (ACD) and isolated 46,XY DSD; the third (50-375 kb 
upstream of SOX9) is associated with more severe campomelic dysplasia (CD). The RevSex 
region of 74 kb is the shortest region of overlap between the duplications identified in 46,XX 
DSD patients24. Recently, the RevSex region was even further refined to a 62 kb region (XXSR, 
pink vertical rectangle), at the same time a 46,XY DSD defining region was proposed (blue 
vertical rectangle)26. Hyon et al. reduced the critical region for XX DSD to 41 kb27.
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fibroblasts, suggesting that its stability 
is compromised, even if aberrant 
mRNA is translated46. This study shows 
the power of integrating whole-genome 
sequencing data with cDNA analyses to 
study deep intronic mutations in AIS 
patients. Previously, one other intronic 
mutation had been identified which 
had an impact on dihydrotestosterone 
binding, no effect on mRNA splicing 
was reported for this mutation47. 
Taken together, the above studies 
emphasize the importance of non-
coding AR mutations in the 
pathogenesis of AIS in case no coding 
AR mutation is found 
ANIMAL MODELS 
SOX9: odd sex mouse and CanRevSex dog 
In 2000, Bishop et al. created an 
insertional transgenic mouse (Odd sex, 
Ods) with the insertion of two 
tyrosinase copies under the control of a 
Dct promoter, accompanied by a 150 kb 
deletion approximately 1 Mb upstream 
of Sox948. This rearrangement manifests 
itself in sex reversal in XX mice. 
Histological analysis and in situ 
hybridization showed Sox9 expression 
in the sex reversed XX gonads. In silico 
analyses did not provide evidence for 
the involvement of a new sex 
development gene, but suggested that 
the phenotype was caused by altered 
regulation of Sox9 expression during 
embryogenesis either by affecting the 
surrounding chromatin structure or by 
rearrangement of tissue-specific, long-
range, cis-acting enhancer/repressor 
elements48. However, two follow-up 
papers showed that the underlying 
mechanism was more complex and that 
perturbed Sox9 regulation alone was 
insufficient to cause the sex reversal 
phenotype49,50. The first paper 
illustrates that the sex reversal 
phenotype is depending on the genetic 
background of the transgenic mouse, as 
crossing with an A/J strain resulted in 
normal female mice. Interestingly, 
amodifier locus on chromosome 18, 
Odsm, was found. Homozygosity for 
the allele from the original mouse strain 
strongly favors Ods sex reversal, while 
the A/J Odsm allele inhibits Ods sex 
reversal49. The second paper shows that 
upregulation of Sox9 was not solely 
249 
 
depending on the removal of a potential 
regulatory element, but that it was 
provoked by the presence of the Dct 
promoter, which had a long-range 
activating effect50. 
In dogs, XX DSD is quite a common 
phenotype, although no molecular 
causes were identified until recently. 
Rossi et al. were the first to identify 
SOX9 encompassing duplications in XX 
sex reversed dogs51. Given the fact that 
in humans both SOX9 encompassing 
and regulatory duplications are 
associated with 46,XX DSD, 
Marcinkowska-Swojak et al. explored 
the canine SOX9 regulatory region. 
Comparative sequence analysis 
revealed that the canine homologue 
(CanRevSex) of the human RevSex 
region (HumRevsex), which is located 
∼0.5 Mb upstream of SOX9, can be 
found about 9 Mb downstream of 
SOX9. Customized high-resolution 
copy number screening revealed two 
highly variable regions CNVR1 and 2, 
respectively upstream and downstream 
of SOX9; however copy number 
variants (CNV) in these regions were 
detected in both affected dogs and in 
healthy controls. For CNVR1, an 
association between high copy 
numbers and XX DSD was noticed, 
suggesting the presence of another 
CNV or genetic variation in this region 
that is associated with the phenotype; 
no such association was observed for 
CNVs in CNVR2 however; although 
this is part of the CanRevSex region52. 
Recently, the assembly of the canine 
SOX9 regulatory region was revised, 
revealing that the CanRev- Sex region is 
also located upstream of SOX9. A new 
in silico analysis shows complete 
homology between the human and 
canine region53. The existence of this 
new assembly suggests that CNVs 
found in dogs should be reassessed to 
gain better understanding of their 
involvement in canine XX DSD. 
FOXL2: regulatory defects in Polled 
Intersex goats and inpiggyBac mice 
A third regulatory animal model with 
sex reversal is the Polled Intersex (PIS) 
goat, characterized by dominant 
polledness and recessive XX sex 
reversal. Linkage analysis located the 
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causal defect to chromosome band 1q43 
(the orthologue of the 3q23 locus in 
humans) and via positional cloning the 
causal genetic defect was identified: a 
11.7 kb deletion affecting the 
transcription of Pis-regulated transcript 1 
(Pisrt1), a long non-coding RNA, and 
Forkhead box L2 (Foxl2)54. The exact 
mechanism behind the sex reversal 
phenotype was unclear at that time. 
Generation of homozygous Foxl2 
knockout mice via zinc-finger nuclease 
mutagenesis proved that isolated loss 
of Foxl2 without affecting lncRNA 
expression is sufficient for developing 
the sex reversal phenotype in mice55. In 
humans, coding FOXL2 mutations and 
deletions have been described in 
blepharophimosis, ptosis, epicanthus 
inversus syndrome (BPES), a 
developmental eye condition 
associated (type I) or not (type II) with 
primary ovarian insufficiency (POI), 
and rarely associated with isolated 
POI56-58. Interestingly, several cis-acting 
regulatory deletions have been 
described in human cases with BPES58-
60. It has been suggested that 
homozygous FOXL2 mutations might 
also result in 46,XX sex reversal, 
however no coding or regulatory 
mutations of FOXL2 have been found in 
46,XX (ovo)testicular DSD cases to 
date61,62. 
A second Foxl2 associated regulatory 
animal model is the piggyBac (PB) 
mouse63. Insertional mutagenesis led to 
the identification of a mouse with a PB 
insertion approximately 160 kb 
upstream of Foxl2. This mutation leads 
to reduced Foxl2 expression and causes 
a phenotype reminiscent of BPES. 
Additional experiments showed 
interaction of the mutated region with 
the Foxl2 transcription start site in 
developing craniofacial tissues, 
showing that the piggyBac mouse is a 
good animal model to study Foxl2 
regulation and the mechanisms 
underlying human BPES63. 
FUTURE PERSPECTIVES AND 
CONCLUSIONS 
The discoveries discussed in this review 
emphasize the importance of correct 
spatiotemporal gene expression during 
sex development and highlight an 
increasing number of non-coding 
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defects in human and animal sex 
reversed phenotypes. While in most 
DSDs cases coding variants in known 
and yet to be discovered disease genes 
are to be expected, it is conceivable that 
at least part of the missing genetic 
variation can be explained by non-
coding mutations in regulatory 
elements. A common action mechanism 
for such regulatory defects is removal 
or malpositioning of tissue-specific 
enhancer or silencer elements, leading 
to perturbed transcriptional activation 
and gene expression. Less frequent 
mechanisms, however, like uORFs in 
AR44 and chromatin alterations in the 
SOX9 region28 will evolve from future 
studies. Finally, the increasing number 
of non-coding defects in DSD illustrates 
that non-coding regions such as 5′UTRs, 
intronic regions, proximal and distant 
cis-regulatory elements, mostly ignored 
in a routine context, should be 
examined in DSD patients with normal 
coding regions.
 
Table 1: Overview of SOX9 regulatory rearrangements 
 References Phenotype Karyotype  Breakpoint locations  
 Inversions  
   
 Maraia et al. 
199164 
Severe CD 46,XX,inv(17)(q12;q25) /°  
 Mansour et al. 
199565 
Mild CD + complete 
gonadal dysgenesis 
46,XY,inv(17)(q11.2;q24.3-
q25.1) 
75-350 kb upstream of SOX916  
 Deletions     
 Pop et al. 
200422  
Case 1: mild CD  
+ 46,XY DSD 
46,XY 379 -1869 kb upstream of SOX9. 
Length: 1.49 Mb 
 
 Benko et al. 
200918 
Family 4: PRS 
 
 
Case 1: PRS 
 
 
 
 
1.38 Mb upstream of SOX9 
(chr17:68,663,405-68,738,405) 
Length: 75 kb 
1.58 Mb upstream of SOX9 
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Case 2: PRS 
 (chr17:68,219,155-68,538,005) 
Length: >319 kb 
1.56 Mb downstream of SOX9 
(chr17:71,641,405-71,677,405) 
Length: 36 kb° 
 Lecointre et al. 
200966  
Familial ACD  
(+ 46,XY DSD in 
child) 
Child: 46,XY 
Mother: 46,XX 
517 kb-1.477 Mb upstream of SOX9 
Length: 960 kb 
 
 Benko et al. 
201117 
Family 4: 46,XY DSD 46,XY 405-645 kb upstream of SOX9  
 White et al. 
201167  
46,XY DSD, cleft 
palate, short stature 
46,XY 235 kb upstream of SOX9 
Length: 1.19 Mb 
 
 Baghavath et 
al. 201468 
46,XY DSD 46,XY 353 kb upstream of SOX9 
Length: 349 kb 
 
 Kim et al. 
201526 
Case 1: 46,XY DSD 
 
 
Case 2: 46,XY DSD 
 
Case 3: 46,XY DSD 
 
Case 4: 46,XY DSD 
46,XY 
 
 
46,XY 
 
46,XY 
 
46,XY  
403.3–639.6 kb upstream of SOX9 
Length: 236 kb 
 
607.1–672.5 kb upstream of SOX9 
Length: 65 kb 
510–646 kb upstream of SOX9 
Length: 136 kb 
132.1–709.0 kb upstream of SOX9 
Length: 577 kb 
 
 Duplications     
 Kurth et al. 
2009 
Family 1: symmetric 
brachydactyly, 
anonychia 
 
Family 2: symmetric 
brachydactyly, 
anonychia 
Family 3: symmetric 
brachydactyly, 
anonychia 
Familial                                                      
                                          
 
Familial 
 
46,XX 
 
Familial 
~97 kb upstream of  SOX9  
(chr 17: 68,053,486-70,019,661) 
Length: 1.96 Mb 
/° 
Length: 1.91 Mb 
/° 
Length: 1.52 Mb 
/° 
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Family 4: symmetric 
brachydactyly, 
anonychia 
Length: 1.21 Mb 
 Benko et al. 
201117 
Family 1: 46,XX DSD 
 
 
 
Family 2: 46,XX DSD* 
 
 
 
Family 3: 46,XX DSD 
46,XX 
 
 
 
46,XX 
 
 
 
46,XX 
~353 kb upstream of SOX9 (max. 
size chr17:69,069,079-69,764,059, 
min. size chr17: 69,107,506-
69,712,726) 
Length: 605-694 kb  
                                                              
447-595 kb upstream of SOX9 
(chr17:69521863-69670036) 
Length: 148 kb 
 
~508 kb upstream of SOX9 (max.  
size chr17:68829028-69609453 and 
min. size coordinates 
chr17:68838024-69599915)  
Length: 761-780 kb 
 
 Cox et al. 
201169 
46,XX DSD 46,XX 600 kb upstream of SOX9 
Length: 178 kb 
 
 Vetro et al.70 46,XX DSD 46,XX 514 kb upstream of SOX9 
Length: 96 kb 
 
 Xiao et al. 
201371  
46,XX DSD 46,XX 510-584 kb upstream of SOX9 
Length: 74 kb 
(chr17:69,533,305-69,606,825) 
 
 Hyon et al. 
201527  
46,XX DSD 46,XX ~600 kb upstream of SOX9 
Length: 83.8 kb 
(chr17: 69,491,366 -69,575,195) 
 
 Kim et al. 
201526  
Case 5: 46,XX DSD 
 
 
Case 6: 46,XX DSD 
 
 
Case 7: 46,XX DSD 
46,XX 
 
 
46,XX  
 
 
46,XX 
516– 659 kb upstream of SOX9 
Length: 143 kb 
 
259–703 kb upstream of SOX9 
Length: 444 kb 
 
264–744 kb upstream of SOX9 (min. 
size chr17:69 371 938– 69 852 771; 
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max. size chr17:69 370 916–69 855 
932) 
Length: 480 kb 
 Vetro et al. 
201572  
Case 1: 46,XX DSD 
 
 
 
 
Case 2: 46,XX DSD 
46,XX 
 
 
 
 
46,XX 
294 kb–658 kb upstream of SOX9 
(min. size chr17:69 458 883 -
69823311; max. size chr17:69 401 099 
– 69 878 197) 
Length: 364 kb 
 
431-572 kb upstream of SOX9 
(min. size chr17:69 544 737-69 686 
379; max size chr17: 69 510 367-
69 764 059) 
Length: 141 kb 
 
 Translocations  
 Young et al. 
199273  and 
Foster et al. 
199474  
Severe CD + 46,XY 
DSD 
46,XY, t(2;17)(q35;q23-24) 88 kb upstream of SOX975  
 Tommerup et 
al. 199376  and 
Wagner et al. 
199477  
Case 1: severe CD + 
46,XY DSD 
 
Case 2: ACD + 46,XY 
DSD 
Case 3: severe CD 
46,XY,t(7;17)(q32;q24.2) or 
(q34;q25.1) 
 
46,XY,t(13;17)(q22;q25.1) 
 
46,XX,t(1;17)(q42.13;q24.2) 
or (q25.1) 
50 kb upstream of SOX9 
 
                                                    134-
142 kb upstream of SOX975,78 
 
173-179 kb upstream of SOX975,78 
 
 Mansour et al. 
199565 
Mild CD/ACD 46,XX,t(4;17)(q21.3;q23.3) /°  
 Ninomiya et 
al. 199679 
ACD + 46,XY DSD 46,XY,t(12;17)(q21.32;q24.2) 
or (q25.1) 
74-88 kb upstream of SOX975  
 Wirth et al. 
199678 
Mild CD+ PRS + 
46,XY DSD 
46,XY,t(6;17)(q11;q24) 212-224 kb upstream of SOX975,78  
 Wagner et al. 
199780  
ACD  46,XY,t(17;22)(q25.1;p11.2) 900.2 kb upstream of SOX975,81 
(chr17:69,216,927-69,217,135) 
 
 Wunderle et 
al. 199816 
Severe CD 46,XY,t(9;17)(p13;q23.3-
24.1) 
110-140 kb upstream of SOX9  
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 Savarirayan 
and Bankier 
199882  
Mild CD 46,XX,t(5;17)(q15;q25.1) /°  
 Pfeiffer et al. 
199975  
 
Case 1: severe CD 
 
Case 2: severe CD 
46,XY,t(10;17)(q24;q23) 
 
46,XX,t(5;17)(q13.3;q24.2) 
228-229 kb upstream of SOX9 
 
288-319 kb upstream of SOX9 
 
 Hill-Harfe et 
al. 200581  
Mild CD Familial t(13;17) 931.8 kb upstream of SOX9 
(chr17:69,185,496) 
 
 Velagaleti et 
al. 200523  
Case 1: ACD + PRS 
 
 
Case 2: ACD + 46,XY 
DSD 
46,XX,t(4;17)(q28.3;q24.3) 
 
 
46,XY,t(4;7;8;17)(4qterr4p15
.1::17q25.1r17qter;7qterr7p1
5.3::4p15.1r4pter;8pterr8q1
2.1:: 
7p15.3r7pter;17pterr17q25.
1::8q12.1r8qter) 
~900 kb upstream of SOX9 
(chr17:69,217,932) 
 
~1.3 Mb downstream of SOX9 
 
 Leipoldt et al. 
200783 
Case 1: mild CD + 
46,XY DSD 
 
 
Case 2: ACD + 46,XY 
DSD 
46,XY,t(1;17)(q42.1;q24.3) 
 
 
 
46,X,t(Y;17)(q11.2;q24.3) 
375 kb upstream of SOX9 (chr17: 
69,741,445) 
 
 
789 kb upstream of SOX9 
 
 Jakobsen et al. 
200719 
PRS 46,XX,t(2;17)( q23.3;q24.3) 1.13 Mb upstream of SOX9  
 Benko et al. 
200918  
Family 1: PRS 
 
Family 2: PRS 
 
Family 3: PRS 
t(2;17)(q32;q24) 
 
t(5;17)(q15;q24) 
 
t(2;17)(q24.1;q24.3) 
1.16 Mb upstream of SOX9 
(chr17:68,663,405-68,738,405) 
1.03 Mb upstream of SOX9 
(chr17:68,219,155-68,538,005) 
1.23 Mb upstream of SOX9 
(chr17:71,641,405) 
 
 Refai et al. 
201084  
46,XX testicular DSD 46,XX,t(12;17)(14.3;24.3) 776-811 kb upstream of SOX9  
(chr17:69,399,629) 
 
 Jakubiczka et 
al. 201085  
ACD + 46,XY DSD 46,XY,t(7;17)(q33;q24).ish 
t(7;17) 
(wcp7+,wcp17+;wcp7+wcp
492 kb upstream of SOX9  
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17+) with a deletion of 
approximately 4.2 Mb  
 Vetro et al. 
201572 
46,XX DSD 46, XX, t(11;17) (p13;q24.3) 929 kb upstream of SOX9  
 Abbreviations used: ACD: acampomelic dysplasia, CD: campomelic dysplasia, DSD: disorder of sex 
development, kb: kilobase, Mb: megabase, PRS: Pierre Robin sequence. Genomic build GRCh37/hg19 was 
used for all genomic coordinates. *: duplication inherited from paternal grandmother, characterized by 
incomplete penetrance. °: the genomic coordinates for these rearrangements were not provided in the cited 
references , therefore they are not shown in Figure 1. 
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DISCUSSION 
With a prevalence of approximately one in 2 000 to 4 500 births, DSD conditions are 
among the most common birth defects. Taking also milder phenotypes like 
hypospadias and micropenis into account, the prevalence approximates one in 200 
births1,2. The birth of a child with manifest genital atypicalities, especially if gender 
assignment is not straight forward, is very distressing for the parents. Care by an 
expert multidisciplinary team, including specialists on the different aspects of DSD, is 
therefore required. Over the years, considerable progress has been made in the 
diagnostic process and availability of diagnostic techniques for, amongst others, DSD 
conditions3,4. However, despite the advent of next-generation sequencing (NGS) 
technologies and subsequent identification of new factors involved in the molecular 
pathogenesis of DSD, an underlying genetic defect can be identified in only ~50% of 
cases5,6. Accurate genetic diagnosis and better understanding of the involved 
molecular pathways can provide information on expected prognostic factors, guide 
management and facilitate acceptance and genetic counselling6. Furthermore, 
elucidation of the molecular pathways involved in DSD, can also shed a light on the 
pathogenesis of related reproductive phenotypes such as male infertility or primary 
ovarian insufficiency (POI), which occur at much higher frequency.  
The Ghent multidisciplinary DSD team has been offering centralized multidisciplinary 
care for families affected by a DSD condition for many years and is internationally 
recognized for its expertise. Over the years, DNA has been collected in a substantial 
number of DSD cases and their parents, enabling our team to contribute to the 
unravelling of the underlying molecular pathways. Accordingly, the main aim of this 
PhD project was to identify new disease genes and mechanisms for some of these 
intriguing conditions. As a first step, we aimed to critically assess the appropriateness 
of the, at that time, available genetic testing in small children with atypical sexual 
development.  
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46,XY neonates and infants with atypical genitalia: who to investigate?  
Before the advent of NGS approaches, genetic work-up in 46,XY children with 
undervirilized genitalia had a diagnostic yield of ~20-40%7,8 and was relatively time-
consuming and expensive. Milder phenotypes had often been related to 
environmental factors, low birth weight and multiple genetic factors rather than to a 
monogenic cause; and therefore, the question arose whether hormonal and genetic 
work-up is truly beneficial in these cases9-11. However, mutations in genes such as AR, 
NR5A1 and WT1, generally associated with more severe forms of genital ambiguity 
had also been identified in milder undervirilization phenotypes12-15. In study 1, we 
performed a systematic, extensive genetic work-up in a cohort of 32 male-assigned 
neonates and infants with a 46,XY karyotype and a variable degree of genital 
undervirilization. External masculinization scores (EMS) ranged from 2/12 to 12/12, 
allowing us to compare the diagnostic yield of our approach in the group with low 
EMS scores (EMS<7) as compared to the group with higher EMS scores (EMS≥7).  
Our data revealed no important differences in diagnostic yield in cases with low versus 
higher EMS scores (17.6 versus 26.5% respectively), suggesting that the decision to 
perform a thorough diagnostic work-up in 46,XY boys with atypical genitalia should 
not be based on the severity of the phenotype alone. A comparable study by Su et al. 
does state that EMS-scores below three indicate a higher likelihood for identification 
of an underlying genetic defect and that this criterion justifies genetic screening. 
However our data do not support this statement as we have a slightly higher 
diagnostic yield in the group with higher EMS scores16. In our cohort, array-CGH 
proved to be a valuable technique for syndromic cases, demonstrated by a 33% success 
rate in this group, but its clinical detection rate drops when including non-syndromic 
cases, which is in line with previous data17. Sequential sequencing of known DSD 
genes in this cohort could only reveal three NR5A1 mutations, and no pathogenic 
changes in AR, SRY or WT1. In accordance with our results, this sequential first-line 
approach has been replaced in our center by a NGS-based DSD gene panel, 
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implemented in the automated workflow described by De Leeneer et al18.This allows 
a more flexible and cost-effective analysis of the most important DSD genes in a clinical 
setting. A very successful example of targeted NGS sequencing in DSD diagnostics has 
been reported by Eggers et al. Using Haloplex enrichment, they sequenced 64 known 
DSD genes and 967 candidate gene in a large cohort of DSD cases. Their strategy lead 
to an overall diagnostic yield of 43% in 46,XY DSD cases and 17%  in 46,XX DSD cases19.  
Despite these promising numbers, a large portion of the investigated cases remains 
unexplained with a targeted approach. Therefore, we anticipate that targeted whole 
exome sequencing (WES), in which WES data-analysis initially focusses on a targeted 
gene panel, or WES in general will gain importance in the diagnostic work-up of DSD 
conditions (both 46,XY and 46,XX DSD), not only in a research setting, but in a clinical 
context as well.  Of interest, several algorithms have become available meanwhile, that 
allow direct copy number variant (CNV) detection on WES data20-22.  Although these 
tools have high specificity and sensitivity, their results still need to be validated with 
more established techniques like array-CGH. Given the lowering costs and technical 
improvements, it can be anticipated that whole genome sequencing (WGS) will be 
introduced as the “one-for-all” diagnostic tool in the near future23. The implementation 
of these exome- or genome-wide techniques in a diagnostic setting is however 
accompanied by ethical concerns as they may result in the identification of secondary 
and incidental finding that are unrelated to the initial clinical question. To address 
these concerns the American College of Medical Genetics appointed a working group 
on incidental findings to make recommendations on the management of these 
secondary findings. The specific recommendations were reported by Green et al. and 
include the screening of genes related to 59 medically actionable conditions24. 
Comprehensive pre- and post-test counseling are of utmost importance and should be 
available to all patients undergoing these tests.  
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Unravelling the molecular pathogenesis of DSD phenotypes 
The main goal of this PhD project was the identification of novel genetic causes or 
mechanisms for DSD conditions and related phenotypes. In our center, first line 
diagnostic testing for DSD currently consists of combined copy number screening 
using genome-wide array-CGH, intersex MLPA (a commercially available MLPA kit 
containing probes against common DSD genes, P185, MRC Holland) and targeted 
resequencing of a DSD gene panel. For those cases in which this sequential approach 
did not reveal a molecular diagnosis, we used WES to identify the underlying 
molecular defect. The main advantage of WES, exploring the entire coding sequence 
of the patient’s DNA, accounts for its main disadvantage as well. In each patient 
thousands of variants are found, but in most cases only one of them is of clinical 
importance, making the quest for the pathogenic variant like looking for a “needle in 
a haystack”. To reduce the size of this metaphorical haystack, two different WES 
strategies were applied. In case of consanguinity, we combined WES with 
homozygosity mapping, as previously described for DSD and other conditions25-30. In 
this project identification of the homozygous regions was done using genome-wide 
SNP genotyping. WES data were subsequently filtered based on these regions. Today, 
several algorithms have been developed that extract these homozygous regions 
directly from WES data, overruling the need of previous SNP-chip genotyping31,32. For 
non-consanguineous families, we opted for a trio-sequencing strategy to reduce the 
number of possibly pathogenic variants. The rationale behind this strategy is that 
unaffected parents do not carry the pathogenic mutation and that only de novo variants 
can be related to the phenotype. Despite disappointing results of this strategy in a large 
DSD cohort19, this strategy has also proven to be very useful in other conditions like 
autism spectrum disorders and intellectual disability phenotypes33-35. However, for 
DSD phenotypes this de novo paradigm has to be used with caution. For instance, 46,XY 
DSD phenotypes can be caused by mutations in pro-testis genes. The presence of a 
mutation in such a gene in the mothers of a child with 46,XY DSD could be ‘tolerated’, 
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as defects in testicular development do not apply to them. Therefore, only variants 
inherited from the parent with the same sex chromosomes can be disregarded when 
filtering WES data for DSD phenotypes. Besides this DSD-specific consideration, the 
possibility of incomplete penetrance should be kept in mind.  
Identification of ESR2 as a novel candicate disease gene for 46,XY DSD 
So far, mutations in several nuclear receptor genes have been implicated in DSD 
pathogenesis: Nuclear Receptor subfamily 5 group A member 1 (NR5A1, also known as 
Steroidogenic Factor 1 or SF1)36, Androgen Receptor (AR, NR3C4)37, Nuclear Receptor 
Subfamily 0 Group B Member 1 (NR0B1, also known as DAX1)38. In the past, ESR2 
polymorphisms had already been associated with subtle differences of sex 
development such as hypospadias and micropenis and a heterozygous missense 
variant has been described in a girl with primary amenorrhea10,39-42. In study 3, we 
identified biallelic and monoallelic ESR2 mutations in one syndromic and two non-
syndromic 46,XY DSD cases respectively, putting forward ESR2 as a novel disease 
gene for 46,XY DSD and expanding the spectrum of nuclear receptors implicated in 
46,XY DSD.  Genetic and structural data were in favor of a potential pathogenic effect, 
however the search for a pathogenic mechanism is not straight forward.    
Nuclear receptors, and hence ER-β, are known to exert their functions via different 
signaling pathways. The most common signaling mode for ERs involves ligand-
dependent receptor dimerization, inducing transcriptional regulation of ER target 
genes43,44. Alternatively, ERs can also interact with other transcription factors and 
modify their transcription responses, and non-genomic pathways signaling via second 
messengers have been described43,44. Furthermore, ligand-independent ER-signaling 
has been described43,44. Interestingly, one of these alternative pathways involves 
MAPK signaling. Unfortunately, only scarce experimental data concerning these 
pathways is available and these interactions are highly cell specific, making gonadal 
specific validation challenging44. 
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The mitogen-activated protein kinase (MAPK) signaling pathway has previously been 
implicated in sex developmental processes; gain-of-function MAP3K1 mutations have 
been found in several 46,XY DSD cases and Map3k4 loss-of-function variants in mice 
result in male-to-female sex reversal45,46, although the mechanisms by which the MAPK 
signaling functions differ between the two species. In humans, MAPK signaling is 
essential for tilting the gene expression balance towards SOX9 expression; gain-of-
function mutations of MAP3K1 lead to a higher phosphorylation of downstream 
targets, causing a decreased expression of SOX9 and an increased expression of 
female-specific genes like β-catenin45,47,48. As a result, the ovary-determining pathways 
can overrule the induction of male-specific SRY expression47,48. In mice, the Mapk 
pathway acts through direct upregulation of Sry; homozygous loss-of-function 
variants of Map3k4 are reflected in a male-to-female sex reversal phenotype46,48. We 
hypothesize that ESR2 gain-of-function variants can cause increased activation of the 
MAPK pathway via a non-genomic working mechanism, thereby tilting the expression 
balance from SOX9 to β-catenin signaling, and resulting in male-to-female sex reversal. 
Further experimental confirmation of this hypothesis is recommended but will be 
challenging as no relevant experimental set-ups are commonly available (see future 
perspectives).  
Identification of NR5A1 as a novel disease gene for 46,XX testicular and ovotesticular DSD 
While many genes have been implicated in the molecular pathogenesis of 46,XY DSD, 
far less is known about genes and mutations underlying 46,XX DSD. Known etiologies 
include SRY translocations, copy number variations and regulatory defects of different 
SOX genes (SOX9, SOX3, SOX10) and inactivating RSPO1 mutations49-57. In study 3, 
we have screened a cohort of 13 cases with 46,XX testicular or OT DSD to identify the 
new molecular causes for these phenotypes. To our surprise, we identified the same 
NR5A1 variant in three of them, (c.274C>T, p.(Arg92Trp)). NR5A1 mutations had 
previously been associated with different 46,XY DSD phenotypes, male infertility and 
POI and the gene has many known functions in both developing and adult 
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gonads36,58,59. Genetic and structural arguments were both in favor of pathogenicity 
although an exact working mechanism could not be demonstrated.  
Initially, we hypothesized that this mutation, located in the Ftz-F1 domain which is 
implicated in DNA-binding stability and specificity, would result in a more stable 
binding of NR5A1 to the SOX9 promoter, thereby directly counteracting the FOXL2-
mediated SOX9 inhibition that normally occurs during female development60. 
However, this hypothesis could not be confirmed by luciferase transcriptional 
activation experiments, as a decreased transcriptional activation of a SOX9 TESCO- 
reporter construct was observed. Furthermore, transcriptome analysis using RNA-seq 
on patient-derived lymphocytes did not show upregulation of other early male-
specific genes, which is not surprising given the limited biological relevance of the 
used material. A second, more attractive hypothesis is that NR5A1 also plays a role in 
triggering the activation of early ovary-specific genes like WNT4. Two animal models 
are in favor of these female-specific NR5A1 actions; namely the Cited2 knock-out 
mouse and the Nr5a1 deficient Nile Tilapia61,62. In addition, Bashamboo et al. have 
demonstrated NR5A1 expression in the early human embryonic ovary, suggesting its 
functional importance63. It is conceivable that this specific NR5A1 mutation affects the 
early ovary-promoting function of NR5A1, ultimately resulting in insufficient/delayed 
expression of female-specific factors and as a result, escape from their testis-
suppressing activity. This subtle balance of testis- and ovary-specific NR5A1 functions 
might also explain the observed phenotypic heterogeneity and incomplete penetrance. 
The final phenotype is dependent on whether certain thresholds of male and female 
specific factors have been reached in a timely fashion.  
Remarkably, at the same time two other studies reporting on the same NR5A1 
mutation in 46,XX DSD cases were published63,64. In the study of Bashamboo et al. the 
p.Arg92Trp variant was identified in a boy with testicular DSD and his sister with 
46,XY partial gonadal dysgenesis. Transcriptional activation assays showed a reduced 
biological activity on AMH and SOX9 TESCO reporter constructs (in line with our 
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findings), explaining the 46,XY DSD phenotype. Furthermore, they assessed the 
capability of mutated NR5A1 (in combination with β-catenin) to activate 
DAX1/NR0B1; the p.Arg92Trp variant showed selective loss of this synergistic 
activation, possibly accounting for the 46,XX DSD phenotype63. A previously identified 
NR5A1 mutation affecting the same codon, p.Arg92Gln, had no effect on DAX1 
activation, which can explain why this variant does not lead to a gonadal phenotype 
in a 46,XX individual with adrenal insuffiency65. This mutation had previously been 
identified in a case of 46,XY gonadal dysgenesis and adrenal insufficiency and it was 
already established to lead to reduced SOX9 activity66. The third study concerning the 
p.Arg92Trp mutation adds two additional cases with (ovo)testicular DSD and puts 
forward an alternative working mechanism. The DAX1-mediated anti-testis action has 
previously been attributed to its antagonizing effect on NR5A1-mediated activation of 
SOX9.  Here, luciferase data showed that mutated NR5A1 is less susceptible to DAX1-
induced suppression on SOX9-TESCO. The authors anticipate that unresponsiveness 
of the mutated NR5A1 to DAX1 suppression would alter the ovarian developmental 
processes64. Overall, our p.Arg92Trp study and the two others agree on the fact that 
this mutation exerts its effect rather by hampering NR5A1-mediated pro-ovarian 
functions than by upregulation of pro-testicular NR5A1 activity. Additional functional 
studies will further elucidate the exact underlying mechanism. 
Interestingly a mutant mouse was generated using CRISPR/Cas9 for mutation 
p.Arg92Trp67. Phenotypical characterization revealed both similarities and 
discrepancies between humans and mice. All Nr5a1R92W/R92W mice had typical female 
external genitalia and no adrenals were present, while in humans the p.Arg92Trp 
mutant has so far not been associated with an adrenal phenotype. Nr5a1R92W/R92W XY 
mice had intra-abdominal hypoplastic gonads and histological examination revealed 
the absence of testicular cords at 13.5-18.5 dpc, reminiscent of the 46,XY DSD case 
described by Bashamboo et al63,68. In Nr5a1R92W/R92W XX mice however the gonadal 
phenotype is not in accordance with the human situation; examination of XX  mice 
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revealed normal or slightly hypoplastic gonads that were histologically 
indistinguishable from wild type counterparts68. These discrepancies between mouse 
and human ovarian phenotypes are reflected in the NR5A1/Nr5a1 expression pattern; 
in humans NR5A1 mRNA expression in the fetal ovary starts at 6-10 weeks of gestation 
while in mice, Nr5a1 transcripts are barely detectable in the sex determining period63,69. 
The anti-testis role for NR5A1 that we suggest is therefore most likely of no importance 
during murine development.  
In conclusion, these new NR5A1 data provide a new, apparently frequent genetic cause 
for 46,XX testicular and OT DSD. Furthermore, these data contribute to the discussion 
whether 46,XX and 46,XY DSD are two different entities or whether they are two end 
points of the spectrum of one underlying condition. The fact that this recurrent 
p.Arg92Trp mutation can result in both 46,XX and 46,XY DSD is strongly in favor of a 
phenotypic spectrum. Intrafamilial phenotypic variability has also been described in 
other families in which the underlying molecular defect remains enigmatic70-72. These 
findings can have an impact on genetic counseling for NR5A1 mutations. Previously, 
NR5A1 mutations had only been related to POI in 46,XX individuals, while our data 
show that other, more severe phenotypes can occur in XX individuals and that within 
families, phenotypic variability can range from 46,XY gonadal dysgenesis to 46,XX 
(ovo)testicular DSD. However, so far only the p.Arg92Trp mutation has been 
associated with 46,XX DSD.   
Identification of FOG2 as a novel disease gene for POI 
Many genes involved in gonadal development remain expressed throughout 
adulthood and may play a role in gonadal maintenance and functioning. Therefore, 
unraveling the molecular pathways involved in DSD can eventually uncover genetic 
mechanisms behind more frequently occurring reproductive conditions such as male 
infertility or POI, as previously mentioned.  
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In the beginning of this PhD project we identified a heterozygous, maternally 
inherited, FOG2 encompassing deletion in a boy with 46,XY gonadal dysgenesis 
without cardiac defects. At that time FOG2 affecting rearrangements had only been 
associated in patients with congenital cardiac anomalies, whether or not in 
combination with 46,XY DSD73,74. In 2014, a paper reported on the first FOG2 missense 
mutations found in two cases with isolated 46,XY DSD. Segregation analysis in their 
families revealed two symptom-free, female carriers75.  
In view of a reported mouse phenotype in Fog2 null mice76, suggesting a role for Fog2 
in the ovary, hormonal investigations in the index’ mother revealed a low AMH level, 
putting her at risk for POI. These combined data led us to hypothesize that FOG2 
mutations could be an underlying cause of POI. Targeted resequencing of the FOG2 
coding region in a French-Belgian POI cohort, convincingly confirmed this hypothesis 
as it resulted in the identification of four additional heterozygous FOG2 mutations 
(1%). Luciferase assays showed a significantly reduced transcriptional activation for 
three out of four of these variants, supporting this hypothesis.  
Given the early prenatal death of Fog2-/- mice, this model is not suitable to study a 
possible Fog2 role in mature ovarian function; however, in vitro evidence has 
implicated the Fog2/Gata4 transcription complex in follicular maturation, via Amh 
induction, and in steroidogenesis77. This situation is reminiscent of the role Nr5a1 plays 
during both sex development and adult ovarian functioning. NR5A1-associated POI is 
also characterized by incomplete penetrance, as is the case for FOG2 mutations and 
POI. Accordingly, it can be anticipated that in concordance with NR5A1, FOG2 might 
be involved in other conditions along the broad DSD spectrum as well.  
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LIMITATIONS OF OUR RESEARCH AND FUTURE PERSPECTIVES 
More DSD genes and mechanisms to discover 
The past four and a half years of work have resulted in the identification of one new 
disease gene for 46,XY DSD and expansion of the phenotypic spectrum of two known 
DSD genes. It goes without saying that the many unresolved cases will extend the DSD 
disease gene list even further. Given the low prevalence of DSD conditions and the 
small size of DSD pedigrees, collaboration between different research groups will be 
key as each of the newly discovered DSD genes will only account for a small portion 
of DSD cases. In that light, the recent foundation of the SDgenematch system (in the 
context of the Cooperation in Science and Technology (COST) action “DSD-net”), 
where research groups will safely disclose their candidate genes, can only be 
welcomed warmly. Such collaborative initiatives will avoid parallel efforts on similar 
projects and will allow the identification of additional patients with defects in the same 
gene. A similar initiative in the field of inherited retinopathies, the European Retinal 
Disease Consortium, has already proven to be very useful (http://www.erdc.info/)78.  
While the search for a genetic cause is still mostly focused on the coding regions of the 
human genome, many examples of non-coding defects have been described in various 
developmental disorders over the last decades79,80. DSDs form a good paradigm for 
these non-coding mechanisms, as gonadal development is strictly regulated by the 
temporospatial expression of different transcription factors. In study 5, we have 
reviewed the currently reported regulatory defects in DSD pathogenesis. Lowering 
costs and technical improvements will soon allow the application of whole genome 
sequencing in a clinical setting, allowing to detect coding and non-coding variation 
and structural defects with one single test. However today one big obstacle remains: 
with the advent of NGS technologies the bottleneck has shifted from variant 
identification itself to variant interpretation. This drawback is even more important for 
non-coding variations as the regulatory code remains poorly understood79. Closing of 
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this “interpretive gap” forms one of the main challenges in the human genetics field80. 
The Encyclopaedia of DNA Elements (ENCODE) consortium has provided massive 
experimental data concerning the function of regulatory elements, and it can 
contribute to the variant interpretation process although it cannot be seen as the 
Rosetta stone for our genetic code80,81. Futhermore, the Roadmap Epigenomics project 
aims to provide a collection of reference epigenomes and to provide a reference for 
comparison and integration of regulatory findings82. The major drawback of both 
ENCODE and Roadmap data, is the fact that the available information is generated on 
differentiated cell types, making them less applicable for DSD variant interpretation.  
Analogous to the development of different algorithms for coding variant annotation, 
several comparable tools have been created for non-coding variants, e.g. Genome-
Wide Annotation of VAriants (GWAVA) and Combined Annotation-Dependent 
Depletion (CADD)83,84.  
New tools for functional validation of candidate genes 
Besides these computational approaches for variant interpretation, reliable approaches 
for in vitro and in vivo functional validation are becoming more important. The 
introduction of RNA-seq was a revolutionary step forward for transcriptome analysis 
and the development of different chromosome conformation capture technologies (3C, 
4C-seq, Hi-C, Capture-C, …) has enabled the assessment of chromatin interactions and 
genomic architecture85,86. Although these techniques have proven their utility, they 
have one disadvantage in common, making them less attractive for the functional 
validation of candidate DSD genes; all of these techniques require the use of relevant 
cell types. Even though several gonadal cell types are available, they are all 
differentiated cell lines87,88. Ideally, functional validation of DSD candidate genes 
should be performed in cell lines resembling the cellular environment of the urogenital 
ridge or the bipotential gonad. The same argument applies to patient-derived gonadal 
tissues, if available; at the time of sampling the gonad is already differentiated.  
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Two promising techniques might be helpful to overcome these issues: induced 
pluripotent stem cells (iPSC) and ex vivo culturing of entire murine gonads. The iPSC 
technology allows reprogramming of differentiated adult cells to pluripotent cells and 
subsequent differentiation to a cell type of choice. Bugamim et al. have described the 
generation of murine induced Sertoli cells89 and several reports on the generation of 
human iPSC-derived germ cells have been published90-93. The next step could be the 
generation of an iPSC-derived cell line that resembles the bipotential gonad. Another 
opportunity can be found in the ex vivo culturing of whole murine gonads94,95. The main 
advantage of this technique is that it preserves gonadal tissue integrity. This way cell 
contacts are maintained and the intercellular signaling between somatic cells and germ 
cells is unchanged. However, despite optimizations of the culturing protocol, the 
surrounding molecular environment will inevitably differ from the in vivo situation94,95. 
Furthermore, this technique uses murine tissues and although mice are the 
predominant animal model used in sex developmental research, differences between 
murine and human sex development might be bigger than initially anticipated. From 
the known differences in SRY expression patterns, we can expect that these differences 
start early on in sex development: in mice Sry is only transiently expressed starting at 
10.5 dpc and fading away two days later while in humans SRY expression is 
maintained throughout adult life96,97. If such an important difference is seen that early 
during sex development, one can only speculate about the deviations further down 
these pathways.     
In an ideal world… 
Working in a DSD multidisciplinary team for the past four and a half years has given 
me the opportunity to witness the extensive efforts of all team members to offer the 
best possible care to children with a DSD condition and their families. It has also 
allowed me to reflect on DSD management from different viewpoints.  
During this PhD fellowship, I have learned the importance of shared clinical decision 
making. Joint consultations attended by an endocrinologist, a urologist and a 
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psychologist, where individuals with a DSD condition and their parents get 
information concerning different aspects of the condition, can only be beneficial to the 
patients and their families. However, to make these collaborative efforts even more 
effective, structural support for DSD teams should be available.  
A standardized approach consisting of a thorough clinical examination and hormonal 
evaluation can form a handhold to guide the genetic diagnostic process.  If no financial 
considerations had to be taken into account, WES or eventually WGS would be 
available for all individuals with a DSD condition. Based on the results of the clinical 
and hormonal work-up an initial targeted search could be performed, followed by an 
exome/genome-wide evaluation of the data. However, the implementation of these 
applications to the routine clinical setting would require better interpretation 
algorithms and a DSD genetics team for functional validation.  
Additional to these clinical and genetic evolutions, I also believe that education is key 
on several levels. First of all, education of health professionals: too often, wrong or 
misleading information is given immediately after the birth of a child with atypical 
genitalia, placing the parents in a very stressful situation. Given that DSDs are rare 
conditions, local obstetricians and pediatricians only see few cases. Earlier and better 
referral to a specialized center, would reduce the stress encountered by new parents. 
However, local practitioners may not even be aware of the existence of an expertise 
center for these conditions. In that light, it would be beneficial for DSD management, 
and by extension, for other rare conditions, if governmental steps would be taken to 
officially appoint centers of expertise, as is often the case in other countries. The 
establishment of European networks of reference for rare diseases (ERN), guided by 
the European Commission, is an excellent opportunity in this matter. These ERNs aim 
to achieve international cooperation concerning treatment and research options for 
rare diseases. However, today the Belgian government has not yet appointed official 
national centers of expertise. In that light and to enhance rare diseases related research 
and care, the Flemish government has founded the Flemish network for rare disorders, 
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although this project is still in its infancy. Second, general education concerning sex 
and gender should be adjusted. Before engaging in this PhD fellowship, I had never 
heard of DSD conditions and I assume this is also the case for most parents at the time 
of diagnosis. Courageous ‘outings’ by people with a DSD condition can help to raise 
awareness but if we really want children with DSD to feel confident, we should make 
sure that variations of sex development are perceived as normally occurring variations 
of nature, such as variations in eye color, length, sexual orientation, …  
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uitgebreide expertise, jullie hebben mij ook gemotiveerd op momenten dat alles  
minder haalbaar leek en terecht gewezen wanneer ik nonchalant werd. Ook aan het 
einde van mijn doctoraatsperiode ben ik nog steeds verwonderd over hoe doortastend, 
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Karolien en Lode, ook jullie verdienen hier een afzonderlijke paragraaf. Karolien, 
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laten proeven van de sfeer in jullie labo. Lode, bedankt om mij op te leiden tot 
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plezier naar jullie labo. 
Reiner, Anne-Laure and the other members of the Paris team. Thank you for 
welcoming me in your lab. Thank you for letting me be a part of the Parisian life, even 
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En tranen...     van mijzelf bij mijn achterban (en natuurlijk 
ook veel gelach en plezier). In de laatste, maar zeker niet minst belangrijke plaats, wil 
ik mijn vrienden en familie bedanken. Een doctoraatsperiode durft al wel eens tot 
twijfels en de daarbij horende emoties leiden (vooral dan de laatste maanden). Dankzij 
elk van jullie, kon ik er steeds weer voor een tijdje tegenaan. 
Voor mijn vriendinnen: de BMW-girls, de SVI-survivors en mijn mede-oudleiding bij 
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komen drinken/eten, weekendjes en andere dates. 
Ook voor mijn familie is een bedankje op zijn plaats. Voor moeke, meter en peter, de 
tantes en nonkels, neven en nichten. Ondanks de grote hoeveelheden eten die we 
steeds samen verorberen, kan nog steeds iedereen door dezelfde deur, iets wat in veel 
families niet vanzelfsprekend is! Ook dat is van onschatbare waarde. Bedankt om 
regelmatig eens te vragen hoe het opschoot, wat ik nu weer net onderzocht, of ik al 
publicaties had en wanneer jullie nu eindelijk naar die lang verwachte receptie 
mochten komen   
Daarnaast wil ik ook graag mijn “schoonfamilie” bedanken. Jullie deur staat ook altijd 
open voor mij en het heeft niet heel lang geduurd voor ik mij ook in jullie huis thuis 
voelde. Roger, Martine, Thomas en Sylvia: bedankt om er te zijn! 
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Ook voor mijn zus Evelien, bedankt om mijn oudere zus te zijn. Om mij te vertellen 
dat alles altijd wel goed komt en om beter te kunnen relativeren dan ik. Bedankt ook 
voor Gaston, de rakker, mijn metekindje (Tim: hiervoor wil ik jou ook een klein beetje 
bedanken ). Jullie kleine, guitige uk tovert steeds weer een lach op mijn gezicht.  
Enkele van de meest bijzondere woorden van dank gaan naar mijn ouders. Bedankt 
papa, om er telkens weer op te hameren hoe belangrijk studeren was en om steeds het 
onderste uit de kan te willen. Het ging er vroeger langs het ene oor in en het andere 
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Bedankt mama, om er telkens voor ons te staan. Als een echt moeke was/ben je altijd 
in de weer voor jouw dochters. Geen vraag is jou te veel, geen boodschap te zwaar, 
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Tot slot nog een grote dank-je-wel voor de hoofdrolspeler in mijn leven, diegene die 
de laatste maanden met al mijn grillen heeft moeten leven en die dat hopelijk nog lang 
wil doen (al zal ik de grillen een beetje proberen te beperken). Lieve Sam, bedankt om 
mij te doen lachen, mij op te peppen, mij te kalmeren, mij soms gewoon te laten zijn. 
Kortom, bedankt voor ALLES. Ik hoop voor jou dezelfde steun en toeverlaat te kunnen 
zijn, terwijl jij jouw doctoraat afrondt.  
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